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1.1 Tuberculosis: A global public health problem 
Tuberculosis workers in India found this ‘prescription slip’ with 




He would have bought and consumed Rifampicin for just two weeks 
without knowing what it was and why he was advised to take this 
drug. This prescription would have been obviously written by a health 
care provider. Rifampicin, a mainstay anti-TB drug which has to be 
consumed by TB patients only along with other drugs in a specific 
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combination in the correct doses and for a definite period and 
unmistakably in conditions that can ensure treatment completion. 
However anti-TB medicines including Rifampicin, can even be 
bought over-the-counter from private pharmacies in many countries. 
Irrational use of anti-TB antibiotics is accelerating the generation of 
mycobacterial resistance to the very few drugs available to cure TB. 
The world is facing an imminent global emergency of multi-drug 
resistant tuberculosis epidemic. In a progressing world, about 10.4 
million people become TB patients every year of whom about 40% 
are not notified to the national programmes. At least 1.3 million 
people lost their lives due to TB which is a curable disease. Where 
did we go wrong? Can we improve TB control to end the enormous 
human suffering and the devastating social impacts due to TB? What 
should we do for that? 
Globally, tuberculosis (TB) is a major public health problem. 
According to the World Health Organization’s (WHO) latest 
estimates, about 10.4 million people have fallen ill with TB in 20161. 
TB is the ninth leading cause of disease worldwide and ranks above 
HIV/AIDS as the leading cause of death from a single infectious 
disease1. A tenth of the new TB cases in 2016 also had HIV infection 
further complicating the diagnosis, treatment and recovery. Growing 
incidence of drug-resistant TB is additionally muddling the situation 
with estimated 490 000 new cases of multidrug-resistant TB (MDR-
TB) in 2016. Despite the existence of reliable tools to diagnose, and 
effective drugs to cure TB, estimated 1.3 million people died of TB 
in 20161.  




1.1.1 Global Efforts to control TB  
WHO has been spearheading the global efforts to control TB which 
gained momentum in early 90’s since the adoption of Directly 
Observed Treatment, Short-course regimen (DOTS) strategy2. 
WHO’s current efforts to control TB are based on the WHO’s new 
‘End TB Strategy’ with a vision of ‘A world free of tuberculosis – 
zero deaths, disease and suffering due to tuberculosis’ and a goal ‘to 
end the global tuberculosis epidemic by 2035’3. The End TB Strategy 
targets reductions by 95% and 90% respectively in the number of TB 
deaths and TB incidence rate by 2035 compared with 20151. The 
strategy also targets Zero TB-affected families facing catastrophic 
costs due to TB by 20201. Because of the global and country-level 
interventions in the past more than two decades, TB mortality and 
prevalence rates fell respectively by 47% and 42% between 1990 and 
20154. Currently, the TB mortality rate is falling at about 3% per year 
while 16% of the TB cases still die from the disease. Similarly, 
globally, TB incidence is falling at about 2% per year1. Various 
international donors and technical agencies are supporting global as 
well as country level efforts in controlling TB.    
 
1.2 TB control in countries  
Control of TB in virtually all countries is aligned to the global TB 
strategies developed by WHO together with its partners. TB control 
in countries are usually implemented by the National TB control 
Programmes (NTP). NTPs in general are under Ministries of Health 
(MoH) of governments and therefore are essentially public-sector 
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entities. However, in many countries, health care providers operating 
outside the NTP also provide services to TB patients.  
 
1.2.1 Health care sectors in countries  
As far as TB control is concerned, the health care sectors can be 
broadly divided into three major types. These are 1) public health 
sector under MoH 2) public sector other than MoH 3) private sector. 
Public sector other than MoH includes governmental ministries, 
organizations or facilities that provide governmental services, for 
example; services provided by the armed forces, police, public 
academic institutions, and public ministries such as transport, 
education, health, justice and welfare5. Similarly, private sector 
includes organizations, businesses or individuals, mission hospitals, 
nongovernmental organizations and faith-based organizations. It 
comprises individual formal and informal private practitioners, for-
profit private hospitals and academic institutions, the corporate 
sector, and voluntary or non-profit sector, which includes charitable 
or nongovernmental organizations (NGOs)1,5. In this thesis, for 
convenience, public or private health-care providers or institutions 
that are not directly under the NTP are labelled as non-NTP providers. 
Such providers include ‘public sector other than MoH’ and ‘private 
sector’ providers.  
 
1.2.2 TB control in public health sector  
As has already been stated, NTPs, essentially public health sector 
organizations, are the primary instruments of the governments to 
implement TB control in a country. NTPs in general are under MoH. 
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Public sector organizations other than MoH such as railways, 
industries or medical colleges may have their own health care 
facilities which are practically outside the purview of the NTP. In 
most such situations, NTPs will not have direct control over the TB 
management practices of these non-NTP public sector health care 
providers. Similarly, TB cases managed by such providers are often 
not notified to the NTPs. Therefore, it becomes the responsibility of 
the NTPs to make additional efforts to ensure standardization in the 
management of TB in non-NTP sectors and notification of all TB 
cases diagnosed or treated by them. 
 
Especially in many high TB burden countries, over the past many 
decades, it had become a reality that NTPs alone cannot manage TB 
control entirely. This has been mainly due to the presence numerous 
health care providers under multiple health sectors, gradual 
weakening of the public health sector and the growth of the private 
sector. Decrease in the allocation of resources to public health 
facilities and the resultant weakening of the public sector continued 
and the public sector in turn failed to cope with the increasing demand 
of health care. Lately the private sector has overgrown the public 
sector especially in terms of technology, expertise, range of services 
and the efficiency in delivery of services6.  
 
1.2.3 TB control in private health care sector   
In many high TB burden countries, private sector is a major player in 
health care1. Majority of poor countries in the world have a large and 
growing private medical sector7.  Consequently, private health sector 
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provides care to significant proportions of TB patients1,4,7-14. In many 
countries, people prefer to first approach private health sector when 
they are sick7. Patients often prefer private health sector even where 
public health sector facilities are available in their neighbourhood15. 
The common reasons for not accessing government facilities for 
treatment of TB were dissatisfaction with the services, non-
availability of government facilities in the neighborhood, long 
waiting time and financial constraints15. Nevertheless, private health 
sector also has its own weaknesses that affect effective TB control. 
Private health sector in many high TB burden countries are largely 
disorganized and unregulated providing services of variable quality 
11,16,17. In addition, significant proportions of the TB cases seen by 
private sector are not notified to the NTPs1. Delays or failure in 
diagnosing TB cases will lead to longer periods of infectiousness and 
increased rates of deaths18. Similarly, inappropriate or inadequate 
treatment of the diagnosed TB cases will accelerate the emergence of 
multidrug-resistant TB (MDR-TB)19. It is assumed that the TB cases 
that missed notification might have sought care from the private 
sector while the information was not communicated to the NTP1. 
There are estimated 4.1 million TB cases that missed notification in 
20161. There is also a higher likelihood of suboptimal care received 
by the TB patients that seek care especially from small scale private 
providers11,14,16,17,20-22. Therefore, engaging all health care providers 
outside the NTPs, especially the private sector, has been identified as 
a necessity in effectively controlling the TB epidemic3.  
 
Chapter 1: Research Problem and Research Questions 
9 
 
1.2.4 Public-Private Mix for TB Care and Control 
The traditional way of thinking was that the respective NTP would 
manage TB control entirely in a country. However, engaging non-
NTP health care providers became a necessity in many countries 
because of the large number of TB cases managed by them, especially 
the private-for-profit health sector, with variable quality in diagnosis 
and treatment. Moreover, most of these cases were not notified to the 
NTPs. Therefore, NTPs have been making efforts to engage non-NTP 
care providers that are outside the authority of the NTP. This was to 
ensure that TB cases are managed by all care providers according to 
standard guidelines and practices in the country. Gradually, these 
efforts evolved as a global strategy called Public-Private Mix (PPM) 
for TB Care and Control. According to the WHO, PPM means all 
partnership mixes between organizations, businesses or individuals 
that are part of the public sector or private sector. PPM off late 
represents a comprehensive approach for systematic involvement of 
all relevant health care providers in TB control to promote the use of 
International Standards for TB Care to achieve global TB control 
targets23. The partnership can hence be public–public (between NTP 
and other public-sector care providers such as general hospitals, 
prison or military health services and social security organizations), 
public–private (between NTP and the private sector) or even private–
private (between an NGO or a private hospital and the neighborhood 
private providers)23,5.  
 
In a broader sense, at global level, the name ‘public’ is often used to 
represent the NTP services under MoH while ‘private’ covers all 
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other health sectors outside MoH23. The name ‘private’ broadly 
includes a wide range of providers from small scale informal 
providers practising systems other than modern medicine to state-of-
the-art health care facilities practising modern medicine. However, 
among all the non-NTP providers, for-profit private health sector is 
the most significant sector as far as global TB control is concerned. 
This is because large proportions of the ‘missing cases’ are due to 
underreporting from this private sector1. In the chapters of this thesis, 
the category ‘private sector’ is mostly used to denote the for-profit 
private sector whose engagement is important due to the large number 
of providers and their diverse and disorganized nature. Similarly, in 
this thesis, the engagement of private sector providers practising 
modern medicine is given more emphasis.     
 
The goal of PPM approaches has been to increase TB case 
notification from the non-NTP care providers, especially the private 
sector, by timely and quality-assured diagnosis, as well as to improve 
the quality of treatment and care to achieve high levels of treatment 
success of TB patients. As a principle, global TB control community 
believes that both public and private sectors have their own strengths 
and weaknesses. PPM therefore uses complementary strengths and 
capacities of both public and private health sectors to achieve better 
TB control. Table 1 summarizes some of the strengths and 








 Strengths and weaknesses of public and private health care 











• Services are usually free 
of cost  
• Infrastructure and staff 
available for home visit 
of patients, follow up 
during treatment and 
retrieval of patients who 
interrupt treatment  
• Failure to satisfy 
patients’ needs   




• Often overcrowded   
• Long waiting time  
• Lack of privacy 
leading to stigma 
• Lack of people’s faith 
in the system  
Private 
sector  
• Better and more flexible 
access 
• Convenient timing  
• Friendly behaviour 
towards patients 
• Shorter waiting time 
• Greater confidentiality 
•  and greater sensitivity 
to user needs 
• People trust the 
providers  





who follow different 
systems of healing    
• Need not necessarily 
follow standard 
guidelines  




• Higher cost  
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International donor agencies have been funding NTPs to implement 
PPM projects in the relevant countries. The Global Fund to fight 
AIDS, TB and Malaria being the biggest international donor in TB 
control has been supporting PPM initiatives through its grants. 
Despite the PPM interventions for about twenty years, the success has 
been modest especially in engaging the non-NTP care providers and 
in notifying additional TB cases. In addition, in the developing 
countries, over the period, quality of services provided by the public 
health sector has been deteriorating while the utilization of private 
health care services by patients has been growing6.  
 
1.3 PPM in TB control of India  
India has the highest TB burden accounting for over 27% of the 
estimated global incident TB cases and with more than 40% of the 
TB cases not notified to its Revised National TB Control Programme 
(RNTCP)1. In addition, private health sector is very large in the 
country which is accessed by 60-70% of the people as the first point 
of care when they fall sick8-10,16. India has been in the forefront in 
experimenting PPM pilot projects since the inception of RNTCP. 
Encouraged by the success of the pilot projects, RNTP in 2003 
implemented a national intensified PPM project and subsequently in 
2008 started to scale up PPM at national level26.  
 
RNTCP faced various challenges during the implementation of PPM 
especially due to resistance from the private health sector arising 
mainly from the lack of proper understanding of the RNTCP 
concepts. In the initial years of RNTCP, private practitioners in 
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general were skeptical about RNTCP’s evidence base, scientific 
validity and feasibility in the Indian context. The important areas of 
conflicts were around four areas; 1) scientific aspects 2) patients’ 
confidentiality and stigma issues 3) lack of trust in the government 
systems 4) potential additional burden to private care providers 
Private health sector also had apprehensions about possible adverse 
impacts of RNTCP on their interests especially related to losing  
clientele to public sector25. To address this challenge, RNTCP 
engaged the Indian Medical Association (IMA) that acted as an 
interface for RNTCP to establish collaborations with the private 
health sector26. RNTCP continued to engage the private sector also 
by developing special schemes that included monitory compensation 
for the engagement of private and NGO health sectors26. RNTCP in 
course of time has been accepting the private sector as a reality and 
therefore continued to adopt measures to work with the private 
sector27,28. Lately, considerable review and refinements of policies 
have been undertaken by RNTCP to accommodate the private health 
sector’s attributes especially with a patient-centered approach in TB 
control28. 
 
1.4 The problem  
TB continues to be a global public health problem disproportionately 
affecting the developing world and the poor people4. In 2016, 
globally, around 40% (4.1 million) of the estimated TB cases were 
not notified to the NTPs1. There were 490 000 incident MDR-TB 
cases of which only a quarter were notified and treated. Results of the 
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recent TB prevalence surveys in high TB burden countries indicate 
that the actual incidence of TB could be even higher than the current 
estimates1. The End TB strategy with the goal of ending TB by 2035 
has set very ambitious targets. However, despite the global efforts to 
control TB and concurrent implementation of PPM strategy, reaching 
the End TB targets for 2035 appears to be a challenging task. In 
addition, achieving desired progress towards universal health 
coverage (UHC) will be essential for ending the TB epidemic as 
envisaged by Sustainable Development Goals (SDG)29. The two key 
UHC financing indicators namely total government spending on 
health as a proportion of gross domestic product and out-of-pocket 
expenditures as a share of total health expenditures will be key to 
meet the ambitious milestones on route to end TB30. The government 
expenditures on health were less than the WHO benchmark of at least 
6% in 150 of 191 countries (79%) in 2014. Out of pocket 
expenditures represented over 45% of overall health expenditures in 
46 countries in 20144.  
 
In the background described above, there are new questions that 
emerge. Are the current PPM efforts adequate for achieving the goal 
and the targets of the End TB strategy? Are there even better ways of 
doing things in TB control? Is PPM the right strategy at all to achieve 
the End TB Strategy’s goal and targets? Is there a need to think of 
modified or newer approaches? This thesis takes the reader through 
its distinctive but closely linked chapters to ultimately arrive at the 
discussion and recommendations on how India and the world should 
address the private sector engagement in TB control in the coming 
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years to achieve the goal and targets of End TB Strategy and thus end 
the TB epidemic globally.   
 
1.5 Research questions  
The overarching research question in this thesis is “In what manner 
and under which conditions can the private sector be engaged in 
health care as to increase the chances of an effective End TB Strategy 
that will achieve its targets for 2035?”  
 
The specific sub questions that are discussed in detail in the following 
chapters are the following:  
  
• How did the TB control program of India try to engage the 
private sector in TB control and what has been the effect of 
the early PPM pilot endeavors?  
 
In Chapter 3, ‘Improving tuberculosis control through public-private 
collaboration in India: literature review’, we are reviewing the 
characteristics of public-private mix projects in India and their effect 
on case notification and treatment outcomes for tuberculosis by 
analyzing the data from 14 PPM projects across India.  
 
• How did India scale up the pilot projects on private sector 
engagement in TB control to national level and what has been 
the learning?  
 
In Chapter 4, ‘Intensified scale-up of public-private mix: a systems 
approach to tuberculosis care and control in India’, we are analyzing 
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the processes and outcomes of the systems approach adopted in the 
intensified scale-up of PPM implemented by RNTCP covering 50 
million population in 14 major cities.  
 
• What has been the role of the Indian Medical Association in 
the engagement of the private sector in TB control and what 
is its relevance? What are the lessons for India and other 
countries to learn from the unique endeavor of engagement of 
medical professional associations in TB control?  
 
In Chapter 5, Role of professional bodies in TB control: An untold 
story of the Indian Medical Association in fighting TB, we are 
investigating the history and the process of the engagement of the 
Indian Medical Association (IMA) in TB control in collaboration 
with the RNTCP.   
 
• What has been the landscape of funding from the Global 
Fund, the biggest international donor in TB control, for the 
engagement of the private sector in TB control?  
  
In Chapter 6, Global Fund financing of public–private mix 
approaches for delivery of tuberculosis care, we investigate the extent 
and scope of PPM interventions in TB control programmes supported 
by the Global Fund. We are examining the evolution of support to 
PPM for TB care and control in the Global Fund-supported TB grants 
as reflected in its official documents and studying the distribution and 
characteristics of PPM initiatives within the Global Fund-supported 
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programs. We are reviewing the data from 14 countries that reported 
to WHO for the Global TB control report of 2010. 
 
• Do prisons that house around 10 million detainees, among 
whom TB is a leading cause of morbidity and mortality, get 
adequate funding for TB control?  
 
In Chapter 7, Global Fund financing of tuberculosis services delivery 
in prisons, we examined the Global Fund grants database to identify 
TB and HIV/TB grants and activities that monitored the delivery of 
tuberculosis treatment and support activities in prisons.  
In Chapter 8, based on the findings of the previous chapters, we are 
examining the possibilities of PPM to achieve the goals and targets 
































































2.1 Tuberculosis  
TB is an infectious disease caused by bacteria called Mycobacterium 
tuberculosis. TB mostly affects lungs (pulmonary TB) though it can 
affect any part of the body. Common symptoms of active pulmonary 
TB disease are cough that lasts for three weeks or more, coughing up 
blood or sputum, pain in the chest, weakness, weight loss, fever, loss 
of appetite and night sweats31. TB is spread when a patient with active 
pulmonary TB expels bacteria into the air by coughing, sneezing, 
spitting or speaking. The bacteria expelled into the air can be inhaled 
by an apparently healthy individual who can get infected31.  
 
People who have been infected by TB bacteria but are not yet ill with 
the disease, are considered to have latent TB infection (LTBI). One-
third of the world’s population is latently infected with TB. 
Individuals with LTBI do not manifest any symptoms and they cannot 
spread TB to others. However, these individuals will have 10% 
lifetime risk of becoming a TB patient31. Conversion from the latent 
TB stage to active TB disease occurs when the dormant mycobacteria 
arouse out of dormancy, become active and multiply in the infected 
person’s body when there is decreased level of immunity often 
associated with HIV infection31.  
 
When a person develops active TB disease, the symptoms may be 
mild for many months. This can lead to delays in seeking medical 
care and thus result in transmission of the bacteria to others. Delays 




in suspecting, diagnosing and treating TB in a patient can lead to 
increased disease transmission in the community. World Health 
WHO estimates that patients with undetected active TB can infect 10-
15 people in a period of one year31. TB is essentially curable if the 
disease is promptly diagnosed and appropriately treated. Unless 
timely and appropriate treatment is provided, on average, 45% of 
HIV-negative people with TB and nearly all HIV-positive people 
with TB will die due to the disease in about three years31,32. 
Tuberculosis generally affects adults in the most productive age 
groups31. TB decreases people's capacity to work and adds to 
treatment expenses, exacerbating their poverty1. Thus, TB continues 
to pose difficult barriers to social and economic development of 
populations especially in the developing nations and 
disproportionately burdening the poor people across the globe1.  
 
2.1.1 Multidrug-resistant tuberculosis (MDR-TB) adds to the 
burden of disease 
Inappropriate, interrupted or inadequate treatment of TB usually 
leads to drug-resistance when the bacteria stop responding to the 
common anti-TB drugs. When the bacteria are resistant to both 
“Rifampicin' and ‘Isoniazid’, the two mainstay drugs in the treatment 
of TB, the condition is called multidrug-resistant TB (MDR-TB) 
which is difficult and very expensive to treat. Extensively drug-
resistant TB (XDR-TB), which is MDR-TB plus resistance to at least 
one fluoroquinoline and a second-line injectable drug, is a more 
severe form of drug resistance against which very few drugs are 




effective31. WHO estimates for 2015 indicate that 3.9% of new TB 
cases and 21% of previously treated cases had MDR-TB and the 
average proportion of MDR-TB cases with XDR-TB was 9.5%1. In 
2015, in addition to the estimated 480 000 new cases of MDR-TB, 
there were an additional 100 000 people with rifampicin-resistant TB 
(RR-TB) who were also newly eligible for MDR-TB treatment1.  
 
2.1.2 Tuberculosis and HIV coinfection  
The probability of developing active TB disease is 20 to 30 time more 
in people who are infected with HIV than in people without HIV, due 
to their weakened immune system31. As per WHO estimates, people 
living with HIV accounted for 1.2 million (11%) of all new TB cases 
in 2015. In addition to the estimated 1.4 million TB deaths in 2015, 
there were an additional 0.4 million deaths resulting from TB disease 
among people living with HIV1.  
   
2.1.3 Non-communicable diseases and Tuberculosis  
Many non-communicable diseases (NCD) are risk factors for 
progression from LTBI to active TB disease and often NCDs can 
complicate management of active TB33. For example, diabetes triples 
the risk of TB disease and therefore TB rates are higher in people who 
suffer from diabetes. Diabetes can also worsen the clinical course of 
TB while TB can in turn affect the control of glucose levels in 
diabetic patients33. Similarly, malnourished people have increased 
risk of reactivation or progression to TB disease and on the other hand 
when people get TB disease, they get malnourished33. Tobacco 
smoking greatly increases the risk of TB disease and death. More than 




20% of TB cases worldwide are attributable to tobacco smoking 
which is also associated with poor TB treatment outcomes 33. Higher 
levels of alcohol consumption increase the risk of TB and contributes 
to poor TB treatment adherence and consequently poor treatment 
outcomes33. There are also a few other NCDs such as silicosis that 
increase the risk of TB disease or complicate the treatment of TB34.  
 
2.1.4 Social determinants of Tuberculosis  
TB cannot be considered a standalone health problem; there are many 
structural determinants of health that generate or reinforce social 
stratification in society which in turn gives rise to an unequal 
distribution of the social determinants of health. According to 
Hargreaves et al, key structural determinants of TB epidemiology 
include global socioeconomic inequalities, high levels of population 
mobility, rapid urbanization and population growth35. These 
conditions give rise to unequal distributions of key social 
determinants of TB, including food insecurity and malnutrition, poor 
housing and environmental conditions, and financial, geographic, and 
cultural barriers to health care access. Similarly, the population 
distribution of TB reflects the distribution of these social 
determinants. Though TB can affect people across social and 
economic barriers, the disease disproportionately affects the poor35. 
Undernutrition is an important risk for developing active TB. WHO 
has identified poverty as a powerful determinant of tuberculosis31. 
Poverty being usually associated with lower health awareness and 
health consciousness provide the milieu for increased exposure to risk 
factors of TB such as HIV, smoking and alcohol abuse31. 




Overcrowding in poorly ventilated small housings resulting from 
poverty increases the risk of indoor tuberculosis transmission35.  
 
2.1.5 Diagnosis of tuberculosis  
Worldwide the primary routine test for TB is the more than hundred-
year-old sputum smear microscopy by Ziehl-Neelsen technique1. It is 
relatively cheap and can be performed in peripheral laboratories by 
general laboratory technicians trained in smear microscopy. While 
the specificity of Ziehl-Neelsen technique is very high, the sensitivity 
is variable (20-80%) due to which many cases can be missed (false 
negative tests)31,36,37. Countries that have developed laboratory 
capacity are also using culture methods which is the current reference 
standard. There are superior tests such as liquid culture and nucleic 
acid amplification tests (NAAT) which are very expensive and 
require sophisticated laboratories as well as well-trained laboratory 
staff. Diagnosing MDR-TB and HIV-associated TB are more 
complex. The new cartridge-based nucleic acid amplification test 
(CB NAAT) can diagnose TB and detect resistance to Rifampicin in 
about 90 minutes. The use of ‘Xpert MTB/RIF® assay’, a rapid 
molecular test to diagnose TB and drug-resistant TB was 
recommended by WHO in 2010 for diagnosis of pulmonary TB in 
adults. Since 2013, it has also been recommended for children and 
specific forms of extrapulmonary TB and is being increasingly rolled 
out globally31, 2, 38.  
2.1.6 Treatment of tuberculosis   
As per the currently recommended treatment, new cases of drug-
susceptible TB are treated with a standard drug regimen of 6-month 




course using 4 first-line anti-TB drugs namely isoniazid, rifampicin, 
ethambutol and pyrazinamide2. The current standard global practice 
is to provide ambulatory treatment for TB patients, except when 
patients are seriously ill and require hospitalization. Drug 
consumption by patients in ambulatory care is advised to be under 
supervision and support by treatment supervisors who can be health 
workers or trained community volunteers31. This is to ensure that 
patients adhere to treatment and in case of treatment interruption, the 
treatment supervisor can provide support to bring back the patient to 
treatment. This is essential to achieve the desired outcomes of 
treatment and to prevent the emergence of drug-resistance. Drug-
resistant TB cases would require treatment using second-line anti-TB 
drugs for longer periods. Second-line treatment is very expensive, 
and the drugs are very toxic31. There are nine drugs in advanced 
phases of clinical trials for the treatment of drug-susceptible TB, 
drug-resistant TB or LTBI. Bedaquiline and delamanid, new drugs, 
have been rolled out in several countries 31.  
 
2.1.7 Prevention of tuberculosis  
Bacille Calmette-Guerin (BCG) vaccine, which was developed 
almost 100 years ago, is widely used for the prevention of TB. 
Countries with high TB prevalence give BCG vaccine to children on 
the first day of their birth. BCG can prevent severe forms of extra-
pulmonary TB disease such as TB meningitis and miliary TB 
especially among children. WHO advises that BCG vaccination 
should be provided as part of national childhood immunization 
programmes based on a country’s TB epidemiology. In 2015, 163 




countries reported providing BCG vaccination as a standard part of 
these programmes. There are thirteen TB vaccines in Phase I, Phase 
II or Phase III trials1. Protective efficacy of BCG vaccine wanes off 
as the children grow into adults39. Therefore, treating and curing 
infectious patients remain a practical and crucial intervention to 
prevent spread of TB3. 
 
2.2 Global efforts to control TB  
Concerted global efforts led by the WHO to address TB as a global 
public health problem have been underway for a long time. In 1993, 
WHO declared TB a global emergency which led to enhanced focus 
on countries with high burden of TB40. In 1995, WHO launched 
Directly Observed Treatment, Short course chemotherapy (DOTS) as 
a strategy that comprised five components namely (1) Sustained 
political and financial commitment (2) Diagnosis by quality ensured 
sputum-smear microscopy (3) Standardized short-course anti-TB 
treatment given under direct and supportive observation (4) A 
regular, uninterrupted supply of high quality anti-TB drugs and 
(5) Standardized recording and reporting2. DOTS strategy helped to 
align national TB programs to a standardized global strategy which 
improved the practices of TB control globally. It also mobilized 
additional resources which contributed to health system 
strengthening and therefore increased TB case notification and 
improved treatment success rates41.  
 
In 2006, a more comprehensive strategy called ‘Stop TB strategy’ 
was launched. The goal of the strategy was to dramatically reduce the 




global burden of TB by 2015 envisioned by the Millennium 
Development Goals (MDG) and the ‘Stop TB Partnership’ targets. 
The strategy had six components namely (1) Pursue high-quality 
DOTS expansion and enhancement (2) Address TB-HIV, MDR-TB, 
and the needs of poor and vulnerable populations (3) Contribute to 
health system strengthening based on primary health care (4) Engage 
all care providers (5) Empower people with TB, and communities 
through partnership (6) Enable and promote research42.  
 
Stop TB partnership founded in 2001 gave a major impetus to the 
global TB control efforts. The partnership consists of around 1500 
partners from more than 100 countries43. The Partnership's mission is 
to serve every person who is vulnerable to TB and ensure that high-
quality diagnosis, treatment and care is available to all who need it. 
The partnership operates through a secretariat hosted by United 
Nations Office for Project Services (UNOPS) in Geneva, 
Switzerland, and seven working groups whose roles are to 1) 
accelerate progress on access to TB diagnosis and treatment; 2) 
research and development for new TB diagnostics, drugs and 
vaccines; and 3) tackling drug resistant- and HIV-associated TB. Stop 
TB Partnership produces the Global Plan for every five years. The 
Global Plan to End TB 2016–2020 is the costed plan for 
implementing the first five years of the End TB Strategy43.  
 
Currently the global TB control efforts are aligned to the WHO’s 
‘End TB Strategy’ 2016–2035 which was endorsed by WHO’s 
Member States at the 2014 World Health Assembly3. The Sustainable 




Development Goals (SDG) of the United Nations and the End TB 
Strategy share a common aim: to end the global TB epidemic. The 
ambitious End TB Strategy’s targets are to reduce TB deaths by 95% 
and to reduce incidence by 90% between 2015 and 2035, and to 
ensure that no family is burdened with catastrophic expenses due to 
TB 3. It has interim milestones for 2020, 2025, and 2030. The strategy 
highlights the importance of engaging partners within and beyond the 
health sector, such as in the fields of social protection, labor, 
immigration and justice2,3. WHO in partnership with other technical 
agencies, donors and national programs have been periodically 
revising global TB control guidelines with the emergence of new 
diagnostic tools, medicines or approaches. WHO continues to seek 
support from partners to implement End TB Strategy44.  
 
2.2.1 International Standards for Tuberculosis Care (ISTC)  
Despite the organized and widespread efforts to standardize the care 
of TB patients by WHO and implemented by National TB Control 
Programmes (NTP), quality of management of TB cases has been 
varying widely across countries and various health sectors. This is 
often due to a wide range of issues that include health system 
constraints and infrastructure limitations within the national 
programs run by the public sector as well as the non-public health 
sector players. Reluctance or failure of non-NTP public health 
sectors, especially private sector, in adopting the national policies and 
guidelines also contribute to non-standardized provision of services 
to TB patients. To facilitate standardization of TB care across 
countries and among all kinds of health care providers, the 




Tuberculosis Coalition for Technical Assistance in 2006 developed 
the ‘International Standards for Tuberculosis Care (ISTC)’ with 
support from major technical agencies especially WHO. The purpose 
of the ISTC is to describe a widely accepted level of care that both 
public and private practitioners should seek to achieve in managing 
patients who have, are suspected of having, or are at increased risk of 
developing tuberculosis. ISTC urges all care providers who manage 
TB patients to recognize that, they are not only delivering care to an 
individual, but are as well assuming an important public health 
function that entails a high level of responsibility to the community 
and to the individual patient. The standards are intended to promote 
the effective engagement of all providers in delivering high quality 
care for patients of all ages and all forms of tuberculosis including 
MDR-TB, TB/HIV and other co-morbidities45. 
 
2.2.2 Financing for global TB control  
Many multilateral and bilateral donors have been providing large 
sums of funding for TB control to the needy countries. Of the US$ 6.6 
billion available in 2016, 74% was from domestic sources1. As per 
WHO estimates, international donor funding for TB has generally 
increased year-on-year since 2006, and reached US$ 1.0 billion in 
2016. The Global Fund to fight AIDS, Tuberculosis and Malaria 
dramatically increased the international funding for TB. Founded in 
2002, the Global Fund is a financing institution, providing support to 
countries in the response to the three major infectious diseases. The 
Global Fund is a partnership between governments, civil society, the 
private sector and people affected by the diseases which raises and 




invests nearly US$ 4 billion a year to support programs run by local 
experts in countries and communities most in need. Between 2004 
and 2013, The Global Fund disbursed TB funding in 105 countries. 
In the same period, 74% of the international funding was provided by 
The Global Fund. The remaining (26%) funding came from 
international donors. The cost per patient treated was US$ 1253 for 
drug-susceptible TB and US$ 9529 for MDR-TB1. As per the WHO’s 
projection, globally, the amount for implementation of prevention, 
diagnostic and treatment interventions would rise from almost 
US$ 9.5 billion in 2016 to US$ 14 billion in 20201. 
 
2.2.3 Accomplishments of the global efforts to control TB   
As per the 2016 WHO global TB report, TB treatment averted 49 
million deaths globally between 2000 and 2015. The MDG target to 
halt and reverse TB incidence has been achieved on a global basis. 
Globally, TB incidence has been declining at an average of 1.5% per 
year since 2000 which brings the incidence to 18% lower than the 
level of 2000. TB mortality and prevalence rates fell respectively by 
47% and 42% between 1990 and 2015. The number of people dying 
from HIV-associated TB has also shown a drop of 32% between 2004 
and 20141.  
 
2.2.4 Major challenges in achieving End TB Strategy  
End TB Strategy targets a global reduction of 95% and 90% 
respectively in the number of TB deaths and incidence by 2035. As 
reported by WHO, there were 10.4 million incident TB cases in 2016. 
Only 6.3 million cases were reported WHO by countries which means 




that globally there was a 4.1 million gap between incident and notified 
cases. Similarly, of the estimated 580 000 MDR-TB cases, only 125 
000 were enrolled into treatment. There were major gaps in HIV 
testing of TB patients with only 55% patients tested and 78% of HIV-
positive TB patients receiving antiretroviral therapy. Only 910 000 
people living with HIV and only 7% of the eligible children under 
five were started on preventive TB treatment1. In 2016, TB was one 
of the top 10 causes of death globally with estimated 1.3 million 
people dying of TB. Among the drug-susceptible TB patients notified 
in 2015, treatment success was 83%. Treatment success of 54% and 
30% were recorded respectively for MDR-TB and XDR-TB cases 
notified in 2013. As has been already discussed, global TB control 
faces funding shortage; the funding gap in 2017 was 2.3 billion1. 
There are several other implementation challenges faced by TB 
control in individual countries due to lack of prioritization, 
inadequate resource allocation and health systems constraints1.  
    
2.2.5 TB control in individual countries  
Governments, especially of high TB-burden countries, have been 
investing increasingly in TB control in the past two decades 
especially with the advent of DOTS strategy. Consequently, there has 
been remarkable improvement in the infrastructure and manpower for 
TB control in countries across the globe. Thousands of health care 
facilities including laboratories were constructed or refurbished to 
provide better access and quality for diagnosis and treatment to 
patients with suspected or confirmed TB. Hundreds of thousands of 




TB workers and general health staff all over the world were trained 
or retrained especially in the evolving aspects of TB control42. 
Though the NTPs in general have a vertical nature in higher level 
programme management, the basic services especially diagnosis and 
treatment are usually integrated with the primary health care system. 
Therefore, any improvement in the health systems in terms of 
infrastructure or quality of care would benefit the TB care services. 
Similarly, the global and local efforts in the past years to improve TB 
care services would have resulted in strengthening the general health 
systems. With the frequently updated WHO guidelines on each 
relevant area of TB control, it became handy for the countries to 
standardize their NTPs and align with the global strategies and 
guidelines. Global efforts led by WHO to establish standard 
mechanisms for disease surveillance, monitoring, reporting and 
evaluation helped NTPs advance in these areas.  
 
2.3 Management of TB cases in the health sectors other 
than public health sector, especially the private sector 
 
2.3.1 Health sectors other than public health sector  
Though the NTPs in countries are mostly led by the public health 
sector, in many high TB burden countries, there are various other 
health sectors that cater to health care needs of populations. As has 
been noted in the Chapter 1, the health sectors are broadly divided 
into three, namely public health sector under MoH, public sector 
other than MoH and private sector. In this thesis, as indicated in 
Chapter 1, the health care providers under health sectors other than 




public health sector are labelled as non-NTP providers. These include 
public sector other than MoH and private sector. Examples of such 
non-NTP health sectors are health care facilities run by public sector 
entities other than the public health services (eg. Army, Prisons, 
Railways), and medical college hospitals, private sector, non-
governmental organizations (NGO), mission hospitals, 
nongovernmental organizations, faith-based organizations and 
corporate (business) sector1,5. Especially regarding TB control, non-
NTP health sectors in the developing world are often outside the 
realm of the NTP that usually implements the national TB program. 
Among these non-NTP health care sectors, the private sector has 
continuously been growing, through the roles it plays, its contribution 
to health care and the influence it enjoys in decision making by 
governments7.  
 
Studies have proved that in many high TB-burden countries, the first 
point of contact for majority of the TB patients is private health sector 
and therefore significant proportions of TB patients are managed by 
private health sector18,8,9,10,11-14. The private health sector providers 
are largely disorganized and unregulated46. They are disorganized 
because of the multiplicity of providers practising different systems 
of healing with competing interests for revenue. They are unregulated 
because of the weakness and failure of the implementation of 
regulations. In addition, the private sector is heterogeneous and 
consists of a large spectrum of health care providers ranging from 
individual practitioners to tertiary care and multispecialty hospitals. 




Similarly, the private sector is very dynamic with large numbers of 
new care providers starting practice every day. The private 
practitioners can belong to a wide gamut of providers that could 
include traditional healers, informal care providers and unlicensed 
practitioners at one end of the spectrum while on the other end there 
will be highly qualified doctors working in state-of-the-art super 
specialty hospitals6. Because of this diversity, the quality of 
diagnostic and treatment practices in the private sector can vary 
widely. In addition, there have been ideological conflicts and 
competing interests between public and private health care sectors 
and among practitioners in each sector47. This often arises due to the 
inherent differences in the motivations that drive each health sector 
in addition to various other characteristics such as the population they 
serve and the attitude towards adherence to public health principles 
in the disease management practices. The behavior of the private 
health care sector is perceived to be influenced by ‘for-profit’ motive. 
This motive to generate income from clients could lead to subjecting 
the patients to costly diagnostic investigations that are not warranted 
for confirmation of TB, over diagnosis of TB leading to unnecessary 
treatment, unwarranted hospitalization of patients who can be 
managed with ambulatory care, prescription of medicines that are not 
essential for treating TB and the application of unnecessary or 
invasive treatment procedures48. These practices that are divergent 
from the guidelines for standardized care for TB could make the 
treatment exorbitantly expensive for the patients treated in the private 
health sector49. Catastrophic expenses due to TB would make the 




already poor patients poorer and the poverty in turn would make the 
patients and family members more vulnerable to new infections or 
repeated disease episodes thus repeating the vicious circle of disease 
and poverty. Low priority and lack of necessary infrastructure in the 
private sector for undertaking public health functions and actions is a 
reality which also contributes to suboptimal quality in the 
management of TB patients. Any deviation by the private sector from 
the standardized practices of TB care would eventually defeat the 
bigger public health goals. Thus, the private health sector especially 
in the developing world is a reality that cannot be overlooked at any 
cost especially because of the significant proportions of patients that 
are catered by it as well as the inability of the public sector to cater 
entirely to the needs of all sections of the population21. Moreover, the 
experience so far proves that the partnerships between the public and 
private sectors in TB control can be mutually complementary50. 
 
2.3.2 Engagement of non-NTP health sectors in TB control   
Globally, organized and systematic efforts to engaging the private 
health sector in TB control has been underway for more than the past 
two decades. These efforts, generally under the broad umbrella of 
‘Public-Private Mix (PPM)’ strategy, consist of various approaches 
to engage non-public health sector care providers in TB control 
programs23. In the area of PPM, WHO has been providing global 
leadership and technical assistance to the various initiatives that 
started as pilot projects in many countries where TB burden is high, 
and the private sector is a major player in health. Based on the 
experience gained in countries, WHO working together with the 




NTPs has developed various guidance documents and tools to 
effectively engage the non-public health sectors, especially the 
private sector in TB control42. A WHO-led global Working Group on 
PPM, established by the Stop TB Partnership's DOTS Expansion 
Working Group, is engaged in developing global policies on PPM 
and in assisting countries to develop and implement national policies 
and guidelines to engage all care providers43. Within the Working 
Group, there is PPM Core Group to guide the Subgroup activities51. 
International donors and technical partners have been supporting 
global and country level PPM initiatives. In the high TB-burden 
countries, there have been several successful PPM pilot projects since 
the second half of 1990 that started along with the reawakening of 
global TB control efforts with the dawn of DOTS strategy in the early 
90s41. The erstwhile Stop TB strategy had clearly stated its emphasis 
on the engagement of private health care providers43. In the current 
End TB Strategy, engagement of private care providers is listed as a 
component under the Pillar 2 - ‘Bold policies and supportive 
systems’3.  
 
In many countries, public sector organizations such as prisons, army, 
railways, ports and government-owned industries have their own 
network of health care facilities. Large numbers of TB patients are 
managed by these health care facilities owned by public sector 
undertakings that are outside the structure and control of general 
health services and NTP. For example, more than 10.35 million 
people are held in penal institutions throughout the world according 
to the latest edition of the World Prison Population List52. The world 




prison population rate, based on United Nations estimates of national 
population levels, is 144 per 100,000. Since the year 2000 the total 
world prison population has grown by almost 20%, which is slightly 
above the estimated 18% increase in the world’s general population 
over the same period52. The estimated prevalence of latent TB 
infection (LTBI) and active TB disease in prison systems are reported 
to be much higher than the average estimates in the general 
population, irrespective of the economic status and the population TB 
burden of the country53. Therefore, engagement of prisons in TB 
control programmes is of significant importance which will need 
prioritization and appropriate funding. Similar is the case of other 
public-sector organizations such as army or ports that cater to large 
numbers of patients.  
 
In summary, in many high TB burden countries, public and private 
health sectors operate as independent entities with limited formal 
interactions. The public health sector care providers, overall 
regulated by the governments, are expected to adhere to standardized 
practices in the implementation of the national disease control 
programmes, However, the private sector often functions outside the 
vigilance of regulatory or quality assurance mechanisms. The private 
sector is diverse with multiple players and is principally disorganized 
within it. Therefore, bigger initiatives from within the private sector 
to address TB as a public health programme cannot be expected. In 
addition, private sector mainly focuses on curative care and there will 
not be much interest to engage with public health services due to 
reasons such as lack of capacity and infrastructure limitations. 




Additionally, the private sector in general lack trust in the public 
sector due to reasons of social, moral and economic dimensions54. 
Weakening of capabilities and deterioration of quality of care in the 
public sector and inconsistency in delivering promises is also a reason 
for the private sector’s mistrust in the public sector25. Nevertheless, 
the fact remains that the private sector caters to at least 40% of the 
TB cases with unknown quality of care. Therefore, it is imperative 
for the TB control programmes to establish public-private 
partnerships to impart and ensure quality of care for patients who seek 
care from the private sector.  
 
2.4 TB Control and PPM in India 
 
2.4.1 India as a case study  
India is chosen as a case study due to the following reasons: (1) India 
has the highest number of incident TB cases (2) Of the 2.8 million 
estimated incident cases in 2015, around 1.1 million cases were not 
notified to the national programme (3) Vast majority of these 
‘missing’ cases seek care from the private health sector that don’t 
notify the cases to the national programme (4) India has one of the 
biggest and diverse private health sectors in the world (5) India was 
one of the first countries where the national TB control programme 
made efforts to engage the private health sector in TB control through 
PPM approaches (6) Ensuring standardized care for TB in the private 
health sector is crucial to end the TB epidemic in India (7) Ending the 
global TB epidemic is heavily dependent on the progress in TB 




control in India where estimated 27% of the global incident TB cases 
are estimated to occur.       
 
2.4.2 Health care system in India 
India follows a federal system of government which has divided the 
areas of governance and operations between the national and state 
governments. Health is a state subject which means the primary 
responsibility to provide quality health care services to the people lies 
with State Governments55. In addition, the state governments 
organize and maintain the infrastructure including staff of the health 
care facilities owned by the state government. The national 
government is responsible for implementation of national 
programmes55.  
 
The health sector in India can be broadly divided into public sector 
and non-public sector. The public sector can be again subdivided into 
two; those run by the state government’s ministry of health and those 
run by the national government’s ministry of health/other public-
sector undertakings. The ministry of health in a state will usually have 
three categories, namely, the Directorate of Health Services, the 
Directorate of Medical Education and the Directorate of systems of 
healing other than modern medicine. Based on the national design, 
State governments run health care facilities that are expected to 
provide free care and services30. The Directorate of health services 
manages the state level network of health care facilities that provide 
primary health and preventive services with curative care usually up 
to secondary levels. Directorate of medical education, through the 




medical colleges, oversees medical education as well as curative 
health care mostly at tertiary level. The medical education is also 
regulated by the national medical council of India that gives 
recognition to the colleges and in maintaining standards of medical 
education. Currently there are 474 medical colleges in the country 56. 
The government department that takes care of systems of healing 
other than modern medicine is broadly known as AYUSH (Ayurveda, 
Yoga, Unani, Siddha, Homeopathy, Naturopathy). There are health 
care facilities owned by public sector organizations under the central 
government or other national public-sector undertakings that provide 
health services to specified populations. For example, the Central 
Government Health Scheme (CGHS) under the national Ministry of 
Health provides health care to the central government employees, 
pensioners and their dependents. Similarly, public sector 
undertakings, for example; Railways, Ports, Prisons and Army, have 
their own health care services to take care of their employees and 
dependents. Employees State Insurance Corporation manages a self-
financing social security and health insurance scheme for Indian 
workers belonging to lower income groups26. 
 
The health care providers owned by the Ministries of Health (MoH) 
or other government organizations are considered as public-sector 
entities. Non-public health sector can be broadly divided into private 
sector, NGO sector, corporate sector and informal care providers. The 
private health care sector comprises the entire spectrum of providers 
ranging from individual doctors in their consultation rooms to 
secondary and tertiary care hospitals. Corporate Industries also 




provide health care to their workers and dependents through their 
health care facilities of varying sizes. There are health care providers 
under NGOs that usually operate as non-profit establishments or 
charity missions especially in the areas where public sector care is not 
easily available. NGO sector also has primary, secondary and tertiary 
level health care facilities. The different types of heath care providers 
in India can be summarized as shown in Table 1.  
 
Table 1. 
Types of health care providers in India 
Public Sector (Government) Non-Public Sector 





1. Directorate of Health 
(primary health)  
2. Directorate of 
Medical Education 
(Medical Colleges)  








Health Scheme  
2. Railways  
3. Employees’ State 
Insurance 
4. Mining, Coal, 
Steel, Ports, 
Prisons, Armed 
Forces   














Source: Technical and Operational Guidelines for tuberculosis control in 
India 2016, Revised National Tuberculosis Control Programme, Ministry 
of Health and Family Welfare, Government of India 
 




The public health care facilities in rural areas of India have been 
developed as a three-tier system (Table 2) which consists Sub Centres 
(SC), Primary Health Centres (PHC) and Community Health Centres 
(CHC); each type serving a defined population. These are established 
and maintained by the state governments as per national guidelines. 
PHC is conceived as a basic health unit to provide an integrated 
curative and preventive health care to the rural population as close to 
the people as possible, with emphasis on preventive and promotive 
aspects of health care57. PHC is the first point to meet a qualified 
doctor of the public sector in rural areas for those who directly report 
or are referred from SCs for curative, preventive and promotive 
health care. A typical PHC covers a population of 20 000 in hilly, 





Health care infrastructure in  








Sub Centre 5,000 3,000 





Source: Rural Health Statistics, Government of India Ministry of Health and 
Family Welfare Statistics Division 2014-15. 





National disease control programmes, including TB control 
programme, are implemented mostly through the PHCs. CHCs are 
for a population of 80,000 to 120,000 each of which serves as a 
referral centre for 4 PHCs. The SC is the most peripheral and first 
contact point between the primary health care system and the 
community which is meant for a population of 3000-5000. Each Sub 
Centre is required to be manned by at least one auxiliary nurse 
midwife / female health worker and one male health worker. As on 
31st March 2015, there were 25 308 PHCs, 153 655 SCs, and 5396 
CHCs in the country59. 
  
2.4.3 Health system constraints 
The government of India in its 12th five-year plan (2012-17) states 
that the health system in India suffers from several weaknesses53. As 
depicted in the plan, the availability of health care services from the 
public and private sectors taken together is inadequate. At the start of 
the 11th five-year plan, the number of doctors per hundred thousand 
population was only 45 against a desired number of 85. The quality 
of healthcare varies considerably in both the public and private 
sectors. In addition, many practitioners in the private sector don’t 
possess the required qualifications to treat patients. Regulatory 
standards for private hospitals are either inadequately defined or 
ineffectively enforced. Affordability of health care is a serious issue 
faced by large proportion of the population. Absence of an extensive 
and adequately funded public health service forces large numbers of 
people to suffer from heavy out-of-pocket expenditures on services 




sought from the private sector. This results in considerable financial 
burden on families during periods of major illnesses. The 12th five-
year plan also foresees further increase in health care costs with rising 
life expectancy, as larger proportion of the population would become 
vulnerable to NCDs requiring expensive chronic treatments. India 
would therefore face health problems reflecting the dual burden of 
communicable diseases and NCDs. Total expenditure on health care 
in India, taking both public, private and household out of pocket 
expenditure, was about 4.1 per cent of Gross Domestic Product in 
2008–09. However, the public expenditure on health was only about 
27 per cent of the total, which is very low by any standard29.  
 
As discussed in Chapter 1, there has been a steady weakening of the 
public health sector over the years. This resulted principally from the 
reduction in the allocation of resources to public health facilities and 
the inability of the public sector to cope with the increasing demand 
of health care. In addition, while the SCs, PHCs and CHCs have 
increased in number in 2014-15, the current numbers are not 
sufficient to meet their population norm59. In addition, doctors and 
other support staff posted in the PHCs in rural areas often may not 
live in their place of posting. Absenteeism of staff and limited hours 
of services at the health centres are also a problem. The services of 
the health care staff are often limited to the days of their visit and the 
hours when the facility is open. This poses barriers to the optimal 
utilization of the government health care services especially in rural 
areas. At the same time, as most of the private medical practitioners 
live in the places they work, they are easily accessible at the 




convenience of patients. Studies by Bhat show that the doctors at the 
PHCs don’t get enough time to spend with each patient due to their 
higher patient volumes6.  
 
2.4.4 Private health sector in India  
The private health sector providers in India vary widely in their size, 
location, package of service delivery, socioeconomic groups they 
serve and several other characteristics. Private sector also includes 
providers practising various systems of medicine that can be broadly 
classified into modern medicine, AYUSH, paramedics and informal 
providers30. Paramedics are those who are trained to support some 
specific aspects of health care based on the advice of physicians and 
who are not expected to treat patients independently. Informal care 
providers include traditional healers or unqualified care providers 
who possess no formal training. 
 
Evidence from surveys of the informal sector by the National Sample 
Survey Organization (NSSO) showed that there were an estimated 1 
million private health care providers in India in the year 2010-1160. 
Seventy-two percent of all health care enterprises are small Own-
Account-Enterprises (OAEs), which are individual or household - run 
business providing out-patient services without hiring a worker on a 
regular basis60. The remaining 28% is composed of medical 
establishments like private hospitals or clinics. Among the one 
million enterprises, only about 50% are in rural areas and the 
remaining are found in urban areas while close to 70% of Indian 
population lives in rural areas60,61. Similarly, eighty per cent of the 




OAEs were located at villages whereas most of the establishments 
were in the urban areas. In ten years between 2000-01 and 2010-11, 
the share of enterprises engaged in hospital activities has increased 
significantly (Figure 1). The number of establishments engaged in 
hospital activities had more than doubled during the same period60. 
The trend shows that new establishments have been coming up 
mostly in the urban areas while the number of OAEs have been going 
down. This indicates that there is a rapid transformation towards 
organized forms of business growing in urban areas while the OAEs 
are declining in number60. The distribution of health care providers 
by main activity is given in Table 3. Based on the activities, National 
Industrial Classification has categorized health care into six sub 
categories. About two third of these enterprises are either hospitals or 
medical care facilities practising modern systems of medicine while 
over one-fifth of all enterprises are engaged in practising AYUSH.  
A census conducted in 62 major cities on organized health care sector 
in 2012 revealed that 95 percent of the total hospital facilities were 
private hospitals60. These private facilities were heterogeneous in 
nature and it ranged from small nursing homes to big corporate 
hospitals. Among the different types of hospitals, private hospitals 
had a share of 71 per cent followed by the nursing homes with 24 per 
cent. Trusts and charitable (NGO) hospitals contributed to around 3 
percent and corporate hospitals 1 percent60.  
In India, private medical practitioners usually serve as the primary 
contacts for people when they fall sick7-10. Therefore, they are the 
providers of first line care for common illnesses and emergencies. 




These practitioners are usually linked to the specialists or higher-level 
care facilities to where they refer their patients when they are unable 
to handle the cases themselves. Because the specialists are less in 
number and they tend to base in towns, patients from villages 
ultimately come back to the local private medical practitioner for 
continued care. Among many, availability and proximity of the 
private medical practitioners are the major reasons for the patients to 
come back to private practitioners.  
 
Figure 1. 
Number of enterprises by type and location in India: 2000-01, 









Source: 57th, 63rd and 67th rounds of NSSO, India (Mukhopadhya, I., 
Selvaraj Sakthivel, & Sharma Sandeep. (2015). changing landscape of 
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0.6 1.2 3.6 15.5 14.9 18.8 
Medical and 
dental practices 
50.5 47.2 63.3 58.8 47.1 53.4 
AYUSH 
practitioners 
27.8 24.2 23.0 13.3 18.1 14.1 
Nursing and 
physiotherapy 
14.9 14.4 5.0 1.6 7.3 1.8 
Diagnostics/ 
Pathology 
1.3 2.3 2.4 9.3 11.3 9.9 
Others 4.9 10.7 2.5 1.6 1.3 1.8 
Total 100 100 100 100 100 100 
 
Source: 57th, 63rd and 67th rounds of NSSO, India (Mukhopadhya, I., 
Selvaraj Sakthivel, & Sharma Sandeep. (2015). Changing landscape of 
private health care providers in India: Implications for national level health 
policy.  
 
Usually, the private medical practitioners have lower patient load and 
they get more time to spend with their patients6. The private medical 
practitioners generally develop good rapport with the patients in the 
local community which positively influences the trust and therefore 




the utilization of services they provide. Studies show that most 
private practitioners have timing patterns that suit the needs of 
clients6 Private sector in India derives part of its appeal from the 
patients’ lack of trust, typically found in developing countries, in 
public health care facilities. Both the rich and the poor go to the 
private sector because of proximity, lack of long queues, convenient 
timing, friendly approach and availability of the service for longer 
hours of the day62. There is also a widespread notion that public-
sector drugs that are given free are of cheaper quality and are not 
effective. Poor people generally prefer the private sector, especially 
the informal sector, due to similar reasons. Private sector would 
comply with the interests and preferences as well as cultural 
perceptions of the people. For example, preference for injections 
among the villagers are entertained by informal practitioners. Giving 
intramuscular injections of analgesics, antihistamines, and 
intravenous drips of glucose and vitamins, often as placebo, are 
common in villages. These injections are often given on patients’ 
demand. Informal providers would give strong doses and mixture of 
many medicines and especially for shorter durations and even for a 
day or a single dose so that the patients can afford the price. There is 
also preference for herbal drugs in the community due to the 
perception that herbal products are safer, and the modern medicines 
are toxic. Private informal providers prescribe herbal medicines and 
medicines of indigenous systems along with modern medicine drugs 
to satisfy the demands of patients. These are some of the reasons for 
patients prefer private sector. In addition, surveys have clearly 




demonstrated that private sector is an important source of care even 
where public services are available15. 
 
2.4.5 TB epidemic and TB control in India  
India has the highest number of incident TB cases and accounts for 
27 per cent of the estimated 10.4 million global incident cases in 
20151. Revised National TB Control Programme (RNTCP) is one of 
the biggest national health programmes in the world. RNTCP, based 
on DOTS strategy, was initially implemented as pilot projects from 
1993. Following the success of the pilots, the national scale up started 
in 1997. RNTCP achieved 100 per cent geographic coverage of the 
country by 2006. The programme has over the years contributed to 
commendable improvements in the access for people to TB care 
services in the country. Nevertheless, RNTCP had realized from the 
beginning itself that the public sector alone could reach only a portion 
of patients and the remaining patients will continue to receive care 
from the non-public health care providers, mainly the private sector. 
Therefore, the programme, as early as in 1995 made efforts to 
encourage the private sector to collaborate with RNTCP26.  
 
2.4.6 Management of TB control programme within the public 
health sector   
National TB Control Programme is one of the oldest disease control 
programmes of India which started in 1962. With the national roll-
out of the DOTS strategy – based RNTCP in 1997, there were major 
revisions in the structure of the national programme at the national 
and subnational levels. Newer staff positions were created up to the 




peripheral levels dedicated for TB service. Important examples 
include the introduction of the positions of deputies to the National  
programme manager, State-level TB officers, creation of sub district 
level TB management unit with designated staff (e.g. Medical officer-
TB Control) and dedicated staff such as Senior TB supervisor and 
Senior TB Lab Supervisor for a population of 500,00030. There are 
peripheral staff namely TB Health Visitors for each 100,000 
population who are dedicated to support the treatment and follow up 
activities especially in urban areas63. In addition, through agreements 
with the related departments of social welfare, RNTCP received 
nationwide support from the workers at Anganwadi Centres (a type 
of rural mother and child care centre) to provide treatment 
supervision and follow up27. Anganwadi workers are part of the 
health system who, stationed at Anganwadi Centres, provide basic 
health care in Indian villages. They take care of health care activities 
which include contraceptive counseling and supply, nutrition 
education and supplementation, as well as pre-school care. There are 
1.34 million operational Anganwadi Centres in India as on December 
201464. These workers in the community provide treatment 
supervision and follow up during TB treatment27,65. Accredited Social 
Health Activists, selected from villages and trained to work as an 
interface between the community and the public health system, are 
also engaged in the community level activities to support TB 
patients27. RNTCP engages community volunteers and provides 
financial incentives to partly compensate for the time they spend for 
TB work. 





2.4.7 TB Control and the non-public health care sectors in India  
RNTCP in the early 90’s was originally designed for continued 
operations of the existing National TB control Programme with the 
revised approaches of the DOTS strategy implemented mainly 
through the public health services of the state governments. Though 
a central government-sponsored programme of significant vertical 
nature, the implementation of RNTCP below the district level was 
intended to be integrated with the primary health care services 
provided by the state governments. However, over the years, the 
primary health care services especially in the rural areas, where 
masses seek health care, have been facing increasing challenges 
especially due to weakening of public health and decreasing 
allocation of resources and the inability of the public systems to cope 
with the increasing demand of health care6. Bigger private sector 
health care providers like secondary and tertiary care hospitals have 
been growing substantially especially into the space created by the 
weakening public health sector and by promptly responding to the 
needs of the population. In the process, private sector over the period 
has become a major stakeholder that has partly replaced the public 
sector mainly in the provision of curative services. Consequently, the 
private health sector has been managing increasing proportions of 
patients that include large numbers of TB cases. Alongside the private 
sector, health care services have been developing extensively under 
the NGO sector, corporate sector industries and government 
departments other than the state government health services6. While 




people would benefit from the multitude of health care providers 
especially because of easy access and patient-friendly services, the 
complexity created as a spinoff in the implementation of national 
health programs is colossal. Compartmental way of functioning and 
impervious territories of control enjoyed by the individual 
government departments made it difficult for the RNTCP to get them 
adopt national programme guidelines. On the other hand, lack of 
regulatory mechanisms or failure to implement the existing 
regulatory instruments continue to pose tougher challenges to the 
engagement of private health sector in RNTCP 66,67.  
 
The ground-breaking study “Treatment of tuberculosis by private 
general practitioners in India’ published by Dr. Mukund Uplekar in 
1991 threw light on the unexpectedly low levels of awareness about 
drug treatment for TB patients among private medical practitioners in 
Mumbai city of India. While there were a few standard, efficient, 
recommended regimens, 100 private doctors in the study prescribed 
80 different regimens, most of which were both inappropriate and 
expensive16. A repeat study ‘Tuberculosis Management by Private 
Practitioners in Mumbai, India: Has Anything Changed in Two 
Decades?’ conducted after about 2 decades in 2010 found that little 
seemed to have changed over the years, with a vast majority of private 
practitioners unable to provide a correct prescription for treating TB. 
Only 6 of the 106 respondents wrote a prescription with a correct drug 
regimen; 106 doctors prescribed 63 different drug regimens17.  
 




Studies show that the private sector is the most preferred source of 
care even where public services are available10,15. Preference for the 
private medical practitioners is observed in the treatment of TB 
also68. However, there is no accurate information about the number 
of private care providers, their TB patient load and the quality of care 
provided to the TB patients that seek care from the private sector. In 
addition, studies in India have found that more than 75% of the 
private medical practitioners practice modern medicine whereas only 
11% of them had a formal degree in it69. This means that large 
numbers of private medical practitioners, who are not scientifically 
trained in modern medicine, are managing TB patients which would 
result in suboptimal quality of care. Delay in diagnosis, missed 
diagnosis, use of non-standard or inappropriate drug regimens, 
insufficient doses, treatment for inadequate durations and lack of 
mechanisms to ensure completion of full course of treatment are the 
major issues found in the management of TB in the private sector70-
72. Poor record keeping practices and failure to document treatment 
outcomes are also issues of concern in the private sector. Private 
sector in general has no systems to undertake public health 
responsibilities of TB treatment, for example, to visit the patients’ 
homes to screen household contacts, provide health education, 
monitor treatment, follow up laboratory tests, retrieve patients 
interrupting treatment and to organize community support73. 
 
2.4.8 History of public-private mix (PPM) in India under RNTCP 
In the initial years of the RNTCP, even before the concept of PPM 
was coined internationally, India had paid special attention to 




building collaborations with the health care providers. However, the 
journey has not been easy due to several historic and concurrent 
reasons. When the previous NTP of India was repackaged into 
RNTCP, the programme had adopted many approaches in the 
management of TB patients which were based on the essential 
principles of the underlying internationally recommended DOTS 
strategy. Many of these new approaches were different from the 
practices that had existed in the private sector for many decades. 
While the doctors working in the public health sector were bound to 
implement RNTCP as per the national guidelines, private 
practitioners challenged many of the policies especially by 
questioning its scientific validity, evidence base in the Indian context, 
feasibility and practicality. The important areas of conflicts and the 
issues raised by the private sector can be classified into four main 
groups namely 1) Scientific aspects 2) Patients’ confidentiality and 
stigma issues 3) Lack of trust in the government systems 4) Perceived 
additional burden to care providers.   
 
1) Disagreements on scientific aspects  
a. Smear microscopy: RNTCP policies insisted that sputum smear 
microscopy should be employed as the primary tool to diagnose 
pulmonary TB. National programme’s reasoning included the 
arguments that 1) laboratories, technicians and materials are widely 
available throughout the country especially through the network of 
PHCs 2) the test is easy to perform 3) the test is cheap and 4) the test 
is very specific. The private sector pointed out the disadvantages of 




smear microscopy; 1) the test has low sensitivity and therefore at least 
50% of the cases will be missed due to false negative results 2) private 
hospitals in general were routinely not performing microscopy 
diagnosis of TB 3) patients, when referred to public facilities for 
smear microscopy, had to stand in long queues to meet the doctor and 
the laboratory technician 4) test needed three sputum samples taken 
on two different days and the results were given usually on the third 
day forcing the patient to make multiple visits74.   
 
b. X-Ray as a primary diagnostic tool: RNTCP policy discouraged 
using X-Ray as a primary diagnostic tool because its high sensitivity 
with low specificity could result in a lot of false positive cases 
diagnosed and unnecessarily treated. RNTCP recommended X-Ray 
only as a tool in classifying a TB case as a smear negative pulmonary 
TB case. When the smear was initially negative, and the cough 
persisted after treatment with a full course of general antibiotics, 
patients were advised to have chest X-Ray done. If the X-Ray had 
shadows suggestive of TB, those patients were considered as smear 
negative pulmonary TB cases.  Private practitioners in general did not 
agree because they have been using X-Ray as a screening tool and if 
the X-Ray was suggestive of TB, they had advised other 
investigations to confirm TB. X-Ray was also used to assess the 
extent of the TB disease and as a follow up investigation to assess 
progress during treatment. In addition, X-Ray was used to diagnose 
many conditions other than TB.  
 




c. Other diagnostic tests: RNTCP also advised doctors to avoid 
unnecessary and expensive investigations such as CT scans unless it 
is clearly indicated for clinical management. The private practitioners 
held the opinion that they have been managing many cases other than 
TB which would need other investigations. For example, there could 
be other concomitant disease conditions which would need diagnosis 
as well as clinical staging. Therefore, private sector advocated for CT 
scans. The Ministry of Health and Family Welfare banned the use of 
serodiagnostic test kits for diagnosis of tuberculosis because of the 
inconsistent and improper test results leading to wrong 
diagnosis. Private practitioners wanted to use serodiagnostic test kits 
when they had diagnostic dilemma due to negative results in other 
investigations in a patient who was strongly suspected of having TB. 
  
d. Drug regimens: RNTCP initially had standard types of blister 
packs of drugs in three categories. In general, Category I for smear 
positive patients, Category II for patients on retreatment and 
Category III for smear negative or extra-pulmonary patients who 
were not seriously ill. These drugs were packed in patient-wise boxes 
for the entire duration of treatment (6 months for Category I and III 
and 8 months for Category II). The drugs were of standard doses and 
had to be consumed by the patients three times a week. However, the 
private sector was in disagreement with the fixed doses as it didn’t 
allow flexible doses for patients of different weight bands. Treatment 
with only 3 drugs in the Category III for non-severe cases of extra 
pulmonary or smear negative cases was another area of disagreement 




where the private sector advocated for at least four drugs. In addition, 
there were no blister packs available for pediatric cases initially. The 
private sector was also against the use of thrice weekly consumption 
of medicines instead of daily intake due to the fear that it was 
inadequate to cure the patients. RNTCP insisted that there was 
enough scientific evidence to prove effectiveness of thrice weekly 
regimen. Similarly, RNTCP was against empirical treatment when 
TB is only clinically suspected and not confirmed by laboratory tests. 
This was to prevent inappropriate or irrational use of anti-TB 
medicines, though many private practitioners continue to try 
empirical treatment68.  
 
2) Disagreement on issues related to patients’ confidentiality and 
stigma 
a. Supervised treatment: RNTCP insisted on directly observed 
treatment (DOT) where the patient must consume drugs in the 
presence of a treatment observer who can be a health facility staff, or 
a community volunteer identified by the RNTCP and agreeable to the 
patient. Provision of a treatment supervisor was opposed by the 
private sector alleging that this would affect confidentiality and 
prevent TB patients from seeking care from the private hospitals68.  
 
b. Patients’ home visit. RNTCP’s field staff were expected to make 
mandatory visits to the patient’s homes for initial health education 
and to establish rapport with the patients to reduce the risk of 
interruption of drug consumption as well as to make the retrieval 
easier if the patient interrupts treatment. Private sector was against 




this for fear of stigma attached to TB. For the same reasons, private 
sector objected to the follow up visits by TB field staff to counsel 
patients to visit laboratory for follow up tests.  
 
3) Issues related to lack of trust in the government systems  
a. Private sector in general didn’t trust quality of goods and services 
offered by the public sector. Therefore, the private medical 
practitioners were reluctant to take the risk of referring their patients 
to the public-sector facilities.  
 
b. Feedback from the public sector about referred patient: One of the 
major grievances raised by the private sector doctors, who had 
referred some of their patients to the public sector, was that they 
didn’t receive regular and prompt acknowledgment and feedback 
from the public sector. There were also concerns about the loss of 
patients to the public sector and therefore loss of revenue.  
 
4) Issues related to perceived additional burden on private care 
providers     
a. Reporting burden: Private sector was opposed to the registration of 
TB patients in the TB register which required collection of many 
details about each patient for cohort analysis as well as for monitoring 
and evaluation purposes. The participating health care facilities were 
expected to keep a variety of forms and registers to facilitate this 
process. The private sector considered this paper work and record 
keeping as additional burden which would also require extra 




manpower. The private sector also had the fear of interference by the 
TB staff in their clinical decisions.  
 
b. Patient follow up and retrieval. Private sector generally doesn’t 
have dedicated manpower for follow up with the patient or to retrieve 
patients if they interrupt consumption of drugs. The financial 
incentives offered by the RNTCP as per the national policy for 
ensuring treatment adherence didn’t seem to be attractive for the 
private sector.  
 
In India, the systems to monitor and control the practices of individual 
doctors is rather loosely implemented. Diagnostic tools and drugs are 
abundantly available in the market. The mechanisms to scrutinize the 
use of diagnostic tools or prescription of medicines by doctors do not 
systematically function. Therefore, it is practically not possible for 
RNTCP to ensure that the private sector also adopts the national 
policy or to control their practices. In addition, public sector doctors 
who engage in private practice after office hours often deviate from 
the national policies which is also not easy to be controlled by 
RNTCP.  
 
2.4.9 The role of the Indian Medical Association 
In this background comes the importance of the Indian medical 
association (IMA), the umbrella organization of the medical 
practitioners of India. With its branches in all the 29 States and Union 
Territories of the country, IMA has over 250 000 doctors as its 
members through more than 1650 local branches spread over the 




country75. IMA in the initial years opposed RNTCP declaring that the 
program is not in the best interests of the country and that the 
programme would create major dents in the TB control 
accomplishments of India. IMA’s opposition to RNTCP gained wide 
dissemination especially among doctors through its publications and 
other forums. It was inevitable for RNTCP to take IMA into 
confidence and use it to reach private doctors and community at large 
to address undesired propaganda about RNTCP. Over the years, the 
partnership between RNTCP and IMA grew progressively and 
culminated in a national project funded by The Global Fund. The role 
of IMA in RNTCP is better expressed in Chapter 5.        
 
Since the initial years itself, RNTCP has been making efforts to 
engage NGOs that had health care facilities as well as private health 
care providers. Engagement of Mahavir Hospital, Hyderabad in 1995 
and the Ramakrishna Mission hospital, New Delhi in 1997 were the 
earliest examples of large-scale partnerships with non-public care 
providers. In addition to the clinical services provided to the patients, 
these facilities were identified as the headquarters of the sub-district 
level RNTCP activities with the responsibility of supervising and 
coordinating with the health care facilities engaged in RNTCP 31. 
After these, gradually, many models of PPM that engaged private 
hospitals came up; the major projects were in Delhi, Kannur, Kollam, 
Mumbai, Pune, Thane and Tea Gardens of the North-East26,76,77.  
 
Using the experience gained from the collaborations with NGOs and 
the private sector, RNTCP published guidelines for the participation 




of the NGOs (in 2001) and private practitioners (in 2002)26. These 
guidelines provided the opportunity for many NGOs and private 
practitioners to formally collaborate with the RNTCP. There were 
different ‘schemes’ available in the guidelines providing specific 
framework for the provision of the RNTCP-approved services, based 
on the capacity of the provider. Signing of a ‘Memorandum of 
Understanding’ between the District TB Control authorities and the 
health care provider made the partnership formal. Health care 
providers engaged through the schemes were eligible for financial 
assistance as a compensation for their time spent in carrying out 
RNTCP activities26.  
 
As the RNTCP gradually expanded in its geographical coverage, 
newer initiatives in general were experimented by more districts in 
various parts of the country. These PPM initiatives demonstrated 
increased case notifications and higher rates of treatment success9,78. 
Economic evaluations undertaken on PPM sites in Hyderabad, New 
Delhi and Bangalore revealed that the cost per patient cured to the 
society was slightly lower in PPM sites compared to RNTCP. The 
studies concluded that PPM was cost-effective and reduced the 
financial burden on the patients as well as the society79-81.  
 
RNTCP took systematic efforts to engage public sector organizations 
namely Employees State Insurance (ESI), Central government Health 
Services and the ministries of Railways, Defense, Prisons, Steel, 
Coal, Mines, Petroleum & Natural Gas, Shipping, Power and 
Chemicals & Fertilizers which resulted in respective organizations 




sending directives to their own health care facilities to adopt the 
RNTCP strategy and notify the patients to RNTCP26. RNTCP has 
also been interacting with the large corporate houses and advocating 
for adoption of RNTCP policies and guidelines in their health care 
facilities. 
 
The expansion of the RNTCP in the public sector was steadily 
progressing with the aim of achieving nationwide coverage by 2006. 
However, the PPM pilot projects remained scattered and isolated 
thereby covering only marginal percentages of the population that 
needed service. The programme noticed that the case notification 
rates remained low especially in large urban areas with high density 
of population and high TB incidence. Large numbers of private health 
care providers of variable sizes in urban areas failed to diagnose and 
treat a lot of TB patients. As a response to this situation, RNTCP 
decided to implement urban TB project in selected cities.   
 
RNTCP has been periodically updating PPM tools and encouraging 
initiatives to experiment newer PPM approaches. In addition, many 
bold and unprecedented steps were taken in the past few years such 
as declaring TB as a disease requiring mandatory notification, 
developing a case-based web-based notification system which can be 
accessed by the private health care providers to notify the cases, 
developing the Standards for TB Care in India (STCI), banning the 
of use of certain unreliable commercial serological tests, and 
controlling over-the-counter sale of TB antibiotics. Moreover, the 
program started providing drug regimens for daily consumption 




replacing the thrice-weekly regimen of RNTCP. In the area of PPM 
also, RNTCP is committed to Universal access to TB care and the 
latest technical and Operational Guidelines published in 2016 
envisions a broader public-private partnership in the place of PPM82. 
RNTCP has also recently published its National Strategic Plan (NSP) 
for 2017-23 where PPM is discussed in the backdrop of the success 
of recent experiments such as online case notification, public-private 
interface agency (PPIA) and application of newer Information and 
Communication Technology platforms.  
 
2.4.10 Public private interface agencies (PPIA)  
Despite the success of pilot models to engage the private sector, the 
efforts of RNTCP to replicate or expand these models didn’t achieve 
considerable success. However, there were good components of these 
models that the programme had identified as potential strategies for 
improvising newer approaches. The concept of interface agencies 
came up in this process. An early example of a successful interface 
agency was ‘Mahavir’ hospital in Hyderabad that worked between 
the public and private sectors. IMA played the role of interface 
agency in the Delhi, Kannur and Kollam models in Kerala and in the 
scale-up of the Kerala model into a national initiative funded by The 
Global Fund. WHO also demonstrated the usefulness of an interface 
agency in the intensified urban TB PPM projects26.  
 
Learning from the various interface mechanisms, RNTCP decided to 
formally establish Public Private Interface Agencies (PPIA) to 
facilitate engagement of the private sector. RNTCP accepted it as a 




strategy in the NSP 2012-1727. PPIA is conceived as an agency that 
is available and capable of functioning as an interface agency which 
will be acceptable to both the public and private providers. Though 
initial pilots are being funded by donors, RNTCP would eventually 
be able to find sustainable mechanisms and resources to establish and 
fund the interface agencies. The PPIA will be ideal to be implemented 
in settings where the TB burden is very high, for example, densely 
populated cities and slums where many TB patients receive care from 
private sector but are not notified to RNTCP. PPIA is perceived to be 
appropriate where the public sector is strong and committed to engage 
the private sector. PPIAs are broadly bound by the policies of the 
national programme and they are expected to align the private sector 
with the national program guidelines and the STCI. PPIAs work 
largely under RNTCP’s supervision especially by the local 
functionaries. PPIAs follow the overall Monitoring and Evaluation 
guidelines of the programme and the data is collected on a mutually 
agreed framework and is shared with the programme. RNTCP and 
donors undertake supervisory visits and evaluation missions in 
addition to audits of the PPIA activities to ensure implementation in 
broader alignment with the RNTCP. PPIA is discussed in more detail 
in chapter 7. 
 
2.5 Conclusion  
TB, despite being a curable disease, continues to be a major global 
public health problem that claims millions of lives globally. 
Accelerated emergence of MDR-TB and HIV coinfection add to the 




impediments. Social determinants also contribute to TB making the 
poor more vulnerable. Despite the concerted efforts to control TB 
based on global strategies of WHO, at least 40% of the 10.4 million 
estimated TB cases are not notified to the NTPs. Delayed diagnosis 
and non-standard treatment received by patients who access care 
from the private health providers further complicate TB control by 
increasing the period of infectiousness, likelihood of developing 
MDR-TB and the chances of death. Experience of several pilot 
projects in engaging the non-public health sectors especially the 
private sector led to the development and frequent adaptations of 
WHO’s PPM strategy. PPM strategy, funded by international and 
domestic donors, has been guiding the PPM efforts in relevant 
countries. Though the implementation of PPM has been underway for 
about two decades, overall, global TB control is yet to experience 
significantly higher rates of case notification, let alone the impact in 
terms of reducing TB incidence and mortality. Weakening of the 
public health sector in many high TB-burden countries further 
contributes to the worsening of the situation. India, the country with 
the highest number of incident cases globally, has been facing many 
challenges due to the disengagement of the private health sector in 
RNTCP. In the initial years, RNTCP faced opposition from the 
private sector. Due to these reasons, PPM projects in India also 
witnessed modest results until the new PPI model that demonstrated 
unprecedented success in terms of TB case notification. While the 
WHO’s End TB Strategy has very ambitious targets, the global TB 
community and PPM advocates are struggling to find an appropriate 




and effective solution to the present situation of 40% of the TB cases 
missing notification and the accelerated emergence of MDR-TB 



































Improving Tuberculosis Control through 










*Dewan, P. K., Lal, S. S., Lonnroth, K., Wares, F., Uplekar, 
M., Sahu, S., Granich, R. & Chauhan, L. S. Improving 
tuberculosis control through public-private collaboration in 





















Chapter 3: Improving TB control through public-private 






More cases of tuberculosis occur in India than in any other country in 
the world. An estimated 1.79 million new cases of tuberculosis and 
352 000 tuberculosis related deaths occurred in 2003, representing 
one fifth of the global burden of incident cases of tuberculosis and 
mortality83. The Indian Revised National Tuberculosis Control 
Programme began large scale nationwide implementation of the 
World Health Organization’s global tuberculosis control strategy 
(DOTS) in 1998 and has since expanded rapidly. Country-wide 
coverage is anticipated by April 2006. However, almost half of 
patients with tuberculosis in India may initially seek help from the 
private healthcare sectors, where diagnosis, treatment, and reporting 
practices often do not meet national or international standards for 
tuberculosis9,71,84. Subsequent delays in diagnosis and inadequate 
treatment may result in extended infectiousness, acquired drug 
resistance, treatment failure, and high rates of relapse—all of which 
may impair efforts for tuberculosis control in India. Collaborations 
between the public and private health sectors, or public-private mix, 
may be an important solution. Public-private mix has been defined by 
WHO as strategies that link all healthcare entities within the private 
and public sectors (including health providers in other governmental 
ministries) to national tuberculosis programmes for expansion of 
DOTS activities85. Published reports of public-private mix projects 
indicate that the approach is feasible and effective, but previous 
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evaluations are largely limited to local and individual experiences 
13,50,86,87 India has the largest collection of such experiences of public-
private mix, few of which to date have been reported88-91. We 
describe the effect of a series of pilot public-private mix projects in 
India on case notification of tuberculosis and treatment outcomes and 
discuss the potential role of public-private mix in improving 
tuberculosis control in India. 
 
3.2 Methods 
After early experiences showed the potential value of public-private 
mix activities88,92, the Indian Revised National Tuberculosis Control 
Programme developed formal guidelines to help local programmes 
structure collaborations with private healthcare providers and non-
governmental organizations93,94. These guidelines offered a diverse 
group of plans for the community of private providers, with options 
to participate in the referral, diagnosis, or treatment of patients with 
tuberculosis. The Indian tuberculosis programme also made financial 
incentives available for local programmes to distribute to cooperating 
providers, although these incentives were not always used. For our 
review we included all collaborations between the Indian Revised 
National Tuberculosis Control Programme and private health 
providers listed in the programme’s surveillance records. To allow 
focus on private practitioners and nongovernmental organizations, 
we excluded collaborations with medical colleges and government 
health facilities outside the authority of the Indian ministry of 
health95. We reviewed only collaborations with non-governmental 
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organizations in which tuberculosis care was delivered to an area with 
a population of at least 500 000. 
 
For each project the evaluation period was the time frame for which 
case notification or treatment data were available. These data were 
collected for each project site in quarterly (three month) increments 
from the Indian tuberculosis programme surveillance records and 
WHO public-private mix project evaluation reports. If available, we 
also collected project area case notification data from the Indian 
tuberculosis programme before the introduction of a public-private 
mix project. In some areas data on tuberculosis surveillance before 
the start of a public-private mix project were not available because 
projects were started from the onset of expansion of the Indian 
tuberculosis programme into the region. Since patients who are 
positive for acid fast bacilli on the basis of a sputum smear test are 
generally considered to be the main source of Mycobacterium 
tuberculosis transmission, we limited data collection to new cases 
whose sputum tested positive for acid fast bacilli. We defined a 
private sector notified patient as a patient diagnosed as having 
tuberculosis or referred by the private health sector, who was 
subsequently recorded (registered) by the Indian tuberculosis 
programme as a tuberculosis case. All other patients registered as 
having tuberculosis were defined as public sector notified patients. 
We defined private provider administered DOT as the administration 
of directly observed antituberculosis treatment to a patient registered 
as having tuberculosis by a private health provider (including 
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community volunteers supervised by private providers). Public sector 
administered DOT was defined as the administration of directly 
observed antituberculosis treatment to a patient registered as having 
tuberculosis by the public sector tuberculosis programme. We used 
standard WHO definitions for treatment outcomes96. A treatment 
success was defined as a new patient with sputum positive for acid 
fast bacilli who achieved cure or completed treatment. For each 
public-private mix project we calculated quarterly case notification 
rates by dividing the number of new case notifications of sputum 
positive for acid fast bacilli by the estimated population of the project 
area. To calculate the mean annual case notification rate for each 
project, quarterly rates were multiplied by 4 and averaged. Population 
estimates were taken from the 2001 census, or local government 
estimates if census data were unavailable. 
 
3.3 Results 
As of February 2004, 24 public-private mix projects met our 
inclusion criteria (see bmj.com), and we were able to collect data 
from 14 (58%) of the 24 projects (table 1)—six of eight (75%) 
collaborations with private practitioners, one of five (20%) 
collaborations with large corporate based practitioners, and seven of 
11 (64%) collaborations with large non-governmental organizations. 
In all projects, the Indian tuberculosis programme provided training 
for private providers to synchronise laboratory, diagnostic, and 
treatment practices with national guidelines. Costs of training were 
uniformly borne by local or state tuberculosis programmes. The 
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public-private mix projects used a variety of methods to link the 
Indian tuberculosis programme and private providers. 
 
Projects in Kannur and Kollam (Kerala) provided training and 
support for private laboratories and encouraged referral of patients 
with sputum smears positive for acid fast bacilli to public sector 
facilities for treatment78. Other projects relied on private providers to 
refer patients with suspected tuberculosis to public sector facilities 
for smear microscopy. In 10 (71%) of the 14 reviewed projects, 
private laboratories provided free smear microscopy, and the Indian 
tuberculosis programme partially reimbursed these laboratories by 
providing free slides and reagents. Professional societies, such as the 
Indian Medical Association, were also essential partners in bringing 
together public and private providers. Although patients were 
generally referred to the public sector for treatment, private providers 
sometimes acted as treatment providers. Treatment providers were 
responsible for administering directly observed treatment regimens 
(intermittent dosing, three times a week) supplied by the Indian 
tuberculosis programme. Staff of the Indian tuberculosis programme 
routinely supervised all treatment providers, and programme staff 
were responsible for attempts to restart tuberculosis treatment among 
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3.3.1 Contribution of public-private mix projects to case 
notification under DOTS 
The six public-private mix projects that primarily involved private 
practitioners were evaluated for a median of 18 months (range 15-30 
months). During this time, 10 985 new cases of tuberculosis on the 
basis of sputum smears positive for acid fast bacilli were reported in 
the project areas, of which 1631 (15%) were from the private sector 
(table 2). This represented 2-26% of case notifications for each of 
those individual projects. In each of the five projects involving 
private practitioners with data available from before and after 
implementation of a public-private mix project, the average quarterly 
number of positive case notifications increased by between 12% and 
98% after initiation of the project (figure).  
 
The eight public-private mix projects that involved collaborating 
partners from the corporate sector or nongovernmental organizations 
were evaluated for a median of 30 months (range 9-48 months). 
During this time 11 129 new cases positive for acid fast bacilli were 
notified in these areas. Since public-private mix projects were the sole 
source of Indian tuberculosis programme services here, all case 
notifications were attributed to the private sector. As local data for 
tuberculosis surveillance were not available before these projects, no 
comparison could be made between notification rates before the start 
of the project. 
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Tuberculosis Case Notification Rate Before and After 
Implementation of Public-Private Mix Project 
 
 
                     
Tuberculosis case notification rate before and after implementation of 
public-private mix project, for collaborations with private practitioners in 
India, 1999-2004. Projects represented are those with data available before 
implementation of public-private mix project 
3.3.2 Treatment outcomes with private provider administered 
directly observed treatment 
In nine (75%) of 12 public-private mix projects with available data 
on treatment outcome, private provider administered directly  
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observed treatment met or exceeded the Indian tuberculosis 
programme target of 85% treatment success (table 3). In two projects 
where treatment outcomes of public sector administered, and private 
provider administered directly observed treatment were compared, no 
significant differences were found 78,90.  
 
3.4 Discussion 
Collaboration between the Indian Revised National Tuberculosis 
Control Programme and private practitioners in India improved the 
case notification of tuberculosis while maintaining good treatment 
outcomes. Compared with historical surveillance data from the same 
project areas in a limited number of projects involving private 
practitioners, higher mean case notification rates were observed after 
implementation of the public-private mix project. Furthermore, 
limited data from non-governmental organizations and private 
industry medical services showed their ability to work with the Indian 
tuberculosis control programme and successfully diagnose and treat 
large numbers of patients with tuberculosis. A strong public sector 
tuberculosis control programme proved critical for provision of 
necessary advocacy, training, and supervision. These findings 
highlight the feasibility of building public-private collaborations and 
the considerable potential they hold for improving tuberculosis 
control in India.  
 
Concomitant efforts by the Indian tuberculosis programme to 
increase case detection through educational campaigns and 
improvement of public sector clinical services likely also played a 
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part. Indeed, national case notification rates from areas without 
public-private mix projects increased over the same general period as 
the evaluated projects, as would be expected in the setting of an 
expanding tuberculosis programme making active efforts to improve 
case detection. Even accounting for this limitation, to the Indian 
tuberculosis programme the benefits of public-private mix have 
proved sufficiently substantive to warrant inclusion into the overall 
Indian tuberculosis control strategy.  
 
Local tuberculosis programmes made substantial investments in the 
training and supervision of private providers. These investments may 
be justified, as recent economic analyses of public-private mix 
projects in Hyderabad and New Delhi support the perception that 
public-private mix is cost effective79. Furthermore, public-private 
mix reduces treatment costs for patients, as drugs are provided free 
of charge by the Indian tuberculosis programme. Programmes should, 
however, avoid diverting resources from public sector tuberculosis 
control for public-private mix, as any erosion in effectiveness from 
public sector tuberculosis control might neutralise the positive 
benefits of public-private mix activities.  
 
As a result of India’s active engagement with these public-private mix 
projects, the scene is set for a broad scale-up of public-private mix 
into routine practice for tuberculosis programmes. Policies and 
operational guidelines are in place to guide local programmes and 
private providers in implementing such public-private mix activities. 
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At the central government level, the Indian tuberculosis programme 
has pursued and formalised agreements with other large government 
institutions. The programme has also sponsored national workshops 
and developed specific procedures for collaboration with medical 
colleges, which treat large numbers of patients with tuberculosis and 
play a crucial part in the management of complicated cases95. 
Consensus recommendations have been developed for the 
management of tuberculosis in adults and children in partnership with 
professional societies, medical colleges, and international experts 
97,98. Urban areas tend to have large numbers of private providers and 
hence are being targeted for intensified public-private mix scale-up. 
Plans are under way for expansion and replication of strategies 
associated with sustained success. 
 
Tuberculosis programmes should recognise public-private mix as a 
public health intervention within their control mandate and engage 
both public and private healthcare providers to ensure equitable 
availability of services99. Providers who treat patients with 
tuberculosis should recognise that they have a responsibility to 
patients and their communities to adhere to standards of care, 
including prompt and accurate diagnosis, reporting, and effective 
treatment in accordance with DOTS100. Furthermore, coalitions with 
third party coordinating organizations may also promote ongoing 
involvement of the community; here public-private mix projects 
using third party interface organizations showed particularly large 
contributions to tuberculosis case detection.  
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What is already known on this topic 
India has almost one fifth of the world's burden of 
tuberculosis, and as many as half of patients with 
tuberculosis see private providers first 
 
Collaboration between public tuberculosis programmes 
and private healthcare sectors is an important strategy to 
ensure equitable access to quality tuberculosis diagnosis, 
treatment, and care 
What this study adds 
In a series of pilot projects in India, tuberculosis case 
notification improved after implementation of public-
private collaboration 
 
The Indian tuberculosis programme is scaling up efforts 
to collaborate with private providers and improve access 




The diverse public-private mix projects we describe highlight the 
feasibility and challenges of implementing public-private 
collaboration in tuberculosis control. Similarly, these public-private 
mix concepts could be applied to other diseases of public health 
importance, including HIV and malaria, which increasingly require 
linkages between governments, private providers, and community-
based organizations. The lessons of Indian public-private mix 
projects have been and continue to be instrumental in shaping the 
global agenda for public-private mix activities in DOTS expansion 
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and may accelerate the achievement of goals for global tuberculosis 
control.  
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In general, public health interventions are planned and designed by 
the public health sector. On the ground, however, significant numbers 
of patients seek care from a variety of care providers that are often 
alienated from organized public health programmes62. To address the 
non-involvement of different care providers, who are a thriving part 
of many health systems, the World Health Organization’s (WHO’s) 
Stop TB Strategy has made ‘engaging all care providers’ an essential 
component of global tuberculosis (TB) control101, using the public-
private mix (PPM) approach. PPM entails a public sector programme 
taking the leadership and providing support to facilitate systematic 
involvement of non-programme providers in TB control. The 
multiplicity of care providers is nowhere as starkly obvious as in 
India, where a plethora of different types of providers operate in 
large, parallel health care sectors (Table 1).  
 
A fifth of the global burden of incident TB cases occur in India; in 
2007, there were an estimated 3.3 million prevalent TB cases, almost 
2 million new cases and around 330 000 deaths due to TB102. 
Conscious of the ground realities, the Government of India’s Revised 
National Tuberculosis Control Programme (RNTCP), along with 
phased DOTS expansion, set up several PPM projects across the 
country. Private providers contributed on average 16% of cases, with 
a treatment success rate of 86%103. The cost-effectiveness of such 
PPM initiatives has been demonstrated79,81. To help scale-up PPM, 
the RNTCP developed national schemes to suit the capacity of 




different providers to contribute and that of the RNTCP to support 
them93. 
 
The RNTCP adopted a systems approach for phased scale-up of PPM 
activities that incorporated 1) local mapping of all care providers in a 
systematic manner; 2) prioritization of providers most likely to 
contribute to TB case notification and treatment; 3) agreement on the 
provider-specific task-mix; 4) setting up of a surveillance system to 
measure the contribution of the different providers; and 5) 
implementation and evaluation of the results of collaboration prior to 
further expansion.  
 
The objectives of PPM scale-up were to study the extent and nature 
of participation by the different health care provider categories and 
its effect on case notification and treatment success rates. This paper 
describes the processes and outcomes of this systems approach for 




The Central TB Division (CTD), the head office of the RNTCP within 
the Ministry of Health and Family Welfare, launched the intensified 
PPM scale-up project in 14 major urban districts* from July to 
September 2003, covering a total population of about 50 million 
(ranging from 600 000 to 6 million per city). The same national 
* Ahmedabad, Bangalore, Bhopal, Bhubaneswar, Chandigarh, Chennai, Delhi, 
Jaipur, Kolkata, Lucknow, Patna, Pune, Ranchi and Thiruvananthapuram. With 
the exception of Pune in Maharashtra, these are the capital cities of the 
respective major states in India. 
 




schemes for engagement with different providers were applied in 
these 14 cities as in the rest of the country. Additional human 
resources were provided in the form of one dedicated PPM medical 
consultant and two peripheral field supervisors per city, whose tasks 
were to assist the district programme managers by advocating for 
PPM, conducting situational analysis with mapping of the health care 
providers, developing action plans, facilitating reporting, sensitising 
and training providers, supervising and monitoring the activities and 
sending monthly progress reports to the CTD. 
 
Local action was backed by the advocacy activities of the CTD, 
which also started collaborative activities with the Indian Medical 
Association (IMA). A concise version of the RNTCP training module 
and an advocacy kit were developed for private medical practitioners. 
CTD then formally communicated with those non-Ministry of Health 
public sector agencies that had health care facilities. To facilitate the 
involvement of medical colleges, task forces were established at 
national and state level. The CTD, assisted by the WHO Country 
Office TB team, conducted regular meetings with the PPM 
consultants, organised training, undertook monitoring and frequent 
supervisory visits, and planned the evaluation. The roles and 
responsibilities to be assumed by the public and private health care 
providers were clearly identified and differentiated. Training, 
supervision, provision of quality-assured free drugs, supplies and 
honoraria, tracing of treatment defaulters and notification of TB cases 
remained the responsibility of the RNTCP, while referral, diagnosis, 




treatment of TB cases as per RNTCP policy, and providing 
information to the public sector about TB patients and treatment 
interruption were responsibilities assigned to the non-public health 
services that became involved with PPM93,104. Unique features of this 
intervention were the existence of national policy and broad 
guidelines, availability of training materials and focused advocacy 
and dialogue 93,104-106. Although no monetary incentives were given 
to the providers, they received increased social recognition and 
credibility due to improved documented treatment success of their 
patients.            
 
4.2.1 PPM surveillance system 
 
To monitor the contributions of the different providers to key TB 
control indicators in the 14 cities, the RNTCP developed a PPM-
focused surveillance system. Providers were grouped into six 
categories, each of which was assigned a code (Table 1). In addition 
to certain process indicators (Table 2), the system was designed to 
measure the extent of contributions to referral of TB suspects, TB 
diagnosis, notification of new smear-positive pulmonary TB (PTB) 











Table 1.  
Coding of different provider categories in  




State-level public sector health facilities (under the 
health department of the respective state 
governments, e.g., hospitals, health centres, 
dispensaries, etc.) 
G 
Public sector health facilities outside the purview of 
the state government department of health 
(ministries/departments under central government, 
e.g., railways, social insurance organization, etc.) 
M 
Medical college hospitals (under the medical 
education department: public and private medical 
colleges) 
C 
Corporate sector health facilities (health facilities 
attached to 
industries, factories, etc.) 
P 
Private health facilities (private-for-profit sector: 
individual practitioners or hospitals; practitioners 
of homeopathy and indigenous Indian systems of 
medicine and traditional healers; community 
volunteers engaged in supervision of treatment) 
N 
Voluntary NGOs (non-profit NGO sector: clinics, 
dispensaries, hospitals) 
PPM = public-private mix; NGO = non-governmental organization. 
 
The surveillance system used routine RNTCP recording and 
reporting formats with minor modifications to enable disaggregated 
data from the different provider categories to be captured. The 
laboratory request form for sputum examination was used for non-
programme providers to refer TB suspects to the RNTCP. When the 




TB suspect reported to a designated microscopy centre (DMC), the 
laboratory technician recorded the name of the referring provider on 
the laboratory form and the laboratory register. The RNTCP 
supervisors reviewed the laboratory register and treatment cards, and 
copied the appropriate provider code into the TB register to note the 
source of referral and place of treatment. Quarterly district reports 




4.3.1 Extent of participation by different providers  
Table 3 summarises the extent of involvement of the different 
provider categories. The majority of the H, G, M, and N sector 
facilities were involved in some activity (referral, diagnosis or 
treatment). The number of cases notified per staff member trained 
was much higher for H and M providers than for the other categories, 
and was lowest for G and P. Although 15 740 providers were listed, 
only a small proportion expressed interest in undergoing training after 
the sensitization efforts by the RNTCP. 
 
4.3.2 Effect on overall case notification rate 
In the 14 cities, case notification rates for new smear-positive (NSP) 
cases and all new cases increased from 52 to 58 and from 146 to 171 
per 100 000 population, respectively. During the same period, in 
other cities of the country, the NSP case notification rate dropped 
slightly from 54 and returned to 54, while the notification rate for all 




new cases dropped from 136 to 132/100 000. Trends from 1999 to 
June 2007 are shown in Figure 1 
 
4.3.3 Contribution to case notification by different provider 
categories 
 
The contribution of the different provider categories to notification of 
NSP cases from April 2004, when data first became available, is 
shown in Figure 2. Health department facilities contributed on 
average 67% of the NSP cases during this period, medical colleges 
16%, private practitioners 6% and NGOs 7%, while other public 
providers and the corporate sector contributed only 3% and 1%, 
respectively. Assuming that one third of the cases from medical 
colleges were notified by private medical colleges, the private sector, 
including NGOs, contributed about 18% of all notified NSP cases. 
  




Table 2.  
PPM evaluation indicators 
Output indicators 
1. Referral of TB suspects:  
Contribution of the respective health care providers in 
referring TB suspects to RNTCP DMCs, as recorded in the 
laboratory registers. 
2. Diagnosis of all smear-positive PTB cases:  
Contribution of the respective health care providers to 
overall smear-positive PTB case diagnosis, measured by 
counting the number of smear-positive PTB cases diagnosed 
in DMCs located at the health facilities of the respective 
health providers. 
3. New smear-positive PTB case notification:  
Contribution (based on source of referral) of the respective 
health care providers to the notification (cases registered in 
the RNTCP) of new smear-positive PTB cases. 
4. DOT provision to TB patients: 
Contribution of the respective health care providers to DOT 
among patients treated under the RNTCP, as ascertained 
from the TB treatment registers. 
5. Treatment outcome disaggregated by the type of provider 
providing DOT. 
Process indicators 
1. Provider sensitization:  
Number of facilities listed, contacted and sensitized as a 
proportion of all providers listed. 
2. Training:  
Number trained as proportion of providers listed.  
3. Involvement of different PPM facilities: 
By formal or informal agreement, in various tasks such as 
referral, diagnosis (laboratory), treatment (DOT provision), 
and both (diagnosis + treatment). 
4. Supervision:  
Number of supervisory visits made to PPM partner facilities 
or sites by type of supervisor and supervised facility. 
 
PPM = public-private mix; TB = tuberculosis; RNTCP = Revised National 
Tuberculosis Control Programme; DMC = designated microscopy centers; 
PTB = pulmonary tuberculosis; DOT = directly observed treatment. 
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Figure 1  
Trend in case notification rates of NSP (A) and all new cases (B) 





The vertical line separates the periods before and after intensified PPM 
scale-up. Case notification/100 000 for 2007 annualized from quarter (Q) 










Figure 2.  
Contribution by different provider categories (see Table 1 for 
details) to case notification in the 14 cities         
 
           NSP = new smear-positive 
 
4.3.4 Inter-city differences 
Substantial variations were observed in case notification trends and 
contributions by the different providers across the 14 cities. In 
Bangalore, for example, there was a continued increase due to 
gradually increasing contributions by medical colleges and some 
increase in contribution by private practitioners (Figure 3). 
 
Some PPM sites achieved case notification rates that were above the 
national and state level figures. In the CTD records, certain common 
factors were identified in these sites, including strong RNTCP 
administration, evidenced by the district TB officer and other district 
and sub-district level key staff in place, adequate numbers of 
supervisory visits, appropriate use of resources and promptness in 




reporting. Similarly, the administration took a proactive role in 
initiating steps such as inviting partners for meetings, sending 
communications requesting them to become involved with the 
RNTCP and sensitising their key staff. The involvement of large non-
public health sector facilities, such as medical colleges, which cater 
to a significant percentage of the population, was also a common 
factor.  
 
4.3.5 Task-specific contributions by providers 
Contributions to referral, diagnosis, NSP case notification and 
treatment are shown in Figure 4. The H sector was the dominant 
contributor to all indicators. Medical colleges (M) were very active 
in identifying suspects and diagnosing patients, while they played 
only a minor role in treatment provision (4%). 
 
4.3.6 Effect on treatment outcomes 
 
Treatment outcomes for all cohorts combined from April 2004 to 
June 2007, disaggregated by treatment provider category, are 
summarised in Table 4. The treatment success rate was above the 
85% target for all sectors combined, and individually for the H, P and 
N sectors. Analysis of treatment outcome trends showed that, except 
for the medical colleges and corporate sector, high cure rates were 
maintained throughout the intervention period. The cure rate in 
medical colleges declined from 86.5% in 2004 to 67.3% in 2006, due 
to a new RNTCP policy decision to register TB cases admitted to 
medical college hospitals in the local TB registers even if the patients 
were residents of other districts. This resulted in a higher percentage 




of ‘transferred out’ patients. For the corporate sector, the number of 
cases was relatively small, and therefore a few ‘transferred out’ cases, 
as in the case of Ranchi, reduced the cure rate considerably. 
 
                      
     







Contribution by the different providers to referral, diagnosis, 
NSP case notification and treatment, 2004–2007 
 





It is evident that the systems approach to the phased scale-up of PPM 
activities—listing all care providers, sensitising a wide number with 
subsequent training of a selected group using standard training 
materials, and prioritising and engaging those who expressed an 
interest through appropriate schemes—was productive in the 14 
cities. Overall, the intensified PPM initiative was associated with a 
12% increase in notification of NSP cases in the 14 cities, with a high 
treatment success rate across all provider types. However, there were 
large variations between cities in relation to case notification trend, 




and the different types of providers varied in their involvement with 
the RNTCP across the different settings. However, we acknowledge 
the fact that populations visiting the various types of providers may 
have different TB prevalence rates. 
 
The public health sector remained the largest contributor to all 
indicators, and strong public-sector implementation was observed to 
be required for successful PPM activities in all sites. The finding that 
all providers who engaged in treatment provision had good treatment 
outcomes endorses the RNTCP policy of engaging RNTCP providers 
only if they can ensure directly observed treatment. As the medical 
colleges contributed a sizeable proportion of cases, the CTD focused 
on these and involved nearly all of them, particularly in the PPM sites. 
However, due to their large catchment areas and limited outreach 
capacity, medical colleges are less suitable for long-term ambulatory 
treatment. They have therefore been encouraged to send cases after 
diagnosis to other providers closer to the patients’ place of residence. 
 
The involvement of large numbers of small private providers (mostly 
single practitioners), each yielding a small number of cases, may not 
be as cost-effective as the involvement of large institutions such as 
medical colleges. However, the substantial contribution by private 




providers in some of the 14 cities shows great potential, as these 
represent the majority of health providers in most parts of India107. 
As private providers are commonly the first contact for people with 
TB, their involvement is of particular importance to reduce diagnostic 
delay and save costs for patients80. The low proportion of listed 
private providers who were involved (25% in referral and 14% in 
treatment) was mainly due to the large number of private practitioners 
generally. Despite sensitisation efforts targeting large numbers of 
private practitioners, only a small proportion expressed willingness 
to attend systematic, formal training and to participate in RNTCP 
activities. A strong, proactive RNTCP administration and the 
presence of a sizeable non-public health sector are understood to be 
important factors for establishing collaboration and thus notify more 
TB cases in PPM sites. Weak regulation, resulting in a private drug 
market that pushes anti-tuberculosis drugs through private medical 
practitioners, variable standards of health care provision by the 
private sector, and a lack of mechanisms for the certification and 
accreditation of private practitioners, are identified barriers to PPM 
implementation. According to the consensus understanding of the 
CTD, even within the RNTCP, at the peripheral level, there was a 
lack of interest and experience in dealing with other sectors and a lack 
of faith in their capacity. Similarly, within the private sector, a lack 
of faith in the public sector health programmes and a low priority for 
public health programmes worked against wider implementation of 
PPM activities73. Anecdotal evidence suggests that lack of political 
will at the district level of RNTCP leadership, coupled with 




reluctance from the private sector to collaborate for fear of losing 
patients, have been impediments to PPM. This aspect was not 
measured by the present study and there is scope for the RNTCP to 
explore it further. This study suggests that the decision as to whether 
and what type of providers should be engaged depends more on 
current delivery trends in a given location than on the type of 
provider. The proportion of TB notifications by provider appeared to 
be highly dependent on how predominant the type of provider was in 
the given city. At the same time, all types of providers were equally 
successful at treatment. This suggests that an important factor to 
consider while designing TB control programmes is where people 
currently receive care. This may be more important than other 
intrinsic provider characteristics. Systematic and continuous mapping 
of private providers by local health administrations would facilitate 
similar interventions for TB and even other diseases, and these results 
need to be shared with the broader health systems audience in 
addition to the narrower TB audience. The results and conclusions of 
this study could be instructive for other disease control programmes 




The different types of health care providers varied in their importance 
and level of involvement with the RNTCP across the country. The 
systems approach adopted by the RNTCP in the 14 major cities led 
to a 12% increase in NSP case notification, with relatively good 
treatment success rates across all providers. Many challenges and 




barriers remain to wide scale-up of PPM TB activities in India. The 
factors identified as leading to the success of the initiative have been 
used to inform the further development of RNTCP policy for the 
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5.1 Introduction  
Tuberculosis (TB) continues to be a major public health threat by 
claiming millions of lives each year. India has an estimated 2.8 
million new TB cases occurring annually which is 27% of the global 
incidence1. India’s national TB control programme (NTP) was 
established in 1962 under the Ministry of Health (MoH). A review by 
WHO held in 1992 concluded that NTP, despite thirty years of its 
existence, had not created any significant epidemiological impact on 
TB burden of the country108. Failure in meeting standards in diagnosis 
and treatment, low rates of treatment completion and lack of adequate 
documentation on treatment outcomes were reported as the major 
weaknesses. To address the weaknesses, Revised National TB 
Control Programme (RNTCP), based on the principles of the WHO-
recommended Directly Observed Treatment, Short course 
chemotherapy (DOTS) strategy, was implemented in the country in 
1997108.  
 
In India, vast majority of qualified doctors, dispensaries and hospitals 
are in the private sector109. As a result, private health sector provides 
care to significant proportions of TB patients also15,60. About 60 to 
70% of TB patients in India first seek care from private health care 
providers8-10. There are close to one million qualified and licensed 
doctors in India, majority of whom work in the private sector 15,60. 
Private health care sector in India is very diverse and consists of 




multiple types of care providers that are largely disorganized and to 
a great extent unregulated46. While 70% of the Indian population live 
in rural areas, only a third of government doctors work in rural 
India110. Therefore, rural India is served mostly by private health care 
providers. Similarly, urban areas have higher numbers of private 
health care providers where the primary health care network of the 
government is not utilized by people as much as in rural areas110. 
Unlike the public health sector, private health sector in general lacks 
systems for ensuring adherence to the diagnostic algorithm designed 
by RNTCP for early and accurate diagnosis of TB cases. Quality of 
treatment also varies across private health sector providers due to lack 
of adherence to standardized treatment guidelines16,17. In addition, 
private health sector is typically not designed to perform public health 
actions for ensuring treatment adherence and to record treatment 
outcomes of TB patients. Due to these reasons, TB patients who seek 
care from the private health care providers would face inordinate 
delays in being promptly diagnosed70. Similarly, TB patients are 
likely to receive inappropriate, inadequate or interrupted treatment at 
private health care facilities8. While delayed diagnosis results in 
increased morbidity, mortality or spread of the disease in the 
community, suboptimal treatment can cause death of patients or 
accelerated generation and spread of mycobacterial resistance to TB 
drugs. Multidrug-resistant TB (MDR-TB) is more difficult and 
expensive to treat compared to drug-susceptible TB18,111. Whereas 
RNTCP achieves high treatment success rates for patients with drug-
susceptible TB, without standardized treatment and prompt follow 




up, treatment success in the private sector can be as low as 30%15. 
Considering the importance of private sector in health care, RNTCP 
since its inception, has been making efforts to engage private health 
care providers26. In this regard, the Central TB Division (CTD), 
RNTCP’s national programme management unit, sought assistance 
from the Indian Medical Association (IMA). IMA, a voluntary 
organization, is the professional association of the doctors practising 
modern system of medicine. IMA with its 1650 branches across the 
country has over 200 000 doctors as its members75. In the transition 
from NTP to RNTCP, while the basic diagnostic tools and drugs 
remained essentially the same, there has been repackaging of 
approaches in the diagnosis and treatment based on the principles of 
the DOTS strategy. However, the modern medicine practitioners in 
the private health care sector, in general, opposed RNTCP. This was 
a major reason for RNTCP to seek the help of IMA in engaging 
private health care providers. This article aims to bring to light the 
untold story of IMA’s engagement in TB control as a close partner of 
RNTCP. The article also touches upon the operational challenges that 
IMA faced in the process.  
 
The objectives of this paper are to study 1) the role of IMA in the 
engagement of private health care providers in TB control and what 
is its relevance and 2) the lessons for India and other countries to learn 
from the unique endeavor of engagement of medical professional 
associations in TB control. 
 




5.2 Methods  
We used standard WHO definitions as given in ‘Definitions and 
reporting framework for tuberculosis – 2013 revision (updated 
December 2014)112. Public-Private Mix (PPM) strategy became 
formalized by the establishment of PPM subgroup of the DOTS 
Expansion Working Group in 2000113. Therefore, the search for 
literature was for the period from 2000 to 2017. Though there are no 
peer-reviewed publications specifically on the processes of IMA’s 
PPM projects, information about IMA’s engagement is available in 
many publications of IMA, RNTCP, and other agencies or 
researchers. The contribution of IMA’s engagement as additional TB 
cases notified is reflected in some published articles. For our study, 
we considered available published articles on the collaborations 
between IMA and RNTCP, internal memos and policy documents.  
 
We reviewed the tuberculosis section of the WHO website to collect 
latest information on TB epidemiology, current TB control situation, 
policy guidelines and TB control data with focus on India114. We also 
searched ‘PPM Resources’ at WHO website115. WHO also publishes 
an annual report on global TB control the purpose of which is to 
provide an annual assessment of the global TB epidemic and the 
progress made in implementing the global TB control strategy. The 
latest WHO report published in 2017, which has used information and 
data from 2016, was reviewed1. We also gathered information from 
various documents available at the RNTCP’s website which includes 
programme guidelines, Technical and Operational Guidelines, 




National Strategic Plan and guidelines on the programmatic 
management of drug-resistant TB (PMDT) and TB/HIV116. We 
reviewed annual performance reports published by RNTCP which 
contain qualitative information as well as RNTCP’s annual 
performance data116. We collected information on IMA-PPM from 
peer-reviewed articles on PPM. We also looked at articles published 
by the journal of Indian Medical Association, peer-reviewed articles 
on other journals, and publications of organizations such as CTD, 
WHO, American Thoracic Society and the Global Fund. We 
conducted interviews with officials of IMA especially the ex - IMA 
national coordinator for RNTCP who was associated with RNTCP 
since 2000 by starting the first RNTCP-designated microscopy centre 
in the private health sector at his own hospital25. We also interviewed 
the erstwhile PPM advisor to IMA and a RNTCP consultant of 
IMA117,118. We held discussions with RNTCP’s key staff at CTD and 
in Kerala state119,120. We met many present and ex- RNTCP staff.  
 
We considered the projects that qualified as PPM as per WHO 
definition in which IMA was engaged115. We defined a project as 
IMA-PPM project where IMA formally collaborated with RNTCP. 
We used two tools namely ‘PubMed/MeSH’ and ‘Google Scholar’ 
for literature search. The search words used were Indian Medical 
Association AND TB, Indian Medical Association AND TB AND 
Public Private Mix, Indian Medical Association AND Public private 
mix, Indian Medical Association AND Revised National 
Tuberculosis Control Programme, Indian Medical Association AND 




Private sector AND TB, Indian Medical Association AND 
Tuberculosis. Only articles published in English were included. 
 
5.2.1 Online questionnaire survey  
An online questionnaire survey was also conducted as part of the 
study. A list of major reasons of opposition from private medical 
practitioners to RNTCP was created after discussions with selected 
experts in TB-PPM in India. The RNTCP policies and the major 
reasons for opposition grouped under four major categories namely 
diagnosis, treatment, patient-related and physician-related were 
listed. This list was produced based on the discussions with selected 
TB PPM experts of India which was validated by the online survey 
among PPM experts/stakeholders representing RNTCP functionaries 
at national and subnational levels, private health sector providers, 
technical agencies including WHO, donor agencies, academia, 
researchers, IMA, social activists and people affected by TB in India 
who have been directly associated with RNTCP and PPM121. These 
experts were selected from the pool of experts used by RNTCP in its 
various functions. Survey was sent to 28 experts and we received 21 
responses which gave a 75% response rate. The results were compiled 
and analyzed. (see Table 1) 
 
The survey clearly validated the reasons for opposition of the private 
sector to the policies of RNTCP. All except one reason received 
agreement by majority of the respondents. In the case of one reason 
(while RNTCP didn't advise sputum culture as a primary diagnostic 
test, private medical practitioners often wanted to use culture as a 




diagnostic/confirmatory test complementary to other tests), there was 
agreement from only 42% of the respondents. However, in this case, 
the percentage disagreed was 47% while 11% was not sure of the 
response.  
 
In addition to the issues shown in the table below, private medical 
practitioners had concerns about potential impact of RNTCP on their 
clientele which used to come out in private conversations with private 
medical practitioners118. This was mainly due to RNTCP’s insistence 
that services provided to presumptive as well as confirmed TB 
patients by private health care providers had to be as per the RNTCP 
guidelines and by using laboratory reagents and drugs supplied by the 
government which the private medical practitioners had to offer free 
of cost to the patients18,118. In addition, private medical 
practitioners  were expected to refer their patients to public health 
facilities whereas they had the fear of losing their clientele or their 
patients facing unfriendly treatment at public health facilities117,118. 
Private medical practitioners were also opposed to the supervision by 
the RNTCP staff. The main reasons for this were alleged policing and 
harassment by government staff and the reluctance of the private 
health sector to provide access for government staff to their own 
registers and records117,118. These concerns were not included in the 
survey because these were often not explicitly expressed by the 
private care providers. This information came from the in-depth 
interviews with some of the PPM experts117,118. This is the 
background where RNTCP decided to take the help of IMA to reach 
the private health sector. 






RNTCP policies and reasons 







RNTCP policies and reasons for 





Diagnosis-related issues  
One of the main reasons for private medical 
practitioners not preferring smear microscopy for 
diagnosing pulmonary TB was low sensitivity of the test  
55 
Multiple visits the patients had to make, long queues and 
unfriendly behaviour at public sector hospitals were 
some of the important reasons for the private medical 
practitioners’ lack of preference for sending their patients 
to public sector hospitals for doing smear microscopy  
95 
private medical practitioners opposed the restrictions by 
RNTCP on using X-Ray in the diagnosis of pulmonary 
TB as the private practitioners wanted to use X-ray to 
rule out conditions other than TB and for clinical 
assessment of the patient during treatment 
95 
While RNTCP didn't advise sputum culture as a primary 
diagnostic test, private medical practitioners 
often wanted to use culture as a diagnostic/confirmatory 
test complementary to other tests 
42 
Private medical practitioners preferred to use commercial 
serological tests for diagnosing TB RNTCP discouraged 
the use of these tests 
95 





While RNTCP insisted on using RNTCP-supplied drugs 
packed in patient-wise boxes for the entire duration of 
treatment of TB, private medical practitioners in general were 
not keen to use these drugs due to lack of trust in the quality of 
drugs provided by the government 
63 
While RNTCP insisted that patients had to be treated using one 
of the three categories of drugs supplied by RNTCP, private 
medical practitioners were not keen to use them as drugs of 
same doses had to be given to patients of a wide range of body 
weights which, they felt, could lead to under dosing or 
overdosing 
74 
While RNTCP advised 4 drugs for new and 5 drugs for re-
treatment patients (first line treatment), private medical 
practitioners often wanted to prescribe more drugs and not be 
limited to the RNTCP-recommended drug regimen 
94 
While RNTCP insisted on treatment of 6 months for new and 
8 months for re-treatment TB patients, private medical 
practitioners often wanted to prescribe drugs for longer 
durations 
68 
While RNTCP advised only 3 drugs for smear negative/Extra 
pulmonary TB cases, private medical practitioners in 
general preferred to use more drugs  
95 
While RNTCP drugs were to be consumed by patients only 
three days a week, private medical practitioners preferred daily 
drug consumption by their patients 
100 
While RNTCP strictly discouraged empirical treatment with 
anti-TB drugs and insisted that 'treatment had to be started only 
if TB was the diagnosis and once started, treatment had to be 
completed until the last dose', private medical practitioners 
wanted to try anti-TB drugs (when in doubt) for a few days and 
withdraw if there was no progress 
89 





While RNTCP insisted directly observed treatment (DOT) for 
TB patients, private medical practitioners in general were 
opposed to it due to concerns about patients’ confidentiality 
89 
While RNTCP insisted on smear microscopy as the follow up 
test to assess improvement and to confirm cure for pulmonary 
TB patients, private medical practitioners wanted to use X-ray 
and other tests for the same purpose 
89 
While RNTCP insisted on notifying all TB cases by 
designated government staff, private medical 
practitioners opposed it for confidentiality and stigma issues 
68 
While RNTCP insisted on patients’ home visit by health staff 
for initial health education and follow up, private medical 
practitioners opposed it for stigma and confidentiality issues 
74 
Physician-related issues 
While RNTCP held the view that completion of TB treatment 
by patients was the responsibility of the doctor who started 
anti-TB treatment, private medical practitioners didn't accept 
it due to lack of mechanisms for following up the patients until 
treatment completion 
95 
While RNTCP insisted in tracking and bringing back the 
patients when they interrupted TB treatment, it was not 
practical for private medical practitioners to do it as they had 
no mechanism to retrieve such patients 
100 
 
5.3 The process of partnership between RNTCP and IMA  
Initially, IMA was also skeptical about RNTCP’s claims as a better 
programme compared to the previous NTP25,117. In addition, IMA 
also had concerns about the private medical practitioners’ 
apprehensions about possible impact on their clientele that RNTCP 




would cause25,117. In the meantime, certain pilot PPM projects had 
come up in New Delhi (1999), Kannur (2000) and Kollam (2001) 
where local IMA units played a key role25,26,78. The New Delhi project 
relied on private health care providers to refer patients with suspected 
tuberculosis to public sector facilities for smear microscopy.  
 
By 2000, when Kerala, a state in the south of India, became the first 
state to achieve hundred per cent geographic coverage of RNTCP, 
CTD advised the state to systematically engage private health sector 
in TB control. Subsequently, Kerala state administration of RNTCP 
chose Kannur and Kollam districts as pilot districts for private health 
sector engagement.  
 
Kannur district developed a model based on a private laboratory 
surveillance network for sputum smear microscopy where free 
training and quality assurance supervision were provided by 
RNTCP78. The laboratories participated on a voluntary basis and there 
was no signed agreement between RNTCP and the laboratories. IMA 
played a major role in developing the model and the project had the 
advantage of the district TB officer (DTO) of Kannur officiating as 
the secretary of IMA’s Kannur branch. Sensitization workshops were 
held at IMA branch meetings. 
 
In Kollam district, RNTCP encouraged smaller private hospitals, 
clinics and individual practitioners to refer presumptive TB patients 
to RNTCP facilities and simultaneously supported relatively bigger 
private hospitals with laboratory facilities to set up RNTCP-




designated microscopy centres25,117. As PPM activities were slowly 
picking up in the whole district, Punalur, a sub district, was chosen 
for intensified PPM activities25,117. One of the reasons for picking 
Punalur was the presence of ‘Deen hospital’, a private facility, owned 
by Dr. Asokan RV, the then secretary of IMA in Kerala. Deen 
hospital was designated as a RNTCP-microscopy centre which, as per 
RNTCP’s basic criteria, had a physician, laboratory for sputum smear 
microscopy, laboratory technician, space to safely store RNTCP 
drugs, space with privacy for supervised drug consumption by TB 
patients, and staff to provide treatment supervision and counseling 
support to TB patients. RNTCP organized training of staff and 
provided laboratory consumables, anti-TB drugs and recording and 
reporting tools. A memorandum of understanding was signed 
between RNTCP and Deen hospital. Treatment supervision of the 
patients living in the neighborhood was agreed upon as the 
responsibility of the Deen hospital while RNTCP staff took care of 
health education, patient counseling, follow-up home-visits, 
recording of treatment progress and reporting of treatment outcomes 
of all patients25,26,117. The Director of Health Services of Kerala state 
inaugurated the Designated Microscopy Centre, which demonstrated 
political will of the government and RNTCP to partner with private 
health sector and IMA122.  
 
WHO’s Country Office in Delhi provided technical assistance to both 
Kannur and Kollam pilots through the WHO-medical consultants 
posted in Kerala. RNTCP showcased New Delhi, Kannur and Kollam 




models as earlier examples of PPM where IMA took a facilitator’s 
role by acting as an interface between RNTCP and the private health 
sector78,122,123. IMA forums and publications gave wide publicity to 
the project25,117.  
 
The results of PPM models in terms of increased TB case notification 
from the private health sector motivated IMA to further expand PPM 
to the entire state of Kerala based on the model developed in Kollam 
district which focused on training private medical practitioners and 
then designating them as a provider of RNTCP services. IMA thus 
trained around 1150 private medical practitioners using a funding 
organized by WHO India country office. Seeing the success of this 
expansion in Kerala state, CTD advised IMA to further expand the 
model to a few more states of India as a regional project which 
happened by 2005124. The repeated success in engaging private health 
care providers and notifying additional TB cases prompted CTD to 
develop a new project to further expand this model which received 
The Global Fund’s Round-6 funding where IMA became a 
subrecipient of funding to RNTCP109,125. IMA simultaneously 
worked with Eli Lilly Foundation and trained doctors on RNTCP in 
Himachal Pradesh and Madhya Pradesh states focusing on training of 
private health sector doctors25. In the process of systematic evolution 
from pilot projects in Kannur and Kollam districts to a national 
partnership between IMA and RNTCP, relationship between the two 
organizations became stronger. IMA also advocated among its 
members for the engagement of private health sector in RNTCP 




through its various forums including the Journal of Indian Medical 
Association25,126. IMA summarizes its PPM strategy around four 
components; profession-based approach, non-financial incentives, 
one-on-one peer sensitization and adherence to International 
Standards for TB care45,127. IMA called it a profession-based 
approach because the association engaged only the doctors and health 
facilities that practise modern medicine. Training, certification and 
endorsement of private health sector facilities to provide RNTCP 
services were the examples of non-financial incentives. One-on-one 
peer sensitization was meant for doctors who couldn’t find time for 
attending training programmes. This was done by meeting doctors at 
their facilities and providing information about RNTCP.   
 
The pilot projects in Kollam and Kannur recorded high percentages 
of participation of the targeted private health care providers. Within 
a year, both districts recorded over 20% increase in case 
notification25,78. Figure 1 shows the increase in case notification in 
Kannur district during the period 2000-200278. Both projects 
achieved treatment success rates above the RNTCP target of  
85% 25,78. 
 
As given in Tables 2 and 3, the IMA-Global Fund project covered 
169 districts and 532 IMA branches serving a population of 415 
million and over 55 000 IMA members. The project in a period of 8 
years from 2007 to 2015 reached 103 254 private medical 
practitioners practising modern medicine through continuing 
medical education and trained 163 86 of them. The project also 




notified 112 409 TB cases. Over 4000 practitioners signed 
agreements with RNTCP and close to 5000 ‘DOTS centres’ were 
established128. The project thus demonstrated the potential of IMA 
in engaging private medical practitioners practising modern 
medicine and thereby increasing TB cases notified. While the 
contribution of this project as a successful demonstration model has 
to be recognized, it has to be remembered that the achievement in 
terms of numbers is not big especially in India where the number of 
qualified doctors practising modern medicine is about a million and 
more than a quarter of TB cases occur.  Despite being a very big 
project that ultimately covered 16 States/Union territory, 25% of the 
districts and more than a third of the population of the country, it 
could reach only slightly over 100 000 private medical 
practitioners while less than 1000 doctors signed a Memorandum of 
Understanding with RNTCP. In addition, only 112 409 TB patients 









Public and private health sector tuberculosis case notification 
rate, new AFB-positive patients, Kannur District, 2000–200278. 
There is a seasonal variation observed in India due to which number of cases 
will be the lowest in the 4th quarter and the highest in the second quarter of 
the year.    
 
5.4 Lessons learned from the IMA-RNTCP partnership  
5.4.1 Lessons for India  
IMA’s engagement helped RNTCP realize the advantage of engaging 
professional associations at the initial planning stages of policy 
development and revisions. RNTCP also realized the importance of 
addressing the reluctance of private health care providers in 
partnering with RNTCP for fear of losing their clientele. This 
learning convinced RNTCP to introduce formal mechanisms for 
partnerships with private health sector which led to the development 




of different RNTCP schemes for partnerships that have the provision 
of appropriate compensations and incentives to private medical 
practitioners 26,28. Absence of a formal agreement between IMA and 
RNTCP is considered as a gap which has led to situations where lack 
of ownership from either or both parties has created bottlenecks for 
the projects. Abrupt ending of funding to the IMA-Global Fund 
project from the government and the disorderly and unsystematic 
closure of the project is cited as an example for this gap by the IMA 
25. In addition, the absence of a dedicated focal point for managing 
this partnership at RNTCP was a major  
gap 25,117,118. 
Table 2.  
States and Union Territory covered  


















Uttar Pradesh 75 113 10,935 199.3 
Punjab 22 59 4,700 27.7 
Haryana 22 43 3,124 25.4 
Maharashtra 36 162 19,291 112.4 
Andhra 
Pradesh 
13 154 16,470 49.4 
Chandigarh 1 1 701 1.1 
Total 169 532 55,221 415.2 





Table 3.  
Achievements of IMA-Global Fund project  




Number of Reviews and workshops held at 
National and state Level 
98 
Number of issues of dedicated RNTCP-IMA 
Newsletter and IMA Journals published and 
distributed to all IMA members in 15 projects 
states and a Union Territory 
31 
Number of Continuing Medical Education 
sessions organized for doctors 
545 
Number private medical practitioners reached 
through continuing medical education 
103,254 
Number of private providers trained in RNTCP 
using RNTCP Module for private practitioners 
and International Standard of Care Guidelines 
16,386 
Number of private health care providers 
signed Memorandum of Understanding with 
RNTCP 
923 
Number of IMA members from the 15 project 
states and 1 Union Territory who have signed 
an Memorandum of Understanding under one 
of the RNTCP PPM schemes 
4,446 
Number of private peripheral Health 
Institutions initiated 
1,828 
Number of DOTS centres started 4,709 
Number of Designated Microscopy Centres 
approved in the project sites 
107 
Number of TB patients notified by private 
medical practitioners 
112,409 





IMA also realized its limitations as a voluntary organization, without 
jurisdictive authority, in engaging private health care providers in 
RNTCP. The important limitations listed by RNTCP are 1) not all 
private medical practitioners are members of IMA 2) doctors are not 
legally bound to follow IMA’s appeals and 3) IMA is not equally 
organized in all states of the country. These resulted in variable 
influence of IMA on its members across states which made it difficult 
to generate the same level of motivation among all branches of IMA 
across the country. Though IMA could mobilize private medical 
practitioners to attend training and capacity building workshops, 
following up with them to designate their facilities as RNTCP- 
centres has been a challenge because IMA didn’t have the 
infrastructure and resources for that. At the same time, RNTCP staff 
who have been already burdened with their routine work were unable 
to supplement this gap. Increase in case notification from private 
health sector after the private medical practitioners got access to the 
RNTCP’s web-based notification system has been an indication for 
the need to expand electronic notification to the private health sector. 
Absence of a formal agreement stating the respective roles and the 
frequency of formal review meetings between IMA and RNTCP 
resulted in reduced levels of interactions between the organizations. 
Absence of a focal person at CTD for IMA-related matters has also 
contributed to weakening of the relationship. RNTCP had no 
earmarked funding for IMA engagement which made the formal 
interactions rather ad hoc.  





RNTCP and IMA learnt important lessons from PPM pilot projects 
also. For example, the intensified PPM in Punalur sub district 
provided an important lesson about the risk of too much of 
decentralization of laboratory services. Recruitment of large number 
of private health care providers in PPM network resulted in additional 
workload of supervision which disrupted the routine work of 
supervisory staff. This in turn impacted the quality of diagnostic and 
treatment services. This experience informed the policies and 
RNTCP in turn decided the criteria of at least 60 adult outpatient 
attendance per day to designate a private health care facility as a 
microscopy center.  
 
5.4.2 Lessons for other countries  
Other countries that have similar situation like India with high TB 
burden, robust NTP, widespread private health sector and presence of 
a professional association of physicians can learn from the IMA-PPM 
model. Moreover, many of the high TB burden countries with private 
health sector as a major player in health care are facing similar 
problems in TB control as India does. For example, countries like 
Pakistan, Bangladesh, Myanmar, Thailand, Vietnam, Indonesia 
Philippines, Nigeria, Kenya and Ethiopia have significant proportions 
of TB patients seeking care from private health care providers1. Such 
patients are likely to reach the NTP very late or may not to reach at 
all resulting in most such patients receiving suboptimal or no care for 
TB. Large proportions of such cases also wouldn’t get notified to the 




respective NTPs1. In many of these countries, professional 
organizations of doctors would have prominent presence and 
considerable influence on private health sector and doctors. Lessons 
from India could inform the NTP policy makers and the leaders of 
professional organizations in these countries.   
 
5.4.3 Achievements of IMA-RNTCP partnership 
RNTCP using its experience and the lessons learnt from the PPM 
pilot projects, including those IMA-PPM models, developed national 
guidelines for the engagement of private medical practitioners26. IMA 
took part in the development of this document to reflect the 
perspectives of the private health care providers25. RNTCP in 2003 
sought IMA’s support in scaling up PPM at national level following 
which IMA’s president in a declaration endorsed RNTCP and urged 
all the doctors to extend support to the national program. Incidentally, 
IMA’s national president had already implemented RNTCP at his 
private hospital which was a RNTCP-designated microscopy centre 
in Kannur district where PPM was pilot tested from 200025,117. In 
2004, RNTCP developed an abridged version of training module for 
private practitioners, which replaced the previous module which had 
very descriptive chapters on administrative, programmatic and 
operational aspects of RNTCP that were not perceived as relevant for 
private practitioners. In 2006, IMA organized a national workshop on 
RNTCP which gave birth to the National Working Group of IMA for 
TB. IMA nominated Dr. Asokan, IMA leader from Kerala, as the 
National Coordinator of the working group with the responsibility of 




leading the partnership with RNTCP. RNTCP in turn coopted IMA 
into the national working group on private sector. RNTCP also 
invited IMA to attend its biannual periodic review meetings and the 
WHO-led joint programme monitoring missions held every third 
year. In 2007, IMA formed IMPACT (Indian Medical Professional 
Associations’ Coalition Against TB), a consortium of the relevant 
professional associations of specialist doctors such as 
pulmonologists, pediatricians and internal medicine doctors25,109,117.  
 
IMA was invited to the global steering committee that was set up to 
draft International Standards for TB Care (ISTC) in 2006 which was 
organized by the Tuberculosis Coalition for Technical Assistance, a 
global project funded by the USAID45. In 2007, IMA endorsed ISTC 
and urged the doctors to follow the standards prescribed in the 
document for diagnosing and treating TB patients 25,130. IMA also 
endorsed ‘Patients’ charter for tuberculosis care’ which defined TB 
patients’ rights and responsibilities. IMA, together with other 
partners, assisted RNTCP in the development the Standards of TB 
Care for India45. 
Upon CTD’s recommendation, WHO nominated IMA to the 
Strategic and Technical Advisory Group for TB which meets every 
year at WHO’s headquarters in Geneva, Switzerland to advise WHO 
in refining TB control strategies and policies. IMA with support from 
WHO and Stop TB Partnership launched ‘Stop TB Asia Coalition’ in 
2015 which was followed by signing of a pledge by the Indian Health 
Minister, global TB leaders and representatives of international 




organizations and partners25. IMA has lately joined hands with 
Confederation of Medical Associations of Asia and Oceania with 
secretariat in Tokyo under Japan Medical Association to be part of 
the global fight against TB25.  
     
5.4.4 Long term attainments of the IMA-RNTCP partnership  
The lessons learnt from the long-term IMA-RNTCP partnership were 
also used in the development of strategic guidelines for formal 
engagement of private health sector providers131. IMA’s act of 
endorsing and deliberations on ISTC contributed to visible 
improvement in awareness among private medical Practitioners  
about the public health aspects of TB control and their responsibilities 
towards TB control25,117. There has been improvement in the quality 
of prescriptions of private medical practitioners as increasing 
numbers of them have been prescribing fixed dose combination drug 
regimens of reputed pharmaceutical companies instead multiple 
drugs which had the risk of consumption of inadequate drugs or doses 
by patients25,117,118. IMA’s interactions with RNTCP also resulted in 
RNTCP’s amendments of policies to accommodate the interests of 
the private health sector. One of such adaptations of IMA is the 
decision to experiment an innovative concept of Public-Private 
Interface Agency (PPIA) that allowed opportunity for neutral non-
government agencies to function as an interface between RNTCP and 
private health sector. This was a shift in the RNTCP’s approaches by 
creating an environment that promotes flexibility for private health 
sector engagement and trust among partners in TB control27. The 




flexibility offered in one of the initial PPIA projects implemented in 
Mumbai city to use a diagnostic algorithm other than that of RNTCP 
was welcomed by the private sector. PPIA project in Mumbai city 
uses X-Ray as the screening tool while Xpert MTB/RIF, an 
automated diagnostic test, is used for confirmation of TB disease and 
identifying rifampicin resistance132. The National Strategic Plan 
2017-25 of RNTCP includes a new scheme to address TB care in 
private health sector which will have incentives for private health 
sector providers and patients to improve reporting TB cases to 
RNTCP28. IMA’s recommendation to simplify the documentation 
processes of TB disease events was also considered in the RNTCP’s 
strategy regarding digital tools for recording and reporting. Concern 
of patients about the lack confidentiality in a system of paper-based 
registers and reports have been raised by IMA which is addressed by 
electronic reporting25,118. RNTCP’s decision to allow private 
practitioners to access its web-based case-based notification system 
led to significant increase in case notification from private health 
sector in the recent years1. IMA points out that this model appears to 
have reduced financial burden on patients due to the availability of 
RNTCP services to patients who access care from private health care 
facilities25.  
 
5.5 Discussion  
India is continuing to be the country with the highest number of 
incident TB cases with a quarter of the share for incident TB cases 
and unnotified TB cases. The End TB Strategy of WHO has set a very 




ambitious goal of ending TB by 2035. Ending global TB will depend 
greatly on the pace of TB control in India which will in turn depend 
on the level of engagement of private health sector in RNTCP. As has 
already been discussed, private health sector in India is a 
heterogenous entity which is controlled by complex dynamics and 
undercurrents which are only partly understood yet. By the inherent 
characteristics and the way of functioning of the for-profit-private 
health sector, its challenging for a national health programme with 
social positioning to engage the private health sector in a public 
health programme that is not overtly aligned to their business model. 
Therefore, engaging the private health care providers in TB control is 
not an easy and straightforward task. Therefore, RNTCP will have to 
resort to multiple mechanisms to engage the various types of players 
in the private health sector to ultimately reach all the TB patients 
cared by them. Particularly to reach the patients in the private health 
sector, RNTCP will need facilitators to interface with the private 
health sector. It is in this background that an overview of the 
engagement of IMA, examining the processes, documenting the 
lessons learned and identifying the challenges became important.  
 
The results from the IMA–RNTCP partnership demonstrates the need 
for and the value addition due to such a partnership in the larger 
interest of public health. It’s clear from the evidence that though 
isolated and local IMA-RNTCP collaborations were there, IMA’s 
declaration of nationwide support to RNTCP in 2003 changed the 
situation within IMA drastically in favour of PPM. This change in the 




approach largely reduced the opposition from the private health 
sector towards RNTCP. In addition, IMA-PPM projects have 
demonstrated improved participation of private medical practitioners 
in RNTCP and resultant increase in TB case notification 
notwithstanding the fact that the achievement in case notification in 
absolute numbers was marginal compared to the size of the TB 
problem.  WHO-led Joint Monitoring Mission that reviewed RNTCP 
in 2015 recommended that major initiatives must be undertaken to 
sensitize and engage private medical practitioners by involving 
stakeholders like IMA and other professional associations133. 
 
The IMA-RNTCP partnership had evolved over more than two 
decades through regular interactions between the two organizations 
that arose out of the need of RNTCP to engage private health care 
providers. Even after establishing a national-level partnership, the 
collaboration faced challenges especially due to administrative delays 
that became bottlenecks specifically in fund transfers to the project. 
Absence of a formal agreement signed between RNTCP and IMA 
was a major gap in addition to the absence of a focal point at CTD for 
PPM affairs. Absence of adequate documentation of the evolution 
and history of the partnership reduced the opportunities for the 
expansion of the model within the country and replication elsewhere. 
The benefits RNTCP received through this partnership is also 
inadequately documented. Even the limited documentation of the 
IMA’s role as an interface contributed to the idea of a neutral 
interface agency between RNTCP and the private health sector for 




building innovative models like PPIA. RNTCP’s decision to scale up 
PPIA projects will be an opportunity for further strengthening IMA-
RNTCP collaborations.  
 
Absence of comprehensive monitoring and evaluation strategy to 
measure the impact of IMA-PPM projects stands out as a major gap 
that would impact future fund mobilization for expanding and 
replication of the model. In the Global Fund project, there were 
delays and interruptions in the fund disbursement to IMA. This was 
mainly because the government was the principal recipient of the 
Global Fund grant and the transfer of funds to IMA, the subrecipient, 
was interrupted or delayed due to bureaucratic bottlenecks and 
slowness of the government systems25,117,118.  
 
IMA has also taken cognizance of the challenges and has defined 
solutions to take this partnership forward. IMA has been reviewing 
its political and geographical strengths and planning to optimize its 
reach within private doctors in India25. RNTCP and IMA has started 
exploring ways of extending this partnership in the scale up of newer 
initiatives like PPIA at national level25,119. IMA being the common 
organization of doctors that can greatly influence its members 
especially in the private health sector will have a continued and 
enhanced role in helping India move towards ending TB. RNTCP 
implementation being primarily led by the government, a strong 
public sector with adequate capacity and willingness to partner with 
private health sector is required to materialize meaningful 
partnerships between RNTCP and the private health sector. 





Having examined the IMA-RNTCP partnership in its entire length 
starting from the pilot projects through the latest developments, the 
recommendations can be listed as follows.  
1. There should be a platform, for example a workshop, to 
examine the status of IMA-RNTCP collaboration leading to 
identification of key issues and challenges in the IMA-
RNTCP partnership. The challenges identified in the process 
of the partnership should give insights to IMA in developing 
solutions aligned with the market practices.  
2. MA-RNTCP collaboration must be revamped and a formal 
signing of agreement between IMA and RNTCP must be done 
to ensure effective contribution from both the organizations. 
There should also be clear division of responsibilities between 
RNTCP and IMA. 
3. A focal point should be identified at RNTCP who will have 
the responsibility of managing the partnership with IMA.  
4. The key issues and challenges should be systematically 
documented.  
5. Similar projects in future should have strong monitoring and 
evaluation systems so that respective partner’s contribution 
can be easily measured.  
6. The scope for IMA to engage more proactively in innovative 
mechanisms like PPIA should be explored.  
7. There should be appropriate and practical approaches to 
address the fear of the private health sector about losing their 




clientele by engaging in RNTCP-related activities.  
8. Appropriate mechanisms and tools must be established to 
ensure that feedback about patients received by RNTCP from 
private health sector is sent to the participating private health 
care providers.  
9. In future occasions of funding by international donors, IMA 
should play the role of principal recipient of the grant to 
address the unnecessary bureaucratic delays in receiving the 
funds from the government as principal recipient.  
 
5.7 Conclusion  
Though RNTCP’s efforts to engage the private health sector was 
initially offset by the opposition from the private health care, IMA’s 
engagement facilitated the process and contributed to success in the 
establishment of partnership with private medical practitioners, 
increasing case notification and maintaining higher rates of treatment 
success. IMA acted as an interface for creating partnerships between 
RNTCP and private health sector in many successful PPM projects. 
The lessons learnt from the IMA-RNTCP projects should inform the 
policy decisions on further strengthening IMA-RNTCP 
collaborations. As donor funding is dwindling, RNTCP should 
consider increased investments in the private health sector using IMA 
as an interface with the private health sector. Professional 
associations like IMA should be engaged more in a strategic manner 
and involved in all the stages of decision making process. There is 
scope for further improvement in IMA-RNTCP collaboration through 




refinement of the existing models as well as experimenting newer and 
innovative models. Every effort to increase TB case notification and 
maintain treatment success in India is a crucial step towards global 
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According to the 2009 Global Tuberculosis Control Report of the 
World Health Organization (WHO), the acceleration in tuberculosis 
(TB) case detection rate achieved over the last decade now seems to 
be stagnating at a little over 60%. The global target of detecting 70% 
sputum smear-positive TB cases was not reached in 2005 and is 
unlikely to be achieved by the end of 2010102. 
 
Globally, efforts to strengthen TB control have been concentrated 
largely within the public sector health services directly under the 
scope of National Tuberculosis Programmes (NTPs)7. In many 
countries, diverse care providers outside NTPs, which manage 
significant proportions of TB patients, are yet to be integrated into 
national TB control efforts. These comprise public sector care 
providers such as prison health services under ministries of interior, 
military health services under ministries of defence or social security 
organizations under the ministries of labour as well as for-profit and 
not-for profit private sector care providers that include private 
practitioners, private hospitals, corporate health services and 
voluntary organizations. In some countries, the private sector has 
outgrown the public sector in health care provision. TB management 
practices of many non-NTP care providers have been shown to be 
uneven and cases detected by them are rarely notified102. However, 
studies show that engaging all relevant care providers through 
public–private mix (PPM) approaches helps to effectively harnesses 
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available capacity in the country by NTPs to expand coverage, 
improve access to quality care and programme outcomes and reduce 
cost of care to patients81,103. 
 
PPM for TB care and control implies public–private collaboration for 
delivery of TB services. It is a comprehensive approach to 
systematically involve all relevant health care providers in TB control 
and achieve national and global TB control targets. International 
Standards for TB Care (ISTC) offers an excellent tool to help 
standardize TB management practices of diverse care providers. In 
practice, countries have used the label PPM to denote ‘public–public 
mix’ when the NTP collaborates with other public sector care 
providers who have not traditionally been part of their network, 
including certain public hospitals or special health services under 
ministries other than the ministry of health, such as prison health 
services; and ‘public–private mix’ when the collaboration is between 
the NTP and private, voluntary or corporate sector care.  
 
The Global Fund to Fight AIDS, Tuberculosis and Malaria (The 
Global Fund) – a major source of funding for NTPs – is a public–
private partnership (http://www.theglobalfund.org). It provides 
around 63% of all international financing for tuberculosis control 
globally; which between 2002 and 2009 amounted to US$ 3.2 billion 
of approved funds102. The Global Fund requires applicant countries 
to set up national level partnerships in the form of country 
coordination mechanism representing diverse stakeholders including 
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civil society and people living with diseases. It finances grant 
implementation by public and private sectors in countries through a 
dual-track financing facility. However, to date, no studies have 
explored the extent to which PPM activities are financed by the 
Global Fund. While a number of country case studies show that 
global mechanisms have helped national and local TB programmes 
to establish and scale up PPM initiatives, the global scale of these 
activities is not known102. Enormous untapped potential still remains 
in translating global and national level partnerships into large scale 
collaborations among providers for delivery of TB care at the 
grassroots. Realizing this potential is essential to meet and maintain 
TB control targets7,134.  
 
The purpose of this paper is to map the extent and the scope of PPM 
interventions in TB grants financed by the Global Fund. It is hoped 
that this will provide useful lessons for NTPs, international technical 
agencies and financiers of TB programmes globally. 
 
6.2 Methods 
Two levels of analyses were applied: reviewing the evolution of 
support to PPM for TB care and control in Global Fund-supported TB 
grants as reflected in its official documents and mapping the 
distribution and characteristics of PPM initiatives within the Global 
Fund-supported programs. We supplemented this analysis with 
relevant data from 14 countries reported to WHO for the Global TB 
control report of 2010. 
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The official documents of the Global Fund include guidelines on 
submission of requests for funding as well as the monitoring and 
evaluation tool-kit, which provide grant recipients with an inventory 
of indicators to measure outputs of their activities135. Applicants are 
required to submit a performance framework with the indicators and 
targets against which grant’s results are later measured136. We 
reviewed all performance frameworks of all TB grants, and 
considered a grant to include a PPM activity if an indicator was 
classified as such within the performance framework or if any of the 
indicators measured provision of any TB service with or through a 
non-NTP entity such as the private sector, prison, municipality, faith-
based organization, and nongovernmental organizations (NGOs). 
The analysis of the distribution and characteristics of PPM initiatives 
within the Global Fund-supported programs, included measurement 
of (i) proportion of TB grants with PPM, in total, over time and their 
regional distribution; (ii) distribution of PPM implementers, 
categorized into prison health services, for-profit private sector, 
NGOs, others and unspecified, including changes in their 
composition over time and regional distribution; and (iii) the 
investment in PPM approaches as part of the overall funding in the 
TB grants studied and their regional distribution. Financing data were 
obtained from the Global Fund’s Enhanced Financial Reporting 
System (EFR) which tracks utilization of Global Fund investments 
by grant recipients. The EFR includes a category ‘PPM⁄ISTC’. Grants 
reporting financial data under this category were used to estimate the 
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investment in PPM. The EFR data used in this study represented 80% 
of Global Fund TB investments disbursed by the end of 2008. 
 
WHO publishes an annual report on global TB control. The purpose 
of the report is to provide an annual assessment of the global TB 
epidemic and the progress made in implementing the Stop TB 
Strategy. For the global TB report of 2010, countries were asked to 
provide the data on the number of cases reported by non-NTP 
providers in the public and private sectors in 2009. Data obtained 
from 14 countries – Angola, Cambodia, China, Ghana, India, 
Indonesia, Islamic Republic of Iran, Kazakhstan, Myanmar, Nepal, 
Nigeria, Pakistan, Philippines, and Tanzania – are presented here. All 
14 countries had received Global Fund grants for scaling up PPM and 
11 reported to be implementing PPM countrywide. It was not 
possible, however, to determine whether the outcomes of PPM 
interventions in terms of contributions of non-NTP care providers to 




6.3.1 Scope for PPM in Global Fund official documents 
The Global Fund guidelines for submitting funding proposals 
promote collaborations among all relevant health care providers 
within countries to deliver health care services. The Global Fund 
supports existing and new innovative programmes both within and 
outside the health sector that promote public, private and non-
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governmental efforts. The Global Fund’s Technical Review Panel 
also considers PPM as an important attribute when assessing the 
technical quality of a proposal. The Monitoring and Evaluation 
toolkit developed by the Global Fund together with various partners 
includes indicators specific to PPM (Box 1). 
 
6.3.2 Distribution and characteristics of PPM initiatives  
The number of countries with PPM activities within the active TB 
grants supported by the Global Fund increased from 13 in 2003, the 
first year of Global Fund disbursement for TB, to 58 in 2008. Figure 
1 shows the incremental numbers of proposals with PPM 
components. The proportion of Global Fund grants with PPM 
activities was highest in Southeast Asia (82%) and lowest in Sub-
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Box 1.  
Examples of indicators for ‘Engage all care providers’ component of 
Stop-TB strategy included in the Global Fund monitoring and 
evaluation framework 
1. Private and Public health providers (different types) 
collaborating with the NTP (number and percentage) 
2. New smear positive TB patients referred by a specific type of 
health care provider among the new smear positive TB patients 
reported to the national health authority (started on treatment 
in NTP) (number and percentage) 
3. New smear positive TB patients managed/supervised by a 
specific type of health care provider among all TB patients 
reported to the national health authority (number and 
percentage) 
4. New smear positive TB patients successfully treated (cured plus 
completed treatment) among the new smear positive TB 
patients managed/ treated by a specific type of health care 
provider (number and percentage) 
5. Private and Public health providers (different types) 
collaborating with the NTP (number and percentage) 
6. New smear positive TB patients referred by a specific type of 
health care provider among the new smear positive TB patients 
reported to the national health authority (started on treatment 
in NTP) (number and percentage) 
7. New smear positive TB patients managed/supervised by a 
specific type of health care provider among all TB patients 
reported to the national health authority (number and 
percentage) 
8. New smear positive TB patients successfully treated (cured plus 
completed treatment) among the new smear positive TB 
patients managed/ treated by a specific type of health care 
provider (number and percentage) 
Source: The Global Fund M&E Toolkit. Available at 
URL: http://www.theglobalfund.org/en/me/guidelines_tools/?lang=en#toolkit. 
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Proportion and number of countries which received Global 




                             
N, Number of countries with active TB grants that include PPM component 
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Number of countries with Global Fund support for PPM 
activities (proportion of the total number of active TB grants), 
by region and by year  
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Number of countries with Global Fund support for PPM 
activities (proportion of the total number of countries with 
Global Fund support for PPM activities),  
by implementer type and year 
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Figure 3 shows the types of care providers engaged in PPM. Between 
2003 and 2008, while collaborations with NGOs and the for-profit 
private sector also increased, there was a sharp rise in NTPs engaging 
prison health services, predominantly in countries of Eastern Europe. 
Care providers involved in PPM varied by region (Table 1). 
Collaboration with the for-profit private sector was greater in South 
Asia and East Africa while collaboration with NGOs was common in 
North Africa, the Middle East and South Asia. Links with prison 
health services were present in other regions including Eastern 
Europe and Central Asia, Latin America and the Caribbean as well as 
West and Central Africa. 
6.3.3 Finances allocated to PPM activities in TB Grants 
supported by the Global Fund  
Analysis of budget and expenditure data showed that by 2008, US$ 
38.3 million (4.4%) of TB funding in the budgets of Global Fund-
supported grants was allocated to PPM. The expenditure for PPM 
activities as a proportion of total expenditure in TB grants amounted 
to 5.4%, higher than that initially budgeted; 99% of the funding 
budgeted for PPM activities was utilized, compared to 80% for the 
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Distribution of PPM implementers within countries with Global 
Fund support for PPM as of end 2008, by region 
 
Region (N) 
Percentage of countries with Global Fund‐
supported PPM 





East Asia and the 
Pacific (8) 
38 38 25 38 0 
Eastern Europe 
and Central Asia 
(11) 




25 63 0 50 0 
North Africa and 
the Middle East 
(8) 
63 25 38 25 13 
South Asia (6) 50 17 67 17 50 
East Africa (5) 0 40 40 0 20 
Southern Africa 
(4) 
25 0 0 50 50 
West and Central 
Africa (8) 
25 63 25 38 13 
All regions (58) 34 48 26 31 16 
N, Number of countries with Global Fund support for PPM activities, per 
region; Green cells – the regions with the highest proportion of countries with 
the specific PPM implementer. 
 
 
The median amount budgeted in Global Fund grants for PPM 
activities was 5% of total. However, this amount ranged from 0.03% 
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to 69% of total, with Kyrgyzstan and Swaziland allocating over 50% 
of their funding to PPM. In most proposals this does not include cost 
of drugs and other consumables for the diagnosis and treatment of TB 




























East Africa 388 0.4 366 0.4 
East Africa and 
the Pacific 
25 684 10.4 26 200 12.8 
Eastern Europe 
and Central Asia 
3 295 1.9 3 737 2.7 
Latin America and 
the Caribbean 
332 0.4 443 0.6 
Northern Africa 
and the Middle 
East 
336 0.4 165 0.3 
South and West 
Asia 
2 343 4.0 1 683 3.7 
Southern Africa 1 338 2.0 1 194 2.8 
West and Central 
Africa 
4 598 6.9 3 988 6.8 
Entire Portfolio 38 314 4.4 37 776 5.4 
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For PPM activities, the investments in China, Indonesia and Ghana 
were $US 18.8 million, $US6.1 million and $US3.5 million, 
respectively. The top two regions with highest share of their budget 
allocated to PPM were East Asia and the Pacific and, West & Central 
Africa (10.4% [US$ 25.7 million] and 6.9% [US$ 4.6 million] 
respectively). While the share of the TB budget allocated to PPM in 
Eastern Europe & Central Asia, and Latin America & the Caribbean 
is lower than in other regions, both regions have many grants for 
collaboration with prison health services, which are not always 
reported as a part of PPM. The expenditure data are based on a 
budget-line that relates to PPM and ISTC yet excludes some grants 
which did not report on their expenditure. 
 
6.3.4 Country data 
The mix of health care providers and health seeking behaviour of TB 
patients varies by setting. In China, hospitals are often the first point 
of care137. In rural areas of Bangladesh138 and Cambodia139, semi-
formal ‘village doctors’ are the first level care providers. In India and 
Kenya, private practitioners are the first port of call for many patients 
with symptoms of TB101. 
 
Data compiled from 14 countries (including nine high burden 
countries) and published in the Global TB Report of 2010140 
demonstrated the important contribution of PPM to case notifications, 
between a quarter and a third of all cases in five countries (Table 3). 
Expectedly, there has been considerable variation in PPM approaches 
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and the provider groups targeted. This includes collaboration with 
pharmacies in Cambodia, private hospitals in Nigeria, public 
hospitals in China and Indonesia, and prison services in Kazakhstan. 
 
6.4 Discussion 
Evidence points to growth globally in the number and size of non-
public sector health care providers in TB control, with a significant 
proportion of TB patients managed by them, albeit often with poor 
quality of care. But proactive engagement of them can yield 
substantial benefits for TB control. There is also a growing body of 
evidence, over the past decade, which indicates that in some countries 
PPM has helped improve programme performance by increasing case 
detection by 10% to 60% while maintaining the treatment success 
rates above 85%141. Importantly, in some settings, for-profit private 
providers engaged through PPM have been able to improve their 
treatment success rates from levels that are often below 50% to above 
the global target of 85103.  
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The importance and the scope of PPM are not often reflected at a level 
commensurate with the evidence, in the TB proposals and budgets 
submitted by countries. More than a third of the countries with active 
TB grants do not have PPM as a component. While the number of 
countries with active TB grants has increased from 22 in 2003, to 93 
in 2008, the proportion of countries with PPM has not increased in 
this period despite additional Global Fund support for PPM. Of 
particular concern is the relatively low proportion of countries in sub-
Saharan Africa with PPM supported by the Global Fund. We further 
observed a relatively low engagement of both NGO and private health 
sectors, which are key for PPM expansion. 
 
There are also concerns regarding the nature of PPM and the way in 
which countries plan for PPM. Judging upon the PPM-related 
indicators used by countries on which Global Fund-supported 
programs report, many focus merely on training of providers, without 
a clear strategy on how to establish effective and sustainable 
collaboration. Proposals submitted to the Global Fund often lack 
explicit mention of what enablers and incentives (financial or non-
financial) will be used for private sector engagement, such as supply 
of anti-TB drugs free of charge to private practitioners on the 
condition that they follow DOTS principles for diagnosis and case 
management141. Larger health care institutions taking on more 
complex roles in TB control will normally require financial 
compensation mechanisms, such as contracting on a capitation or fee-
for-service basis. These aspects are rarely highlighted in proposals. 
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Similarly, the support structures for PPM, such as continuous 
supervision, monitoring and evaluation, are often inadequately 
described. Finally, in the reports submitted to the Global Fund there 
is often little information on the proportion of non-public health care 
providers involved and the percentage contribution by different 
providers136,142. All this will require more ambitious and better 
designed PPM plans to expand the engagement of non-public sector 
institutions in TB control to scale up services and improve outcomes. 
 
There is useful guidance available to countries on PPM, including a 
tool to undertake a national situation assessment to decide on the need 
and scope of PPM in a country143 (used successfully by at least a 
dozen countries), a PPM guidance document and a PPM toolkit that 
advises on different steps of implementing PPM in phases, and also 
steps to engage different types of providers101. These documents also 
include a planning framework for PPM in Global Fund applications; 
this framework is further elaborated in the Stop TB Planning Matrix 
and Framework for Global Fund TB proposal preparation144. The 
Global Fund currently does not have specific guidance on PPM, 
however, clearer guidance in the future would enable greater uptake 
of PPM. 
 
The current median budget allocation for PPM activities of 5% is 
probably sufficient for limited engagement however the scaling up of 
PPM initiatives, especially those involving financial incentives 
requires more investment. In addition, a significant portion of the 
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budget has been allocated to training activities. The Global Fund 
recommends that countries follow the Stop TB Strategy and the larger 
tranches of funding for TB approved in R8 and R9 should further 
contribute to PPM activities.  
 
The study could have underestimated the PPM within TB grants 
supported by the Global Fund, as there are limited data on sub-
recipients of Global Fund grants including activities implemented by 
NGOs and the private or corporate sector, many of which are of PPM 
nature. Further limitation is the categorization of PPM types. Global 
Fund data highlights the recent expansion of PPM to prisons, and has 
ample examples for PPM in NGOs and the private sector, but none in 
public health facilities that are not part of the NTP, due to the 
difficulty in identifying such facilities within grant indicators. A 
further problem is the categorization of an activity under PPM. For 
example, in many grants, DOTS implementation in prisons was not 
classified as PPM. This partially explains the relatively low share of 
the TB budget allocated to PPM in Eastern Europe & Central Asia 
and Latin America & the Caribbean. Finally, the Global Fund is not 
the only financier of PPM activities and there is a lack of sufficient 
information to estimate the contribution from other funding agencies. 
All these limitations require further in-depth case studies. 
 
Wide implementation of PPM requires good collaboration between 
the public and other health sectors. Innovative mechanisms 
appropriate to the nature of the settings such as certification of 
Chapter 6: Global Fund Financing of Public-Private Mix approaches 




provider and financial incentives should be put in place to ensure such 
cooperation. There are good examples from countries like India, 
where NTP tries to encourage and formalize PPM though initiatives 
that develop guidance documents to facilitate PPM partners to 
formally engage in PPM activities. We need robust case studies to 
illustrate further examples of good practice that has resulted in 
improved outcomes. Mechanisms aimed at providing appropriate 
incentives and providing online reporting tools to establish and 
sustain such collaborations are to be considered based on the 
relevance in specific settings.  
 
PPM is cost-effective in diverse country settings79,81,145,146. A deeper 
analysis of PPM components of Global Fund country proposals and 
of the performance related to PPM could be of immense benefit not 
only to countries themselves but also to the technical and financial 
agencies supporting them. South-South learning opportunities should 
be encouraged, and lessons learned from country cases more carefully 
harnessed and disseminated. Clearly, significant untapped potential 
still exists in scaling up PPM across countries, particularly in light of 
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In the last 2 decades there have been concerted global efforts to 
scale up tuberculosis control. Efforts began with the introduction of 
the directly observed treatment, short-course (DOTS) strategy in the 
early 1990s, followed by the World Health Organization (WHO) 
Stop TB Strategy 2006, and in 2010 the Global Plan to Stop TB 
2011–2015. These efforts have coincided with large amounts of new 
external financing, predominantly from the Global Fund to Fight 
AIDS, Tuberculosis and Malaria. However, despite these efforts and 
increased external financing, in 2009 there were >9 million new 
tuberculosis cases140. Although just over half of the 22 countries 
with a high burden of tuberculosis were on track to achieving the 
Millennium Development Goal 6 of halting and reversing 
tuberculosis incidence by 2015, less than half were on target to 
halving tuberculosis deaths by the same year140. Multidrug-resistant 
(MDR) tuberculosis poses a major threat for all countries, yet case 
notification was 30 000 globally in 2009, just over one-tenth of 
global estimates140.  
Although the Global Plan to Stop TB 2011–2015134calls for early 
detection and treatment of all tuberculosis cases and intensifying 
screening for the most-at-risk populations, including people in 
confinement, tuberculosis continues to be a social issue affecting the 
world’s most marginalized and disadvantaged communities. 
Prisoners are an especially vulnerable population, with increased risk 




of ill health, high levels of mental disorders, risk of self-harm, and 
high rates of infectious diseases such as tuberculosis and human 
immunodeficiency virus (HIV)147. Prisoners often come from the 
lowest socioeconomic groups in societies and, in many cases, from 
minority or migrant groups, all of which are marginalized groups that 
have a higher incidence of tuberculosis and MDR tuberculosis 
compared with the general population148. 
 
7.2 Tuberculosis in prisons 
The latest available estimates suggest that as many as 10 million 
people worldwide are held in penal institutions. This prison 
population is expected to increase in the near future. Compared with 
estimates from 2007, by 2009 prison populations had increased in 
71% of all countries, by 64% in African countries, by 76% in Asia, 
and by 68% in Europe149. Among this prison population, tuberculosis 
is a major cause of illness and death150. Globally, there is limited 
reliable information on the prevalence and incidence of tuberculosis 
within correctional facilities such as prisons and other types of 
detention centers. Furthermore, the contribution of tuberculosis rates 
in prisons to the transmission rates of new Mycobacterium 
tuberculosis infections in the general population is unclear151,152. 
However, available estimates suggest that tuberculosis prevalence 
rates within penitentiary settings are between 5 and 50 times higher 
than the rates observed in the general population153. 
 
In countries with a high prevalence of tuberculosis, the annual case 
notification rate of all forms of tuberculosis in prisons can be as high 




as 7200 per 100 000 population154. In the countries of the former 
Soviet Union, prisons and other correction facilities, such as pre-
detention centers, have some of the highest MDR tuberculosis rates 
reported globally. For example, the percentage of MDR tuberculosis 
in prison populations, as revealed by studies in Russia, has ranged 
from 12% to 55% in previously treated patients155,156. African 
countries such as Zambia and Botswana have drug-sensitive 
tuberculosis rates that are close to 4000 per 100 000 prison 
population157, and in Tanzania up to 41% of prisoners had active 
tuberculosis158. In the context of Africa and the former Soviet Union, 
these very high rates of tuberculosis are particularly alarming given 
the potential for comorbidities of tuberculosis and HIV, the high HIV 
prevalence in sub-Saharan African countries159-162, and high HIV 
levels in the injection drug user population in the countries of the 
former Soviet Union - a marginalized group that has 
disproportionately high levels of incarceration150.  
 
7.3 Prisons as breeding grounds for tuberculosis 
The physical environment found in penitentiary settings provides an 
ideal breeding ground for tuberculosis. Overcrowding, inadequate 
ventilation, and lack of quarantine facilities all encourage efficient 
transmission of tuberculosis150, and the lack of importance accorded 
to prisoners’ health often results in inadequate financial and human 
resources to provide health services for treatment and prevention of 
infectious diseases. This is further exacerbated by factors that 
increase the risk of tuberculosis, including poor nutrition163, personal 




hygiene, drug addiction, and high-risk behaviors and practices, such 
as needle sharing and unsafe sex154,164. The structural environment 
under which prisons are managed and operated also creates 
challenges to tuberculosis prevention, control, treatment, and care, 
including the low priority placed on funding for healthcare services 
for prisoners, lack of control measures, lack of proper training in 
standard tuberculosis treatment and care practices, and lack of testing 
facilities and/or quarantine services for isolation164.  There are often 
no linkages between the ministries of health that manage national 
tuberculosis programs (NTPs) and the ministries of interior or justice 
that manage prisons and the penal systems. As a result, prison settings 
often have both poor case and program management, as reflected by 
the high rates of drug-resistant tuberculosis and comorbidities such 
as HIV/AIDS/tuberculosis in prison settings153.  
 
The Stop TB Strategy envisions involvement of all public, voluntary, 
corporate, and private healthcare providers through public–private 
mix (PPM) DOTS approaches165. The strategy expands and enhances 
the basic components of DOTS and includes tuberculosis control 
strategies to effectively cater to marginalized populations such as 
prisoners. Expansion of DOTS services to prisons helps strengthen 
active case-finding activities among prisoners. The Global Plan to 
Stop TB 2011–2015 targets a case detection rate of 84% (for all cases 
and smear-positive cases specifically) and treatment of about 1 
million confirmed MDR tuberculosis cases according to international 
guidelines by 2015. The Global Plan also pays special attention to the 




protection of populations vulnerable to tuberculosis and drug-
resistant tuberculosis to achieve its goals Drobniewski.  
 
Despite the efforts spearheaded by WHO and supported by many 
international technical agencies and donors to expand PPM DOTS 
approaches, these novel approaches have had very limited uptake 
globally, with substantial variation across regions. Between 2003 and 
2010, there was a sharp rise in NTPs engaging in prison health 
services, predominantly in Eastern European countries. Links with 
prison health services are increasingly evident in regions of Eastern 
Europe and Central Asia (EECA), Latin America and the Caribbean 
(LAC), and West and Central Africa (WCA)166. 
 
7.4 Neglect of tuberculosis prison health services 
Prisons, considered to be a major stakeholder in the PPM DOTS 
concept, are not yet covered by the general public health services in 
many countries, especially when there is a separate healthcare system 
for the penal sector. Consequently, services under the NTPs, which 
are normally managed under the auspices of the public health 
services, do not cover prisons. This creates parallel systems for 
tuberculosis case management in prisons. Wherever the penitentiary 
sector is not covered by an NTP, there is a high likelihood of 
nonstandard diagnosis and care for tuberculosis patients. Even in 
settings where an NTP has established linkages with the penitentiary 
sector, tuberculosis patients may receive care, as defined by 
international guidelines, only during the period of confinement. 




Those released from prisons when still under treatment for 
tuberculosis are more likely to discontinue treatment due to lack of 
follow-up once in the community. In many settings, mechanisms to 
follow up on such patients by placing them in another basic 
management unit of an NTP through ‘‘transfer out,’’ as envisaged in 
the DOTS strategy, may be difficult to organize owing to poor 
working relationships between prison authorities and community 
health providers167. 
 
7.5 Financing of tuberculosis services in prisons 
Financing the diagnosis, treatment, and care for tuberculosis patients 
in penitentiary systems is an additional problem that needs to be 
addressed. Of the $47 billion needed for implementation of the 
Global Plan 2011–2015, the cost of DOTS implementation is $22.6 
billion and the cost for interventions to manage drug-resistant 
tuberculosis is $7.1 billion. Although acknowledged as an important 
problem in global tuberculosis control, there are no estimates of the 
funding requirements for effective control of tuberculosis in prison 
settings. Similarly, to date, no studies have estimated the financing 
needed for tuberculosis control activities in prisons. Despite the 
evidence of higher rates of tuberculosis in prisons and the potential 
public health implications for the general population, available 
information indicates that the funding for tuberculosis control 
activities in prisons is disproportionately low166.  
 
The Global Fund, which has emerged as the largest international 
financier of tuberculosis control globally, is estimated to have 




provided more than four-fifths of all external finances for 
tuberculosis in 2011. The financing went to support low- and middle-
income countries with treatment; care and support; and advocacy, 
communication, and social mobilization interventions, including 
management of marginalized groups. By 2010, approximately $2 
billion was invested for tuberculosis control in low- and middle-
income countries168. The Global Fund’s Framework document169 
underpins the principles that guide its operations. This document 
emphasizes country ownership in the allocation of Global Fund 
investments for programs to provide additional funding to support 
AIDS, tuberculosis, and malaria programs in order to reach the 
populations with the greatest need for treatment, care, and prevention 
services. Table 1 provides a brief summary of the Global Fund 
funding processes for country grant applications. 
 
The Global Fund is also a major investor in tuberculosis control in 
prisons166, although the extent and distribution of this investment has 
not been previously quantified. Therefore, we conducted a study to 
explore investments by the Global Fund for tuberculosis control in 
prisons and the services delivered for prisoners through Global Fund–
financed grants between 2003 and 2010. 
 
7.6 Search strategy, methods, and analysis 
The Global Fund grants database, with an aggregate approved 
investment of $21.7 billion in 150 countries, was reviewed. We 
identified and analyzed 230 tuberculosis and HIV/tuberculosis grants 




for which a grant agreement had been signed with the recipient 
country. We reviewed in the performance frameworks of 230 
tuberculosis grants which had activities benefiting prisoners all grant 
output indicators (n 5 4031). We determined that a grant supported 
such an activity if the indicator referred to a target population as 
‘‘prisoners’’ or ‘‘incarcerated population’’ or if the service was 
delivered in a prison setting. Our search included prison population–
specific tuberculosis detection and treatment; care and support; 
screening and monitoring; and advocacy, communication, and social 
mobilization. It also included activities aimed at strengthening policy 
and the structural environment in order to facilitate better tuberculosis 
programs within prisons, for example, activities related to capacity 
strengthening of prison health staff to deliver and manage 
tuberculosis programs. Two multicountry grants in the Global Fund’s 
East Asia and Pacific region were excluded because there was limited 
information based on the performance frameworks regarding the 
geographic locations of the services delivered through the programs 
supported by these grants. We also limited the scope of this exercise 
by excluding HIV grants, which would have delivered activities such 
as harm reduction for prisoners. 
 
We mapped the extent of tuberculosis services provided by Global 
Fund–supported programs in prison settings by examining the trend 
and evolution of tuberculosis prison support by region from 2002 to 
2010, the distribution of such activities by status of high tuberculosis 
and MDR tuberculosis burden140, and the regional median prison 




population rate per 100 000 national population by Global Fund 
region. In our mapping exercise, we used the country-level prison 
population rates for December 2008 obtained from the International 
Centre for Prison Studies149 and excluded countries and territories not 
financed by the Global Fund–supported tuberculosis programs and 
those not eligible for funding due to high income status. 
      
We also mapped services delivered by type of principal recipients, 
which include primary contract holders with the Global Fund that 
implement programs financed by the Global Fund. This was done to 
understand the extent of public–private partnership in tuberculosis 
program delivery in each setting and the nature of the various services 
provided to gain an overview of the comprehensiveness of an overall 
package of services delivered for tuberculosis care in prisons. Also, 
we analyzed the performance of tuberculosis grants that include 
tuberculosis services and those that do not include these services by 
comparing performance at grant and indicator levels. The Global 
Fund funds grants in 2 phases: phase 1, comprising 2 years of 
funding, and phase 2, comprising 3 years of funding. Grants are 
assessed for performance at the end of phase 1 to determine the 
amount of funding that will be provided in phase 2. 
Grant performance is rated at 4 levels of performance: A1, B1, B2, 
and C, where A1 is the highest level and C is unacceptable. We 
compared the percentages of well-performing (A/B1) and poorly 
performing (B2/C) grants that included a tuberculosis service 
delivery component in prisons with those that did not. 




Table 1. Summary of Global Fund Processes for Grants 
Proposals are submitted by eligible countries, reviewed for 
soundness by the independent technical review panel, and 
recommended for approval by the Global Fund Board.  
Potential principal recipients are nominated by the country 
coordinating mechanisms and assessed for implementation 
capacities, including financial and program management, 
monitoring, and evaluation, by the local fund agent, which is 
contracted by the Global Fund in each country. Weaknesses and 
gaps are identified and addressed before grants begin operation.  
The local fund agent also provides grant oversight during the 
grant’s life cycle.  
For routine data reporting to the Global Fund, countries are 
encouraged to adopt a set of core output indicators that are agreed 
upon and defined in conjunction with international partners in the 
Monitoring and Evaluation Toolkit,170 available 
at www.theglobalfund.org.  
For each grant, countries select a set of indicators, with targets and 
reporting periods negotiated and agreed upon between the principal 
recipients and Global Fund in grant performance frameworks.  
For disbursement requests, principal recipients are required to 
submit progress updates on results achieved for indicators in 
performance frameworks; this is usually done quarterly or 
semiannually.  
Prior to submission to the Global Fund Secretariat, reports are 
verified by the local fund agent for content and accuracy.  
Data verification processes include onsite data verifications on 
selected programmatic indicators and data quality audits on 
selected grant samples.  





By December 2010, 53 of the 105 countries (50%) with Global Fund–
supported tuberculosis programs delivered services within prison 
settings. The funding allocated to tuberculosis grants, which included 
tuberculosis service delivery in prison settings, consisted of $558 
million, accounting for almost 28% of the $2 billion invested in all 
tuberculosis programs benefiting from Global Fund support. Of the 
$558 million disbursed for grants that included tuberculosis service 
delivery in prisons, $304 million (54%) went to nongovernmental 
principal recipients from civil society organizations, the private 
sector, and development partners. Based on reported expenditures 
from principal recipients by the end of 2010, an estimated $56 million 
was spent on PPM approaches (10% of $558 million), which would 
have included various services delivered in prison settings. However, 
no systematically captured data were available that would enable 
quantification of direct funding allocated in tuberculosis care and 
delivery within penitentiary settings. 
 
Figure 1 shows the number and proportion of countries/territories that 
included tuberculosis service delivery in prison settings, by year. In 
terms of overall global support in these countries, there was a steady 
increase between 2003 and 2010, as the number of countries 
implementing tuberculosis service delivery in prison settings 
increased from 5 countries in 2003 to 53 by 2010. This increase was 
in tandem with the rise in overall number of countries receiving 




Global Fund financing for all tuberculosis program support, which 
rose from 21 countries in 2003 to 105 countries by 2010. 
                     
Figure 1. 
 
Number and proportion of countries/territories that included 
tuberculosis service delivery in prison settings, by year  
 
 
(Number of countries/territories with tuberculosis service delivery within 
prison settings number of all countries/territories with tuberculosis service 
delivery supported by the Global Fund).  




Figure 2 shows that there is great regional variation in tuberculosis 
services delivered. Nearly 90% of all countries and territories (16 of 
18) in the EECA region with tuberculosis grants included 
tuberculosis activities for prisoners. Approximately two-thirds (10 of 
15) of countries in the WCA region with Global Fund–supported 
tuberculosis programs included tuberculosis services for prison 
populations. Between 2003 and 2010 in the WCA region and the 
Middle East and North Africa region, the number of tuberculosis 
grants providing tuberculosis services to prison populations 
substantially increased. This contrasts with the other 2 African 
regions of East Africa and Southern Africa, where many countries 
have high and rising HIV-tuberculosis coinfection rates and have few 
countries delivering Global Fund–financed tuberculosis services in 
prisons, with only 1 (Swaziland) of 10 countries in the Southern 
Africa region and 4 of 10 countries in the East Africa region 
























(Number of countries/territories with tuberculosis service delivery 
within prison settings/number of all countries or territories with 
tuberculosis service delivery supported by the Global Fund) 
Number and proportion of countries that included tuberculosis 
service delivery in prison settings, by region and year 
 





Figure 3 shows the distribution of tuberculosis service delivery in 
prisons in the WHO 22 high tuberculosis burden countries and the 




Distribution of tuberculosis service delivery in prison settings by 
region and status of tuberculosis burden  
(High tuberculosis burden [HBC] or high multidrug-resistant 
[MDR] tuberculosis burden). 
 
 
*The Eastern Europe and Central Asia region includes the high MDR 
tuberculosis burden countries Estonia, Latvia, and Lithuania, which are 
not eligible for Global Fund support.  




Global Fund–supported tuberculosis programs were delivering 
services in prison settings in 18 of the 36 (50%) countries with either 
high tuberculosis or high MDR tuberculosis burden or both. The 
EECA region had the greatest number of tuberculosis/MDR 
tuberculosis burden countries receiving Global Fund–supported 
tuberculosis services in prison settings (n 5 10). Although the EECA 
region had the highest number of MDR tuberculosis countries 
worldwide and the second highest median prison population rate (145 
per 100 000 national population), 5 countries in the region did not 
deliver tuberculosis services within prisons through Global Fund–
supported programs. Of these 5 countries, 3 are ineligible to receive 
Global Fund financing due to their income status (Estonia, Latvia, 
and Lithuania). 
 
In the Southwest Asia region, 4 countries have both high tuberculosis 
and high MDR tuberculosis status, namely, India, Afghanistan, 
Bangladesh, and Pakistan. None of these high tuberculosis/MDR 
tuberculosis countries were implementing Global Fund–supported 
tuberculosis services in prisons. Similarly, in the Southern Africa 
region, not a single high-burden country (Mozambique, South Africa, 
and Zimbabwe) was providing any tuberculosis service in prisons, 
although this region has the third highest median rate for incarcerated 
population (140 per 100 000), as well as a high prevalence of 
HIV/AIDS and tuberculosis comorbidities. The East Africa region of 
Ethiopia, Kenya, and Tanzania had considerably higher prison 
populations both in terms of rates per 100 000 national population 




and absolute total prison population compared with countries such as 
the Democratic Republic of Congo (DRC), Madagascar, and Uganda. 
These countries were providing tuberculosis care for prisoners using 
Global Fund finances. By contrast, DRC, Madagascar, and Uganda 
had programs providing tuberculosis services for prisoners through 
Global Fund–supported programs. Also of note is the WCA region, 
where 9 countries were delivering tuberculosis prison services 
through Global Fund–supported programs, although the region has 1 
high-burden country (Nigeria) and the lowest median prison 
population rate (37 per 100 000) compared with the other 7 Global 
Fund regions. 
 
Figure 4 depicts the comparison of service delivery by principal 
recipient types between tuberculosis grants delivering tuberculosis 
care in prison settings and grants without such delivery. Of the 228 
grants examined, 73 (32%) delivered interventions in prison settings, 
while 155 did not specify similar services in their performance 
frameworks. A higher proportion of grants (146 of 228; 64%) 
delivering tuberculosis services in prisons were managed and 
implemented by governmental principal recipients (eg, ministries of 
health) compared with 130 of 228 (57%) grants with no mention of 
tuberculosis services provided for prisoners. However, this difference 
is not statistically significant (P>.05), with more than one-third of 
grants providing tuberculosis care in prison implemented by civil 
society, the private sector, and development partners. 
 
 






Comparison of service delivery by principal recipient type 
between tuberculosis grants delivering tuberculosis care in 
prison settings and grants without such delivery. 












We examined the nature and types of services delivered to the 
incarcerated populations to ascertain the extent and scope of the 
package of services delivered as tuberculosis care in prisons in 6 
areas: (1) tuberculosis detection and treatment, including diagnosis 
and treatment of smear-positive tuberculosis cases; (2) screening and 
monitoring, that is, screening of tuberculosis by chest radiograph, 
tuberculin skin test, etc, and monitoring, such as drug susceptibility 
testing, smear conversion, and treatment default; (3) advocacy and 
communication; (4) care and support, such as the provision of good 
nutrition, incentives, or enablers and psychosocial support to 
facilitate adherence; (5) treatment for MDR tuberculosis due to 
higher rates of MDR tuberculosis found within confined settings; and 
(6) strengthening of prison tuberculosis service delivery, such as 
monitoring policy and structural aspects of tuberculosis control to 
ensure an enabling environment conducive to effective service 
delivery in prisons (eg, prisons with tuberculosis control programs, 
prisons equipped with quarantine and isolation facilities, training of 
prison staff in tuberculosis referral and care, and doctors trained in 
infection control in prison settings). 
 
Figure 5 shows the distribution of tuberculosis services delivered in 
prisons through Global Fund–supported grants. Nearly half (36 of 73; 
49%) of the 73 grants delivering tuberculosis services in prisons 
focused on the provision of diagnosis and treatment of tuberculosis 
cases, while 27% (20 of 73) provided screening and monitoring 
services. More than half of the grants financed activities aimed at 




strengthening tuberculosis service delivery capacity and providing an 
environment that could facilitate better program management and 
delivery within a penitentiary setting. By contrast, only 7% of grants 
(5 of 73) delivered MDR tuberculosis services in prisons, where drug-
resistant tuberculosis is a major issue, especially among those who 
are confined. Similarly, in terms of the different types of services 
offered, the majority (50 of 73; 69%) of grants supported by the 
Global Fund offered only 1 type of service, with less than one-fifth 
delivering 2 types of services. 
 
Figure 6 depicts the distribution of the different tuberculosis services 
delivered in prisons through Global Fund–supported grants, by 
region. There were regional differences in the extent of services 
delivered. Although countries outside the EECA region had 
predominantly 1 type of service delivered, countries within the EECA 
region had, by comparison, the highest number of services delivered, 
ranging from 2 to 3 areas of service. 
  






                          
Figure 5. 
 
Comparison of services delivered in prisons through Global 
Fund–supported grants. ACSM, advocacy, communication, and 
social mobilization activities; MDR, multidrug-resistant. 
  









Distribution of number of different tuberculosis services 
delivered in prisons through  
Global Fund–supported grants, by region. 
 
  




Figure 7 compares the performance of grants with tuberculosis 
service delivery in prisons. It shows that those with service delivery 
performed better compared with those without service delivery (P 
>.05). Comparison of performance of the tuberculosis grants shows 
that grants with tuberculosis service delivery in prisons had a slightly 
higher percentage of grants in the A/B1 category (85%) compared 
with grants without prison services (81%), although this difference is 




Grants with tuberculosis service delivery 










Tuberculosis morbidity and mortality among populations 
incarcerated in penal institutions are often many times higher than 
within the general population, posing an increased risk of 
tuberculosis for inmates of these institutions as well as the general 
society159-161,164. The physical environment of prisons concentrates 
and disseminates tuberculosis through overcrowding, poor 
ventilation, poor personal hygiene, and risky behaviors. In addition, 
the structural deficiencies of prison healthcare management, such as 
lack of funding for healthcare and inadequate infrastructure, staff 
resources, and expertise, adversely affect the quality of tuberculosis 
treatment and care. The all-too-frequent absence of linkages between 
the ministries of health and the ministries of justice and the limited 
interaction of the latter with NTPs, civil society, and the affected 
communities further exacerbate problems faced by inmates during 
their tenure and following discharge. Follow-up and referrals of 
tuberculosis patients in penal institutions during incarceration and 
upon discharge are not systematically tracked, and NTPs are not 
always notified of new cases, leading to an inadequate estimation of 
the size of the problem. Consequently, prison settings often have poor 
tuberculosis case and program management, resulting in high levels 
of drug-resistant tuberculosis and other comorbidities. 
 
Incarcerated populations also have higher HIV prevalence compared 
with the general population147, with prevalence levels.10%within 
prison settings in 20 countries171. This is, in part, exacerbated by high-




risk behaviors such as drug injection that lead to comorbidities 
beyond HIV such as high levels of hepatitis B and C. As the largest 
financier of international funding for tuberculosis, the Global Fund 
provides financing to tuberculosis programs to meet the needs of 
disadvantaged groups, especially the most vulnerable populations. 
Our study examined the scope and extent of Global Fund financing 
for tuberculosis service delivery in prison settings to gain an 
understanding of the current status of financing for this high-risk 
group by global region, the types of service delivered to prisoners, 
and the performance of these programs. 
 
Our analysis shows that an increasing number of countries are 
benefiting from Global Fund support that funds the delivery of 
tuberculosis services in prisons. Although in many of these cases 
governments were the principal recipients of such grants, a 
significant proportion of these services were managed and 
implemented by civil society organizations, the private sector, and 
international agencies. This funding scenario demonstrates the 
potential scope for full, multisectoral collaboration and engagement 
of all providers, both private and public, which is an essential 
component of the Global Plan to Stop TB. 
 
Tuberculosis grants to programs that included delivery of 
tuberculosis services in prison settings were performing equally well 
compared with tuberculosis grants without tuberculosis services in 
prisons. In relation to the scope and scale of tuberculosis services 
delivered in prisons, there was some variation across regions, with a 




large number of countries in the EECA region delivering a range of 
services for prisoners, while the coverage of such services was almost 
nonexistent in Southern Africa. By contrast, a number of countries in 
the WCA region reported Global Fund support for tuberculosis 
service delivery for prisoners, despite the relatively lower 
tuberculosis burden and the lowest prison population rate in Africa. 
Of equal concern was the fact that no high tuberculosis burden 
countries in the Southwest Asia region had tuberculosis grants that 
were supporting activities aimed at delivering tuberculosis care 
within prison settings. 
 
The particularly low coverage of tuberculosis services in Southern 
Africa, a region with a heavy HIV and tuberculosis burden, merits 
further investigation, especially given its relatively high median 
regional prison population rate and the large number of countries with 
rates twice as high as the global median and high absolute numbers 
of prisoners and populations infected with tuberculosis. The same 
holds for the Southwest Asia region, which has attracted no funding 
from the Global Fund for prison-based tuberculosis services. All 
regions need to scale-up further prison-based tuberculosis services 
because support is not always consistent with current needs, as 
measured by either high tuberculosis/MDR tuberculosis or HIV 
burden or high prison population rates. 
 
There is a need to further examine the reasons for the good coverage 
achieved in the WCA region and to draw lessons learned for 
implementation in other regions. With the exception of the EECA 




region, most prison-based tuberculosis programs supported through 
Global Fund grants offer limited services for prisoners. Therefore, 
there is a need to better define and promote a more comprehensive 
package of tuberculosis care tailored and adapted to delivery within 
congregate settings. In particular, the minimal provision of MDR 
tuberculosis services was highlighted in our analysis, perhaps not 
surprisingly, because drug-resistance management requires extensive 
expert resources and dedicated infrastructure and is even more of a 
challenge in prison settings, where medical and specialized skills and 
the available resources are severely constrained. This issue will need 
to be addressed with a sense of urgency given that MDR tuberculosis 
is particularly prone to propagation within prison walls172. 
  




Table 2.  
Information Gaps and Challenges Identified in the Study 
• Lack of systematically available financial data for tracking 
the funding allocated for tuberculosis service delivery in 
prisons from the Global Fund or other major international 
donors.  
• Lack of financial information such as budgets and 
expenditures from correctional facilities to monitor 
domestic fund sharing.  
• Different countries have different modalities for 
delivering tuberculosis treatment within penitentiary 
settings, e.g., as private–public mix or as part of regular 
public health service.  
• Lack of a standard set of indicators for monitoring 
tuberculosis service delivery in prisons, with services 
delivered through Global Fund–supported programs not 
documented in grant performance frameworks.  
• No information on how linkages between ministries of 
health and others function in the delivery of tuberculosis 
services for the incarcerated population.  
  
  




We encountered several limitations during this analysis, primarily a 
shortage of relevant data globally and for the grants supported by the 
Global Fund (Table 2). First, there were no standardized financial 
data available from the Global Fund grants database that were 
codified to enable quantification of funding allocated and expended 
on prison-related tuberculosis service delivery at an aggregate level. 
Also, there was a paucity of systematically compiled information on 
the extent of international financing provided for tuberculosis service 
delivery in prisons by other major funding agencies, such as the 
World Bank and other bilateral and nongovernmental 
organizations167. This made it difficult to examine the Global Fund’s 
contribution within an appropriate context of total funding for these 
services. Second, there was a lack of internationally agreed-upon and 
standardized tuberculosis service indicators specific to monitoring of 
program delivery in prison settings. This hampered our efforts to 
accurately capture the full extent of services delivered within Global 
Fund–supported programs because not all activities carried out in 
these programs were monitored by the performance frameworks for 
these grants, which track indicators deemed to be the most suitable 
for monitoring grant performance. In other instances, many countries 
did not include tuberculosis treatment and care activities as PPM in 
prisons because often there is no separate healthcare delivery system 
in prisons; tuberculosis care services are extended to prisons under 
regular public health functions. Thus, the true extent of service 
delivered to prisoners through Global Fund support might have been 
underestimated. Third, there are no systematically available estimates 




of budget allocations for prison healthcare costs and expenditures by 
country. Typically, the budgets for NTPs do not include tuberculosis 
service delivery costs in penitentiary settings because these are the 
responsibility of ministries of justice or ministries of the interior, 
which oversee correctional facilities. Fourth, there is scant 
information on the linkages between ministries of health and other 
ministries involved in financing and delivering tuberculosis services 
in prisons. The absence of reliable financial information on prison-
based tuberculosis services makes it difficult to explore factors that 
influence the uptake of Global Fund finances to deliver tuberculosis 
or other health services within penitentiary systems and to ascertain 
future resource needs and funding gaps. 
 
7.9 Conclusions 
Our study is an important first step in establishing an overall picture 
of financial support for prison-based tuberculosis services from 
international sources to protect and improve the health of prisoners, 
a disadvantaged and marginalized group. There are many areas in 
which tuberculosis control and overall healthcare provision in prisons 
can be improved. Prison settings have obvious advantages for direct 
observation of treatment and provision of high-quality care for a 
highly marginalized group with high levels of tuberculosis154. There 
is an urgent need to better understand the financing needs and cost-
effective service delivery models for tuberculosis care in prisons, 
including models that provide meaningful linkages to affected 
communities and civil society, in order to mount a truly multisectoral 
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8.1 Introduction  
The overarching research question in this thesis is “In what manner 
and under which conditions can the private sector be engaged in 
health care as to increase the chances of an effective End TB Strategy 
that will achieve its targets for 2035” as given in the Chapter 1. This 
discussion chapter attempts to summarize the analysis of the manner 
and the various conditions of private health sector engagement in 
view of the targets of the End TB Strategy of the World Health 
Organization (WHO), by drawing relevant findings from the previous 
chapters of this thesis. To put the discussion into perspective, a quick 
recollection of the background including the global TB situation, End 
TB Strategy and the challenges in TB control especially in the 
backdrop of the private health sector is provided here.  
 
8.1.1 Global TB situation 
As discussed in the previous chapters, TB remains a major global 
public health problem and is one of the top 10 causes of death 
worldwide1. As per WHO’s global TB report of 2017, there were 10.4 
million incident TB cases in 2016 of which 10% were living with 
HIV. In 2015, 1.3 million people died of TB recording a mortality 
rate of 17 per 100 000 population1. There were 600 000 new cases 
with resistance to rifampicin (RR-TB) of which 490 000 had 
multidrug-resistant TB (MDR-TB). In addition, 123 Member States 
of WHO reported extensively drug-resistant TB (XDR-TB). Eighty 




five percent of the 476 774 notified HIV-positive TB patients were 
started on antiretroviral therapy1.  
 
8.1.2 End TB strategy 
WHO’s End TB Strategy targets 95% reduction in TB deaths and 
90% reduction in TB incidence by the year 2035 compared with 
levels in 2015. The current annual decline in deaths and incidence 
rate are respectively 4% and 1.9%1. The strategy has milestones set 
for 2020 and 2025 to achieve the 2035 targets. To achieve the End 
TB targets globally, the entire health system and all types of health 
care providers of especially the high TB burden countries will have 
to take part in TB control based on their levels of engagement and 
share in health care provision. WHO organized the first global health 
ministerial meeting in Moscow in November 2017174. The 
conference, attended by 79 Ministers and a total of 117 country 
delegations, came up with a declaration which reaffirmed the 
countries’ commitment to end the TB epidemic by 2030 as envisaged 
in the Agenda 2030 for Sustainable Development of the United 
Nations and its Sustainable Development Goals (SDGs), End TB 
Strategy of the World Health Organization (WHO), and the Global 
Plan to End TB 2016-2020 of the Stop TB Partnership175. It is in this 
context that the findings of this thesis to be viewed. 
 
8.1.3 Different types of health care providers in the context of TB 
control 
As we have seen in the previous chapters, there are three types of 
health care sectors that are important in TB control namely the public 




health sector under the ministry of health (MoH), health sectors in the 
public sector other than the MoH and the private health sector. In this 
thesis, for convenience, we included the health sectors outside the 
purview of MoH-led NTP under a group called non-NTP sectors. 
Within the private sector, the private-for-profit sector that practises 
modern system of medicine is the most dominant and relevant non-
NTP health sector due to the large numbers of TB patients they cater 
to and the inability of the private sector to perform public health 
functions in TB control which ends up in suboptimal levels of care 
received by TB patients. Therefore, the thesis has additional focus on 
the private-for-profit sector that practises modern medicine. The 
remaining health care providers under private sector include 
providers that practise systems other than modern medicine (e.g. 
Homeopathy), indigenous or traditional systems of healing (eg. 
Ayurveda) and the informal care providers (eg. 
Unqualified/untrained practitioners, traditional healers, insufficiently 
trained paramedical staff). It has been important for NTPs to engage 
these practitioners to reduce the delays in diagnosis, prevent 
unauthorized and non-standard prescriptions of anti-TB drugs and to 
obtain their service as community stakeholders to increase the 
awareness about TB as well as to support patients to ensure treatment 
adherence.  
 
8.1.4 Missing TB cases and the related TB control challenges 
A simple calculation of how many TB patients are being notified and 
successfully treated in the current scenario will explain the vastness 




and seriousness of the challenges in TB control. WHO reports that, 
of the estimated 10.4 million incident TB cases of 2016, only 6.3 
million (61%) were notified. This means that 4.1 million TB cases 
are ‘missing’ from notification about whom the national TB 
programmes (NTP) have no information. When only 61% of the 
estimated 10.4 million incident TB cases are notified and 83% of 
these 61% (6.3 million) cases are successfully treated, as per available 
data, eventually we have the information about successful treatment 
of only 50% (61/100X83/100 which is 50% and equivalent to 5.2 
million cases) of the incident 10.4 million TB cases. In addition, even 
among the notified TB cases, 1.1 (that is 6.3 - 5.2) million cases have 
met with unfavourable treatment outcomes other than treatment 
success such as failure, death, lost to follow up or not evaluated. 
There will also be a small proportion of patients who don’t seek any 
care and will die due to TB in a short time. However, majority of the 
4.1 million un-notified TB cases of 2016 would have sought care 
from non-NTP health care sectors, mostly private care providers. 
There is no guarantee that these patients received care as per 
international standards. Such TB patients broadly fall into four 
groups; 1) those who have not sought any care 2) those who sought 
care, but TB was not diagnosed 3) those who were diagnosed to have 
TB at a non-NTP health facility but received inappropriate or 
inadequate treatment with anti-TB drugs and were not reported 4) 
those who were correctly diagnosed and successfully treated, but 
were not reported to NTP. Most of those who have not sought care or 
those who are not diagnosed of TB even after seeking care would die 




within a few years. Studies of the natural history of TB disease before 
the discovery and use of anti-TB antibiotics recorded 70% death rate 
among sputum smear-positive pulmonary TB within 10 years of 
being diagnosed1. Those patients who received inadequate or 
inappropriate treatment with anti-TB drugs are likely to develop 
MDR-TB176-180. It has been proved that there are plenty of issues in 
the diagnosis and treatment of TB cases in the private sector which 
lead to delayed or missed opportunity to diagnose TB as well as very 
low rates of treatment success. These in turn contribute to long 
durations of illness, increased rates of disease transmission in the 
community and larger percentage of people dying of TB. 
 
8.2 Main findings of the thesis 
The specific questions that the thesis discussed in detail in the 
preceding chapters are the following:  
  
- How did the TB control program of India try to engage the 
private sector in TB control and what has been the effect of 
the early public-private mix (PPM) pilot endeavors?  
- How did India scale up the pilot projects on private sector 
engagement in TB control to national level and what has been 
the learning?  
- What has been the role of the Indian Medical Association in 
the engagement of the private sector in TB control and what 
is its relevance? What are the lessons for India and other 




countries to learn from the unique endeavor of engagement of 
medical professional associations in TB control?  
- What has been the landscape of funding from the Global 
Fund, the biggest international donor in TB control, for the 
engagement of the private sector in TB control?   
- Do prisons that house around 10 million detainees, among 
whom TB is a leading cause of morbidity and mortality, get 
adequate funding for TB control?  
 
• How did the TB control program of India try to engage the 
private sector in TB control and what has been the effect of 
the early public-private mix (PPM) pilot endeavors?  
 
From the beginning of the implementation in 1997, Revised National 
TB Control Programme (RNTCP) of India has been making 
continuous efforts to partner with private health sector. Subnational 
units of RNTCP had implemented multiple pilot projects of PPM 
from 1999 onwards through collaborations developed locally. 
Chapter 3 of this thesis has given an overview of the analysis of the 
14 documented PPM projects between 1999 and 2004. Six PPM 
projects that engaged private practitioners and another eight projects 
that engaged corporate sector or non-governmental organization 
(NGO) partners demonstrated significant increase in TB case 
notification; around 15% for the first group and between 12% and 
98% for the latter. There were no significant differences between 
NTP and non-NTP health sectors in treatment success rates78,90. Thus, 
these pilots demonstrated that collaboration between RNTCP and 
private practitioners in India improved the TB case notification while 




maintaining good treatment outcomes. It also demonstrated the 
ability of NGOs and private industry medical services to work with 
RNTCP. It was also noted that the presence of a strong public sector 
was critical for provision of necessary advocacy, training, and 
supervision. The findings highlighted the need and feasibility of 
building public-private collaborations and the significant potential 
they hold for improving TB control in India. These PPM projects 
informed RNTCP that the scene was set for a broad scale-up of PPM 
into routine practice for tuberculosis programmes. 
 
• How did India scale up the pilot projects on private sector 
engagement in TB control to national level and what has been 
the learning?  
 
Encouraged by the results of the various PPM pilot projects, RNTCP 
in 2003 implemented an intensified national scale-up of public-
private mix (PPM) DOTS initially covering 50 million population in 
14 major cities across the country181. It was done in a systematic 
manner based on national policy decisions of RNTCP and following 
uniform processes in all the cities while providing sufficient 
flexibility for necessary adaptations based on the local context. The 
project while working closely with the district level units of RNTCP 
and its functionaries recruited additional human resources to absorb 
the extra work due to intensified PPM implementation. To begin with, 
all the health care providers were mapped followed by basic 
sensitization on RNTCP and PPM. Newer tools targeting private care 
providers such as advocacy kits and a concise training module were 
also developed. Providers’ recruitment was prioritized based on the 




number of patients they managed which means those with higher 
number of clientele were enrolled first. A PPM-focused surveillance 
system was developed by the project to capture the implementation 
data disaggregated by various provider characteristics (eg. type, size) 
and patient characteristics (eg. age, gender). RNTCP’s national 
schemes for engaging different types of providers were used for 
entering into formal agreements with private care providers. The 
national schemes offered support to private providers that included 
financial compensation and provision of logistics in addition to 
assistance in public health aspects such as registration of TB patients, 
treatment adherence support and recording of treatment outcome. 
There were also national advocacy campaigns undertaken by RNTCP 
to complement the local initiatives.  
 
The project sensitized close to 16 000 health care providers whereas 
only a small proportion expressed interest in taking part in training. 
This was one of the lessons learnt about the challenges in getting 
private practitioners even for shorter sessions of training. In the 14 
cities together, notification rates for new lung TB cases diagnosed by 
microscopy as well as all (diagnosed by microscopy and other tools) 
new cases increased respectively by 12% and 17% per 100 000 
population. During the same period, in the comparison cities of the 
country, case notification rate of new smear positive and all new cases 
had registered a slight decline. All the non-NTP health care providers 
together had a share of 33% of the cases notified by RNTCP of which 
medical colleges had contributed 16%, private practitioners 6%, 




NGOs 7%, other public providers 3% and corporate sector 1%. This 
helped RNTCP take decisions on prioritizing medical colleges for 
immediate engagement. Private sector including NGOs, contributed 
18% of all notified new cases that were diagnosed by microscopy. 
Overall treatment success rate of the project was above the 85% target 
of RNTCP. However, in the case of medical colleges, cure rates were 
relatively low which was because the medical colleges due to their 
popularity had attracted patients from far off places who had to be 
transferred out to their own districts after a short period of 
hospitalization182. Treatment outcome information of many such 
patients were not available which led to relatively lower cure rates 
recorded. This helped RNTCP in framing policies for referral of such 
patients back to their neighborhood and mechanisms to follow up 
them until the treatment outcomes were reported, like in the case of 
patients managed by local RNTCP. Similarly, through this PPM 
project, RNTCP learnt that prioritization of large numbers of small 
scale health care facilities or individual private providers may not be 
as cost-effective as the engagement of large institutions such as 
medical colleges. Nevertheless, they constitute most private 
practitioners in the country who are approached by substantial 
proportions of patients107. Lessons from this project prompted major 
decisions by RNTCP to study the cost effectiveness of PPM and 
formulate mechanisms to engage small and individual health care 
providers in an effective manner81.   
 




• What has been the role of the Indian Medical Association 
(IMA) in the engagement of the private sector in TB control 
and what is its relevance?  
 
As discussed in Chapter 5, RNTCP, from the time of initial days of 
its implementation, had made efforts to engage IMA though with very 
limited success. However, private medical practitioners were initially 
very doubtful about the claims RNTCP to be a superior programme 
compared to the previous NTP of India. While NTP transitioned to 
RNTCP, there has been repackaging of approaches in the diagnosis 
and treatment based on the guidelines of the DOTS strategy. 
However, the modern medicine practitioners in the private health 
sector had opposition to the principles of RNTCP. The opposition 
was around four major areas namely diagnosis, treatment, patient-
related issues and physician-related issues as discussed in Chapter 5. 
IMA at national level was silent on this issue in the initial years. 
However, in the PPM pilot projects that evolved in New Delhi, 
Kannur and Kollam, IMA had acted as an interface between RNTCP 
and the private sector. All these pilot projects recorded very high 
percentages of participation of private health care providers and 
demonstrated significant increases in case notification103. These PPM 
projects also achieved high treatment success rates. In Kollam, a 
district in Kerala state of India, IMA’s state secretary was directly 
engaged in PPM where his private hospital was designated as a 
RNTCP-endorsed facility. In Kannur, another district in Kerala, the 
secretary of IMA was the district TB officer who ensured IMA’s 
close participation in the PPM pilot. Encouraged by the results of 




these models, IMA and RNTCP together expanded the Kannur and 
Kollam models to the entire state of Kerala. When the state level 
expansion also resulted in increased participation of private 
practitioners and resultant increase in TB case notification, RNTCP 
requested IMA to expand this model to a few other states of India. 
All these models focused on training of private doctors and then 
linking their private care facilities to RNTCP. Better acceptance to 
the training and recruitment into RNTCP done by IMA among private 
doctors led to the decision of RNTCP to include IMA as its 
subrecipient for the Round 6 funding of the Global Fund’s grant in 
2007. In this project, IMA took the responsibility of expanding its 
private sector model to more states of India. As discussed in Chapter 
5, IMA-Global Fund project covered 169 districts and 532 IMA 
branches serving 415 million population and over 55 000 IMA 
members. The project in a period of 8 years from 2007 to 2015 
reached 103 254 private doctors through continuing medical 
education, trained 163 86 doctors and notified 112 409 TB cases. 
Over 4000 practitioners signed agreement with RNTCP and close to 
5000 ‘DOT centres’ were opened128. IMA-RNTCP partnership also 
helped in strengthening the relationship between RNTCP and the 
private sector and contributed to the development of strategic 
guidelines for formal engagement of private sector providers131. 
Lessons from this partnership also contributed to the evolution of the 
innovative concept of public-private interface agencies (PPIA) in 
India to facilitate the public-private collaborations. PPIAs are now 
being implemented in bigger urban areas where diverse kinds of 




private sector providers dominate the health care system27. However, 
lapses like lack of clear mechanisms to measure the contribution of 
IMA and the absence of a formal agreement between RNTCP and 
IMA led to gradual weakening of this partnership. In addition, the 
IMA-Global Fund project, had no systematic mechanisms to follow 
up with the private practitioners after the training to establish 
RNTCP-approved services at their facilities. Evolution of the 
RNTCP-IMA partnership, the lessons learnt, and the challenges faced 
are valuable information that could feed into the policies of global TB 
control regarding the engagement of medical professional 
organizations.    
 
• What has been the landscape of funding from the Global 
Fund, the biggest international donor in TB control, for the 
engagement of the private sector in TB control?  
 
Multiple international and domestic donors had provided funding for 
PPM pilot projects in the initial years. As discussed in Chapter 6, The 
Global Fund, is the biggest international donor (currently 
contributing to 65%) of the total international funding for TB 
control166,168. Despite the global efforts to promote PPM, there was 
no information on the prioritization of PPM in the funding proposals 
as well as actual funding allotted and spent for PPM. Chapter 6 
‘Global Fund financing of public–private mix approaches for 
delivery of tuberculosis care’ is the landscaping study of PPM 
interventions in TB control programmes supported by The Global 
Fund166. The study observed that the importance and the scope of 




PPM were not often reflected in the TB proposals and the budgets 
submitted by countries. The proportion of countries with PPM had 
not increased despite additional Global Fund support for PPM. 
Relatively lower engagement of both NGO and private health sectors 
was also noted. The study commented that the median budget 
allocation for PPM activities of 5% was insufficient for scaling up of 
PPM initiatives. Initiatives in India such as mechanisms to formalize 
PPM through tools like guidance documents were highlighted by the 
study. The study recommended the need for innovative mechanisms 
such as certification of provider and financial incentives, depending 
on the local needs. Considering the 5 to 50 times higher TB 
prevalence rates within penitentiary settings compared with the 
general population, the study highlighted the need for expansion of 
PPM activities to prisons with adequate funding.  
 
• Do prisons that house globally around 10 million detainees, 
among whom TB is a leading cause of morbidity and 
mortality, get adequate funding for TB control?  
 
Among the prison population, tuberculosis is a major cause of 
illness160. Chapter 7, ‘Global Fund Financing of Tuberculosis 
Services Delivery in Prisons’, did a study as a follow up to previous 
study on Global Fund financing for PPM (Chapter 6). As discussed 
in Chapter 7, TB morbidity and mortality among prisoners are often 
many times higher compared with the general population and it poses 
an increased risk of TB for inmates as well as the general 
population159,161,164,183. The shortages in the physical environment and 
infrastructure of healthcare management in prisons affect the quality 




of TB treatment and care. As of December 2010, 50% of Global 
Fund-supported TB programs delivered services within prison 
settings. Global Fund–supported TB programs were delivering 
services in prison settings in 50% of the countries with high TB 
burden. The funding allocated to tuberculosis grants, which included 
tuberculosis service delivery in prison settings, accounted for about 
28% of the US$ 2 billion invested in all TB programs funded by The 
Global Fund. However, no systematically captured data were 
available that would enable quantification of direct funding allocated 
in tuberculosis care and delivery within penitentiary settings. The 
study was an important first step in establishing an overall picture of 
financial support for prison-based tuberculosis services from 
international donors. The study found that there were many areas 
where TB control and overall healthcare provision in prisons could 
be improved. The study also noted that there is an urgent need to 
better understand the financing needs and cost-effective service 
delivery models for TB care in prisons.  
 
8.3 Chances of PPM  
 
Having discussed the experience from different PPM projects and in 
the light of the discussion so far on the various related aspects of 
PPM, it’s appropriate now to discuss the chances and challenges 
encountered by PPM.  
 
8.3.1 Is there a need to engage the private sector?  
There has always been a philosophical question: “Is it good or bad to 
engage the private sector in TB control and can’t the public sector 




alone run the NTP?” As has already been discussed in the previous 
chapters, if there is a strong, efficient and easily accessible public 
sector running the national TB control programme and if the people 
are generally accessing health care from the public-sector health 
facilities, there is no need to heavily engage the private sector. 
However, as discussed in the earlier chapters, public health sector in 
the developing world is generally weak, inefficient and failing due to 
which patients don’t have trust in it6,184,185. The private sector in these 
countries will be competing with the public sector in broadening the 
clientele base and to maintain it. The private providers would also be 
deviating from the standard guidelines of diagnosis and treatment due 
to multiple reasons especially financial reasons. Especially in the 
high TB burden countries, there are public health sector-driven NTPs 
which run the programme, but large proportions of people access care 
from the private sector. Therefore, good performance of the NTPs 
alone is not sufficient to attract all TB patients to NTP services. Here 
comes the need for the NTPs to take initiatives to engage the private 
sector. 
 
8.3.2 PPM improves case notification and ensures standard care 
to all patients  
As discussed in the previous chapters, PPM interventions across the 
globe in general have proved that collaboration between the NTPs 
and non-NTP health care providers could significantly improve TB 
case notification while maintaining high rates of treatment success103. 
In addition, PPM ensures standard care for TB as determined by the 




NTP is provided to patients irrespective of the sector from where they 
seek care. The contribution of PPM to total 
TB notifications increased by more than 10% between 2012 and 2016 
in Bangladesh, India and the Philippines, especially in areas where 
monitoring was in place1. 
 
8.3.3 Scope for innovations and adaptation 
PPM strategy with flexibility for adaptation to local contexts and 
innovation allows NTPs to experiment newer approaches. Countries 
such as India are now moving towards a more inclusive approach 
with government’s willingness to understand better the nature and 
challenges of the private sector and to implement practical and 
friendly approaches to engage the private sector instead of imposing 
the NTP policies on the private sector. PPIA model in India, 
communication campaign that advised people with symptoms of TB 
to report to NTP-endorsed private care facilities and use of Xpert 
MTB/RIF test in the private sector in Dhaka and Jakarta are examples 
for this transition from the conventional approaches of NTP27,186-188. 
 
8.3.4 PPM is cost effective  
The first study on effectiveness, cost and cost-effectiveness of PPM 
in India was undertaken as early as in 2003. In this study, pilot 
projects in the cities of Hyderabad and Delhi, each serving around 
500 000 population, were considered79. As far as effectiveness was 
concerned, the PPM projects in Hyderabad and Delhi detected 
respectively 26% and 47% additional TB cases than the comparison 
areas in the country. Both the projects registered high treatment 




success rates close to or exceeding the then WHO target of 85%. For 
patients and their attendants, treatment in the public sector and in 
PPM projects allowed a substantial reduction in costs compared with 
those in the private sector that didn’t offer RNTCP services79. The 
finding that there were no additional costs to the public sector for the 
extra cases successfully treated in Hyderabad proved the cost 
effectiveness of the project. PPM also resulted in an improvement in 
the number of cases successfully treated. The study proved that PPM 
in India was an effective, affordable and cost-effective approach to 
improving TB control in India. The study also had recommended that 
successful approaches to PPM should be scaled up alongside 
continued implementation and expansion of the public sector RNTCP 
programme79.  
 
A subsequent study done in Bangalore city of India in 2005 recorded 
the patient delay and health system delay in TB are shown in Table 
1. While the mean patient delay was 21 days, the health system delay 
was 52 days. A health system delay of more than 7 weeks was 
positively related to large number of health contacts and a private 
practitioner as the first health care contact80. As shown in Table 2, 
patient had already spent US$ 145 before treatment for TB. The cost 
of treatment outside RNTCP was 6 times (US$ 127) than the cost in 
RNTCP (US$ 21)80. The study also proved that PPM implementation 
substantially reduced costs to patients, such that the average societal 
cost (the total cost to society which includes both private costs of 
patient plus any external costs) per patient successfully treated fell 




from US$154 to US$132 in the 4 years following the initiation of 
PPM81.  
 
Table 1: Patient and health system delays (source: Economic 
evaluation of public-private mix for tuberculosis care and control, 
India. Part I. Socio-economic profile and costs among tuberculosis 
patients. International journal of Tuberculosis and Lung Diseases. 
13(6):698–704. 2009); Pantoja et al80,81.  
 
Table 2: Average cost per patient ($US) incurred by patients and 
attendants before and during treatment of TB within and outside the 
RNTCP. (source: Economic evaluation of public-private mix for 
tuberculosis care and control, India. Part I. Socio-economic profile 
and costs among tuberculosis patients. International journal of 









* Refers to associated drugs, including food packages, for patients treated under the 
RNTCP, and anti-tuberculosis drugs for patients treated outside the RNTCP. † 
Time lost due to directly observed treatment for costs during TB treatment, which 
implies the patient going to the health centre to take the medicines every day during 
the initiation phase and occasionally during the continuation phase. RNTCP = 
Revised National TB Control Programme; TB = tuberculosis; NA = not available. 
 




As described in the study of cost and cost-effectiveness by Pantoja et 
al, when both patients treated in the RNTCP and those treated outside 
the RNTCP were considered, implementation of PPM in two phases 
(Phase 1: introduction of PPM that began in mid-2001; Phase 2: 
intensified PPM that began in 2003) led to a fall in societal costs 
(Figure 1)81.  
 
The study explains that this was because while costs for providers 
increased over time, the total costs incurred by patients and their 
attendants decreased. This was the reflection of a shift of patients 
from non-RNTCP treatment to less costly RNTCP treatment. Costs 
incurred by patients and their attendants had come down from 75% 
of total societal costs pre-PPM to 23% of total societal costs in PPM 
Phase II. 
Societal perspective ($US, 2005). Assumes that the total number of 
patients treated, within and outside the RNTCP, is the same in all 
three phases. However, there is a shift of patients treated outside the 
RNTCP to the RNTCP which results in a reduction in total costs 
during treatment for patients/attendants. Costs include costs for all 
providers within the RNTCP as well as for patients and attendants 
treated within and outside the RNTCP. These studies clearly showed 
that the implementation of PPM on a large scale can be cost-effective 
and that PPM implementation can increase treatment success rates 












Annual costs of patient/attendant and provider 
                    
 
 
(source: Pantoja et al.  Economic evaluation of public-private mix for 
tuberculosis care and control, India. Part II. Cost and cost-
effectiveness. International journal of Tuberculosis and Lung 
Diseases. 13(6):705–712. 2009)81  
  




8.4 Challenges encountered by PPM 
While there have been consistent global efforts to engage non-NTP 
health sectors in TB control, led by NTPs applying PPM strategy, 
there are many existing and emerging challenges faced by PPM 
initiatives. Despite the implementation of TB control programmes 
globally in an organized manner since the early 90’s, the TB epidemic 
has not changed much. The recent TB prevalence surveys in some 
high TB burden countries proved that TB incidence in many countries 
were grossly underestimated1.  
 
TB is concentrated mainly in lower income countries and populations 
and therefore a range of strategies are required to finance various 
public private mix (PPM) models in different settings. Currently, the 
predominant source of financing for PPM is input-based domestic 
and donor financing, Funding gap faced by TB control programmes 
affect investments in PPM also1. As reported by the USAID and The 
World Bank, sustainability of financing of PPM will rely in part on 
the incorporation of TB and PPM into domestic health financing 
streams189. 
 
Despite many innovative PPM interventions, PPM in India is faced 
with multiple challenges. The number of private health care 
providers, both formal and informal, is increasing exponentially. A 
repeat study ‘Tuberculosis Management by Private Practitioners in 
Mumbai, India: Has Anything Changed in Two Decades?’ conducted 
in 2010 as a 20-year follow up on the pioneering study in 1991 done 




by Mukund Uplekar found that things have not changed much over 
the years. Clear majority of private practitioners are still unable to 
correctly prescribe medicines for a TB patient. Only 6 of the 106 
respondents wrote a prescription with a correct drug regimen for TB; 
106 doctors prescribed 63 different drug regimens17. This is in 
comparison with the study in 1991 by Mukund Uplekar ‘Treatment 
of tuberculosis by private general practitioners in India’ that had 
thrown light on the unexpectedly low levels of awareness among 
private medical practitioners about treatment for TB. This study was 
done in Mumbai city of India where the TB burden has been very 
high with estimated current annual incidence of 60 000 TB cases. 
Hundred private doctors in the study prescribed 80 different drug 
regimens, most of which were both inappropriate and expensive16. 
Similarly, despite the presence of regulatory frameworks including 
mandatory TB case notification in many countries, enforcement of 
such regulations remains a challenge.  
 
The private sector, especially in India, is likely to continue to be 
diverse and largely disorganized due to the multitude of practitioners 
of different systems of medicine, running various types of health care 
facilities in contrasting settings. For example, in India, private 
practitioners practising systems other than modern medicine 
(AYUSH- Ayurveda, Yoga, Unani, Siddha, Homeopathy and 
naturopathy)190, traditional healers and informal providers (those 
without any academic qualification/license to practice) are widely 
spread across the country. In certain geographical locations, 




especially remote villages and urban slums, informal providers have 
a major presence60.  
 
A study done in Chennai, India, to understand the awareness, 
perception and barriers on TB notification among private 
practitioners showed that three-fourth of private practitioners were 
aware of the TB notification order by the government of whom only 
33% had ever notified a TB case191. People especially the poor who 
are forced to access health care from the private sector due to the non-
availability of services or suboptimal quality of care at the public 
health facilities are further disadvantaged due to this. Out-of-pocket 
and catastrophic expenditures make people poorer and more 
vulnerable to diseases including TB. People living in places such as 
remote villages, difficult to access tribal areas or urban slums heavily 
depend on the private providers available in their respective areas and 
they incur catastrophic expenses. Reaching the poor and 
marginalized, who have more likelihood of contracting TB and 
thereby by suffer from out-of-pocket and catastrophic expenditures, 
through PPM approaches remains a big challenge.  
 
The above stated multiple challenges and the complex situation make 
it difficult for the TB programme managers also to organize 
systematic PPM activities. As has been pointed out earlier, adverse 
factors such as overburden in the public sector, diverse nature of 
private sector, difficulties in convincing the private sector to engage 
in partnerships due to lack of trust, inadequate resources, and often 
lack of capacity within the public sector or low priority for PPM act 




as barriers for the programme managers. Inadequate funding and low 
priority pose challenges for researchers also.        
 
8.5 Lessons from India for other countries  
Despite the experimentation of the various fruitful pilot projects of 
PPM, RNTCP of India couldn’t successfully scale up such models to 
bigger geographies at subnational or national levels. This is how 
RNTCP started considering newer strategies and innovative 
approaches. Some of the recent changes in the approaches and 
strategies of PPM in India are paradigm shifts from the conventional 
PPM thinking which are showing positive results in terms of 
enhanced funding for PPM and dramatic increases in terms 
notification of additional TB cases. Some of the newer approaches 
and innovations, as summarized below, would serve as examples for 
other countries that have situations similar to that of India.  
 
8.5.1 Additional focus on PPM  
In the recent years, the concept of PPM has been gaining a broader 
meaning in India. The National Strategic Plan (NSP) for TB 
elimination 2017–25 strategizes to replace mistrust between public 
and private sectors by constructive partnership. NTP would also work 
with the private care providers to deliver quality-assured Standards 
for Tuberculosis Care in India - compliant services to the entire 
population. For achieving this, RNTCP has established a scheme that 
offers incentives to the private providers for notifying TB cases and 
to TB patients for reporting to RNTCP. There is another scheme to 




provide medicines free of cost to TB patients seeking care from 
private sector. NSP is developing a modern management information 
system (MIS) to monitor the delivery of drug kits to the patient as 
well as compliance to treatment. This will link to the sale of anti-TB 
drugs by the private pharmacies to link patients into the MIS. India 
plans to augment the availability of rapid molecular tests to make 
more diagnostic facilities available for patients referred by the private 
providers.  
 
8.5.2 New Technical and Operational Guidelines (TOG)  
RNTCP in its TOG published in 2016 describes a broader public-
private partnership (PPP) based on the principles of ‘Universal Health 
Care’82. The PPP is different from the PPM as it considers all health 
sectors as partners with equal responsibility in the implementation of 
TB control instead of using them as passive health care providers who 
will be approached by the public sector – driven RNTCP to share only 
certain roles based on their capabilities. RNTCP is working towards 
this goal with the basic philosophy that government is not the sole 
provider of services for TB and optimum efforts should be made to 
utilize the resources in the private sector. With this changed outlook, 
RNTCP is trying to move from the ‘public health sector-centred’ 
approach in TB control where the government is the controlling 
authority to the new ‘patient-centred’ approach where all 
stakeholders are considered equal partners who produce synergistic 
effects whereby TB patients are benefited82. To engage private sector 
providers, RNTCP has implemented a package of interventions in the 
project ‘Universal Access to TB care’. The interventions are aimed at 




improving TB notifications by offering information and 
communication technology support that is convenient to providers, 
free TB drugs for notified TB patients, and extending public health 
services including adherence support to treatment outcome for 
patients diagnosed and treated in the private sector.  
 
8.5.3 Mandatory notification of TB  
Declaring TB as a mandatorily notifiable disease by an executive 
order of the national government was a bold step taken by RNTCP192. 
RNTCP has also simultaneously developed a web-based case-based 
notification system ‘Nikshay’ which can also be accessed by the 
private health sector care providers to notify the cases they diagnose 
or treat. By 2016, as per Nikshay data, 70 952 private practitioners, 
34 591 hospitals and 9835 laboratories were engaged in RNTCP. 
These providers notified 184 802 patients in 2016 which included 65 
249 patients notified by private clinics and 46 263 patients by private 
laboratories186.  
 
8.5.4 Standards of TB Care in India 
RNTCP developed Standards for TB Care in India (STCI) along the 
lines of International for TB Care. RNTCP took the help of 
organizations like IMA to propagate STIC.  
 
8.5.5 Banning of commercial serological tests 
India also lately banned the use of serodiagnostic test kits for 
diagnosis of TB due to its inconsistent and imprecise findings 
resulting in highly variable values for sensitivity and specificity193.  





8.5.6 Control on over-the-counter sale of anti-TB drugs 
Steps were taken to control the over-the-counter sales of anti-TB 
antibiotics, though these actions have seen variable levels of success 
across the country186. Most recently, the program started providing 
drug regimens that can be taken daily replacing the existing thrice-
weekly regimen with which the private sector has disagreement186.  
 
8.5.7 New and innovative approaches 
RNTCP established PPIA to facilitate engagement of the private 
sector. Interface agencies were engaged in Patna and Mumbai cities 
to implement PPIA projects. PPIA mechanism helped in providing 
quality assured services efficiently to the patients who seek care from 
private health sector. Mumbai is a densely populated city of India 
with more than 12 million residents of whom at least 60% live in 
slums of very deplorable living conditions. Of the annual estimated 
60 000 TB cases, the public sector was notifying only around 30 000 
and the rest of the cases were assumed to have been seeking care from 
the private sector. The project is now notifying between 1500 and 
2000 additional TB cases each month from the private health sector. 
In Patna city, the baseline case notification rate was very low and 
subsequent to the PPIA implementation, the case resulted in a steep 
increase achieving fourfold increase (Figure 2). PPIA models in 
Mumbai and Patna demonstrated the potential of PPIAs to 
dramatically increase TB case notification especially in urban areas. 
In the city of Mehsana, where the case notification showed a steady 




increase, the public sector RNTCP enhanced its efforts to engage the 
private sector and encouraged the RNTCP staff to manage the service 
delivery intervention without an external agency as the interface186.  
 
Figure 2 Increase in TB case notification in PPIA sites  
(Source: RNTCP Annual Report 2017) 
                      
 
Directorate General of Health Services, Government of India)186. 
Picture shows the large increases in the TB case notification in 
Mumbai and Patna cities of India with the support of PPIA from the 
year 2014 when PPIA started implementation. 2013 shows the 
baseline figure. Blue, red and green lines represent the case 
notification trends respectively in Patna, Mehsana and Mumbai cities.    
 
8.5.8 Digital health 
Innovative approaches such as digital health and mobile phone 
applications are increasingly being used in PPM sites in the entire 
spectrum of TB care. This is contributing to the increase in the 



































patients on TB treatment. In what manner and under which conditions 
can the private sector be engaged in health care as to increase the 
chances of an effective End TB Strategy that will achieve its targets 
for 2035 (What does it take the End TB Strategy to meet its 
milestones and targets?) Before discussing the manner and conditions 
under which the private sector can be engaged in health care to increase the 
chances of End TB Strategy achieving its targets, it’s important to review 
the WHO’s general framework to achieving this.    
 
8.5.9 WHO modeling for achieving End TB Strategy Targets 
WHO has modeled certain scenarios to end TB by 2035 as shown in 
the figure 31. The modeling predicts that if the global TB control 
progresses at the current pace, there will be only 25% reduction in TB 
incidence by 2035 against the End TB Strategy’s targeted 90%. As 
can be seen in the figure 3 below, only by ensuring optimized use of 
current and new tools as well as ensuring universal health coverage 
and social protection by 2020 and introduction of tools such as new 
vaccines, drugs and regimens for treatment of active TB disease and 
latent TB infection, and a point-of-care test by 2025, 90% reduction 
in TB incidence can be achieved by 2035. To achieve the milestones 
of the End TB Strategy set for 2020 and 2025, the WHO model calls 
for an annual decline in incidence of 4-5% per year by 2020, and then 
to 10% per year by 2025. Similarly, the proportion of people with TB 
who die from the disease (the case fatality ratio) will have to be 
reduced to 10% by 2020 and then to 6.5% by 2025 (equal to the 
current level in many high-income countries) which is not easily 




achievable in most of the high TB burden countries with the present 
levels of access to high-quality treatment. WHO also recognizes that 
ending the global TB epidemic will be feasible only if there is a 
dramatic decline in TB deaths and cases, elimination of economic and 
social burden of TB and reduction in the out-of-pocket expenditure 
for TB treatment1. The second of the three pillars of the End TB 
Strategy ‘Bold policies and supportive systems’ has included 
‘Engagement of public and private care providers’ as one of its 
components1.       
       
Using the learning from the chapters of this thesis and based on the 
discussions so far, the manner and conditions under which the private 
sector can be engaged in health care to increase the chances of End 
TB Strategy achieving its targets is summarized as follows.                             
Figure 3. 
Projected interventions required 
to achieve End TB targets for 2035.1  
 
Source: The End TB Strategy, World Health Organization3 




8.5.10 Understanding of the situation 
Proper understanding of the nature of the epidemic, functioning of 
private health sector in the broader canvas of the health system and 
the behaviour of patients is an important condition for designing and 
planning private sector engagement. Nature of the epidemic is 
available from prevalence surveys and estimates. Mapping of private 
health care providers will give information about the nature and 
functioning of the private health care providers. There should also be 
complete understanding of the interactions between the public and 
the private sectors. Patent pathway studies will give information 
about the care seeking behaviour of the patients.  
 
8.5.11 Adequate financing 
As we have seen earlier, TB control is faced with inadequate funding 
and PPM doesn’t receive the priority that is deserves in investment. 
International as well as domestic funding have to be ensured for PPM. 
In addition, investment directly in the private sector has to be 
encouraged in order to bypass bottlenecks in the public-sector 
mechanisms. Pooling of resources will reduce the cost while the 
participation will improve.  
 
8.5.12 Commitment and the readiness of the NTP 
NTP should be the political commitment, ownership and the required 
resources to contribute to PPM. NTP should be taking lead in 
providing stewardship as well as supporting in problem solving. 
Appropriate levels of sensitization will have to be provided to the 




public-sector staff. There has to be a private sector focal point and 
adequate manpower to coordinate and work with the private sector.  
8.5.13 Appropriate model 
We assume that the WHO-projected interventions required to achieve 
End TB targets for 2035 fall in place as planned. However, the 
engagement of non-NTP health sectors, especially the private sector, 
is likely to remain as a barrier to reaching the 2035 targets. Depending 
on the context, appropriate models of private sector engagement have 
to be developed and implemented in high TB-burden countries with 
private health care sector as a major player. Pilot initiatives give the 
opportunity for innovations and learning and adapting while doing. 
The models should be able to be inclusive of all care providers. The 
roles and responsibilities of all partners should be clearly defined 
before the work is started. Engagement of private providers should be 
based on prioritization to avoid too much spreading and resultant 
thinning of the impact. For example, there is no need to directly 
engage all the formal and informal providers in service delivery. 
However, proper mechanisms should be there for referral and 
feedback between all bigger and smaller providers. Care should be 
taken to use the existing channels of communication and transactions 
between the providers and not to disturb the ecosystem. The private 
care should be aligned to adapt and practise the international or 
country-specific standards of care. The models should have enough 
flexibility for adaptations and midcourse corrections. In order to 
arrive at the best model, it will be ideal, to experiment pilots. 
Documentation of the experience and lessons learnt will be important 




before the scale up. Scaling up at the appropriate time is important to 
create a dent on the epidemiology. The PPM should be innovative, 
have flexibility in approaches and have willingness to change, modify 
and adapt.   
8.5.14 Sensitization/Training 
Providing sensitization/training to the public sector about the need for 
PPM is important to make it convinced about the need for engaging 
private sector. Mentoring and creating a pool of trainers from the 
private sector is important. Appropriate and user-friendly tools 
should be used for training.  
 
8.5.15 Provision of commodities 
NTP should be responsible for ensuring commodities like laboratory 
reagents, drugs and other logistics. Newer and faster diagnostic tools 
and quality assured drugs have to be provided to all patients.    
8.5.16 Information Communication Technology Platforms  
Appropriately designed Information Communication Technology 
(ICT) platforms should be used to reduce human intervention and to 
make the processes faster and efficient. ICT has to be used in 
transmission of laboratory results, registration of TB patients, TB 
case notification and ensuring treatment adherence.  
8.5.17 Engagement of professional organizations 
Professional organizations of health staff especially doctors have to 
be engaged in the process from the beginning stages itself considering 




their influence on the staff and their negotiation skills. In many 
settings, professional organizations would work as interface agencies.   
 
8.5.18 Regulations 
PPM will work only in an environment where there are regulations 
and they are implemented adequately. Regulations should cover areas 
such as proper adaptation of the laboratory guidelines, appropriate 
use of drugs, mandatory TB case notification, patient follow up and 
drug sales.  
 
8.5.19 Incentives 
Appropriate monitory or social incentives to public and private care 
providers, patients and treatment supporters from the community will 
contribute to the sustainability of PPM model. Mechanisms like 
accreditation of health care providers and facilities will work as social 
incentives. In addition, social business models will encourage more 
private care providers to participate. 
 
8.5.20 Monitoring and Evaluation 
Simpler tools for collecting, compiling, reporting and analyzing data 
has to be there for documenting, learning, adapting and replicating 
PPM models. Evaluation including cost effectiveness evaluation of 
the models will provide validation for replication/expansion. 
 
8.5.21 PPM has to go beyond the government and NTP 
It’s a fact that the overall responsibility and liability of TB control in 
any country ultimately lies with the government due to its 
accountability to her people as well as global health. Nevertheless, in 




the current scenario, vesting the entire responsibility of TB control on 
the NTPs is not practical or justifiable. This is mainly due to three 
factors in most of the high TB burden countries. These are 1) large 
proportions of TB cases continue to seek care from private health 
sector 2) slow but indisputable weakening of public health sector, the 
owner of NTPs and 3) steady and profound growth of the private 
health sector. This is the situation where there has to be consensus at 
all levels that nothing less than wider and comprehensive engagement 
of private health care sector can result in effective TB control. As 
already discussed earlier, there are non-NTP public health sector care 
providers that cater to large proportions of TB patients. These include 
health care settings of government organizations like prisons, 
industries like mines or public-sector undertakings like railways. 
Engagement of these health care providers is of extreme importance 
in order to achieve the global targets to end TB. Extensive coverage 
of prisons with standardized TB control is crucial as prisons house 
large numbers of people and provide conducive environment for the 
spread of TB.     
 
8.5.22 Mere increase in case notification is not enough; successful 
treatment is equally important 
It’s a fact that the focus of PPM has been on increasing care 
notification by engaging private sector. However, the question 
whether detection of more cases is just enough comes up. 
Successfully treating all notified cases is equally important to achieve 
the goal and targets of End TB Strategy. To achieve this, there has to 




be mechanisms to first notify the large numbers of TB patients 
receiving treatment from the private sector and to ensure treatment 
compliance by all such patients.   
 
8.5.23 Quality of care under NTP has to be maintained 
While there is increased emphasis on the engagement of the non-NTP 
health sectors in NTP, its crucial to ensure that the quality of care 
within the NTP is not compromised. It is important to ensure that all 
care providers adhere to international standards for TB care in the 
entire spectrum of services provided to TB patients. Adequate 
financial investment based on the needs especially for building and 
maintaining compact quality assurance mechanisms must be ensured.      
 
8.6 Conclusion 
There have been many successful PPM pilot projects across the 
world. As WHO reported, there have been more than 10% increase 
in case notifications between 2012 and 2016 in countries such as 
Bangladesh, India and the Philippines1. However, many countries 
face multiple challenges in implementing and scaling up PPM due to 
several factors already explained.  
 
The overarching research question in this thesis is “In what manner 
and under which conditions can the private sector be engaged in 
health care as to increase the chances of an effective End TB Strategy 
that will achieve its targets for 2035?”  
 




The End TB Strategy was formulated by WHO in a situation where 
the estimated TB incidence and deaths due to TB are very high while 
the targets in TB control must be achieved in a very short time. The 
vision of ‘A world free of tuberculosis’ and the goal of ‘End the 
global TB epidemic’ is not that easy to achieve especially with the 
current approaches and the level of efforts by the NTPs. Engaging 
and coordinating a multitude of diverse and unorganized health care 
providers, especially the private sector, is the biggest need and 
challenge to achieving higher rates of TB case notification and 
treatment success.  
 
In order to materialize the concept of a TB-free world, WHO-
projected interventions (as shown in Figure 3) such as optimal use of 
current and emerging tools as well as introduction of new vaccine, 
new drugs for treating TB disease and latent TB infection, a point of 
care test for diagnosing TB and pursuing Universal Health Coverage 
and social protection are non-negotiable. In addition, newer strategies 
and innovative approaches that have demonstrated success in PPM in 
countries like India have to be replicated and expanded in other 
relevant settings and countries. This would also require changes in 
the attitudes and approaches to the private sector especially by 
considering the private sector as a reality and therefore an opportunity 
rather than viewing it as a competitor or a barrier to effective TB 
control. NTPs will have to be more receptive and welcoming to 
partnerships and more flexible to accommodate the inherent 
distinctiveness and interests of the non-NTP sectors especially the 




private sector. NTPs will have to demonstrate willingness to adapt to 
situations while the quality of care to TB patients is preserved. 
Appropriate and context-specific monitoring and evaluation tools 
will have to be developed and used to measure both quantity and 
quality of the contributions from the non-NTP sectors in TB control. 
Extensively use ICT platforms and digital tools will be required in 
facilitating the engagement of especially the private health sector. To 
achieve all these, there should be adequate resources especially 
funding which will be the primary responsibility of NTPs that will be 
supplemented by donor agencies. Introduction of new and 
enforcement of existing regulations to ensure standardized 
management of TB cases and to enable notification of all TB cases 
are two important areas to be given serious attention by countries. 
Engagement of all pertinent technical partners including medical 
professional associations will be key to the success of PPM 
interventions.             
 
In a developing economy like India, in the background of the stark 
economic and social realities, achieving the End TB targets doesn’t 
appear to be an easy task. This is mainly due to the disconnect 
between the public sector that controls the RNTCP and the private 
sector that cater to large proportions of TB patients without notifying 
clear majority of such cases to the RNTCP. While the public health 
sector is overall regulated by the government’s guidelines, the private 
sector is often outside the dominion of these mechanisms leading to 
lapses in providing standardized care to TB patients. Private health 




care facilities that generally exist as for-profit establishments 
wouldn’t normally undertake public health functions of RNTCP for 
fear of impact on their income. Partnering with the RNTCP would 
necessitate the private health care facilities to either provide free 
services offered by the NTP or refer the patients to the public sector, 
either of which has direct impact on the income of private facilities. 
In addition, the public health activities to be undertaken as part of the 
national programme have costs that the private sector is naturally 
reluctant to bear by itself. Private sector in the usual practice 
considers TB as a health problem of an individual patient and 
therefore the private practitioners cannot be expected to spend time 
and resources to address the public health requirements. However, 
the independent operations of the private sector in TB case 
management leads to major public health problems impacting the 
whole world.  
 
It’s a global need that all TB cases are diagnosed and appropriately 
treated in India because a quarter of the global case load is in the 
country. India with a wide array of health care providers of which 
private sector being the biggest and most complex needs newer 
solutions as well as successful scale up of the proved mechanisms. 
Similarly, there is no ‘one size fits all’ solution available to engage 
the private sector care providers. New measures such as regulatory 
actions to implement mandatory TB case notification, restricting the 
use of non-standard diagnostic tools and drugs, subsidizing services, 
incentivizing patients and community, compensating non-public care 




providers for their services, ensuring local ownership, using interface 
agencies to engage private sector and mobilizing domestic funding 
have to be widely employed. For achieving a dramatic progress in TB 
control, it is crucial to look for new solutions outside the routine 
national programme and boldly implement innovative approaches.  
 
A survivor of MDR-TB in India in a meeting of the civil society 
consortium of India on 21 February 2017 said “When I became very 
sick, I didn’t know what it was. I consulted many doctors in my 
neighborhood who repeatedly prescribed cough mixtures and general 
antibiotics for many weeks. When I was finally diagnosed to have 
TB, I couldn’t believe it. I thought a person like me of higher socio-
economic status can never get TB. The treatment I received didn’t 
work and later my condition was diagnosed as MDR-TB which was 
a lifetime shock for me. Due to confidentiality issues, I didn’t want 
to visit government hospitals which are often not friendly towards 
patients. But I had to struggle a lot a get treatment for MDR-TB as 
the drugs were not available in the private sector from where I sought 
care. They said there are restrictions by the government. I heard a lot 
of discussions about partnership between the government and the 
private sector while I was running from pillar to post for second-line 
TB drugs for my treatment. I, as a patient, wanted to get cured of my 
MDR-TB. My parents and relatives wanted to save my life. I wanted 
medicines from some source or other to come back to my previous 
life.  I was not concerned about who gives me medicines. I was not 




interested in the conflicts between the public and private sectors. I 
needed the right medicines to kill the bacteria in my lungs” 
 
This is a loud and forceful message which tens of thousands of 
desperate TB patients echo around the world and especially in India. 
Governments, private health care providers, NGOs, technical 
agencies and donors anywhere in the world can no more turn a deaf 
ear to such messages. We need to act urgently and responsibly. We 
are already late by decades.   
 
8.7 Suggestions for future research  
In the past few years, several developments have happened in the area 
of TB control. For example, use of new and faster diagnostics, new 
drugs, modified drug regimens, incentives, use of digital technology 
and innovative approaches in implementation such as engaging 
informal health care providers have been introduced in TB control. 
Most of these changes have implications on the engagement of 
private sector. Future research should focus on the usefulness of these 






















































































Chapter 1. Research problem and Research Question 
This chapter presents the research problem as well as research 
questions in the background of a brief overview of a few aspects such 
as TB as a global public health problem, global and country-level 
efforts to control TB, TB control issues in the public and private 
health sectors and public-private mix in TB control as a strategy.  
 
The overarching research question in this thesis is “In what manner 
and under which conditions can the private sector be engaged in 
health care as to increase the chances of an effective End TB Strategy 
that will achieve its targets for 2035?” The specific sub questions that 
are discussed in detail in the following chapters are the following:  
  
• How did the TB control program of India try to engage the 
private sector in TB control and what has been the effect of 
the early PPM pilot endeavors?  
• How did India scale up the pilot projects on private sector 
engagement in TB control to national level and what has been 
the learning?  
• What has been the role of the Indian Medical Association in 
the engagement of the private sector in TB control and what 
is its relevance? What are the lessons for India and other 
countries to learn from the unique endeavor of engagement of 
medical professional associations in TB control?  
• What has been the landscape of funding from the Global 
Fund, the biggest international donor in TB control, for the 
engagement of the private sector in TB control?  




• Do prisons that house around 10 million detainees, among 
whom TB is a leading cause of morbidity and mortality, get 
adequate funding for TB control?  
 
Chapter 2. Introduction 
This chapter provides a comprehensive picture of TB disease 
epidemiology, multidrug-resistant TB and other comorbidities of TB, 
especially HIV/TB. The chapter also discusses the social 
determinants of TB. The various modes of diagnosis, treatment and 
prevention of TB are discussed in this chapter. The chapter also 
touches upon the ongoing global TB control efforts and explains the 
problems faced due to the suboptimal engagement of the private 
health sector in TB control. The development and evolution of 
Public-Private Mix (PPM) approaches in TB and the challenges faced 
are also discussed in adequate detail. TB control situation of India 
which has the highest TB burden and managed by a health system 
with heavy presence of private health sector is discussed. Indian TB 
program’s long history in the engagement of private sector and the 
development of innovative PPM models are presented as a case study.  
 
Chapter 3. Improving tuberculosis control through public-
private collaboration in India: literature review (article published 
in British Medical Journal).  
This chapter reviews the characteristics of public-private mix projects 
in India and their effect on case notification and treatment outcomes 
for tuberculosis. The study analyzed data from 14 projects and found 




that PPM activities were associated with increased case notification, 
while maintaining acceptable treatment outcomes. The study 
recognizes that collaborations between public and private providers 
of health care hold considerable potential to improve tuberculosis 
control in India. 
 
Chapter 4. Intensified scale-up of public-private mix: a systems 
approach to tuberculosis care and control in India (article 
published in International Journal of tuberculosis and Lung Disease). 
This chapter describes the processes and outcomes of the systems 
approach adopted in the intensified scale-up of PPM implemented by 
the India’s National Tuberculosis Control Programme (NTP) 
covering 50 million population in 14 major cities. Intensified PPM 
resulted in a 12% increase in notification of new smear-positive 
pulmonary TB cases. Treatment success was above the 85% target 
for all sectors combined. The study concluded that the systems 
approach to the intensified PPM scale-up was productive, however, 
many challenges and barriers to scale-up of PPM in India remains. 
 
Chapter 5: Role of professional bodies in TB control: An untold 
story of the Indian Medical Association (IMA) in fighting TB 
The study tries to summarize the history of Indian Medical 
Association’s approaches to the Revised National TB Control 
Programme (RNTCP) of India and the role IMA played in PPM in 
TB control of India. The study also analyzes the barriers in the IMA’s 
journey in PPM including, reluctance and lack of experience on both 




public and private sides, the ways and means through which these 
barriers have been addressed through the engagement of IMA, the 
level of success and the remaining challenges.  
 
Chapter 6. Global Fund financing of public–private mix 
approaches for delivery of tuberculosis care (article published in 
Tropical Medicine and International Health).  
This chapter maps the extent and scope of PPM interventions in TB 
control programmes supported by the Global Fund. The study found 
that fifty-eight of 93 countries and multi-country recipients of Global 
Fund-supported TB grants had PPM activities in 2008. Engagement 
with ‘for-profit’ private sector was more prevalent in South Asia 
while involvement of prison health services has been common in 
Eastern Europe and central Asia. In China, India, Nigeria and the 
Philippines, PPM contributed to detecting more than 25% TB cases 
while maintaining high treatment success rates. The study concluded 
that in spite of evidence of cost-effectiveness, PPM constitutes only 
a modest part of overall TB control activities. Scaling up PPM across 
countries could contribute to expanding access to TB care, increasing 
case detection, improving treatment outcomes and help achieve the 
global TB control targets. This study threw more light on the TB 
control situation in prisons. The study found that while the share of 
the TB budget allocated to PPM in Eastern Europe & Central Asia, 
and Latin America & the Caribbean is lower than in other regions, 
both the regions had many grants for collaboration with prison health 
services, which were not always reported as PPM. The study 




recommended deeper analysis of PPM components of Global Fund 
proposals and of the performance of grants. 
 
Chapter 7. Global Fund financing of tuberculosis services 
delivery in prisons (article published in Journal of Infectious 
Diseases):  
This chapter gives the review of The Global Fund grants database to 
identify TB and HIV/TB grants and activities that monitored the 
delivery of tuberculosis treatment and support activities in 
penitentiary settings. The study mapped the distribution and trend of 
number of countries with tuberculosis prison support by year, 
geographic region, tuberculosis or multidrug-resistant tuberculosis 
burden, and prison population rate. The study found that fifty-three 
of the 105 countries (50%) with Global Fund–supported tuberculosis 
programs delivered services within prison settings. Nearly two-thirds 
(64%) of these grants were implemented by governments, with the 
remaining by civil society and other partners. In terms of services, 
half (36 of 73) of grants provided diagnosis and treatment and an 
additional 27% provided screening and monitoring of tuberculosis for 
prisoners. The range of services tracked was limited in scope and 
scale, with 69% offering only 1 type of service and less than one-fifth 
offering 2 types of service. 
 
Chapter 8. Discussion 
This chapter summarizes the analysis of the manner and the various 
conditions of private health sector engagement in view of the targets of the 
End TB Strategy of the World Health Organization (WHO), by drawing 




relevant findings from the previous chapters of this thesis. The chapter also 
discusses the chances of PPM, the need for PPM, scope for innovations and 
adaptations in PPM, cost effectiveness of PPM, the challenges faced by 
PPM, lessons learnt from India and other countries and finally what does it 
take the End TB Strategy to meet its milestones and targets. Multiple 
challenges and the complex situations make it difficult for the TB 
programme managers to organize systematic PPM activities. In order to 
achieve the concept of a TB-free world, WHO-projected interventions such 
as optimal use of current and emerging tools as well as introduction of new 
vaccine, new drugs for treating TB disease and latent TB infection, a point 
of care test for diagnosing TB and pursuing Universal Health Coverage and 
social protection are non-negotiable. In addition, newer strategies and 
innovative approaches that have demonstrated success in PPM 
interventions in India and elsewhere have to be replicated and expanded in 
relevant settings and countries. The chapter pronounces the need for NTPs 
to proactively engage the private sector in order to make standardized 
services to all TB patients. 
  






Hoofdstuk 1. Onderzoeksprobleem en onderzoeksvraag 
De overkoepelende onderzoeksvraag in dit proefschrift luidt: "Op 
welke manier en onder welke voorwaarden kan de particuliere 
sector betrokken worden bij de gezondheidszorg om de kansen te 
vergroten op een effectieve “Beëindig Tuberculose-Strategie” 
(Engels: End TB Strategy) die zijn doelstellingen voor 2035 zal 
bereiken?"  
Specifieke deelvragen worden in detail in de hoofdstukken 
behandeld: 
• Hoe probeerde het Tuberculose-bestrijdingsprogramma van 
India de particuliere sector te betrekken bij de bestrijding 
van Tuberculose (TB) en wat was het effect van de eerste 
pogingen tot Publiek-Private-samenwerking? 
• Hoe heeft India de proefprojecten over de betrokkenheid van 
de particuliere sector bij de bestrijding van tuberculose 
opgeschaald naar het nationale niveau en wat is het 
leerproces geweest? 
• Wat was de rol van de Indian Medical Association bij de 
betrokkenheid van de particuliere sector bij het beheersen 
van TB en wat is de relevantie van deze rol? Wat zijn de 
lessen voor India en andere landen om te leren van deze 
unieke inspanning van een medische beroepsorganisatie bij 
TB-bestrijding? 




• Wat was het financieringslandschap van het Global Fund, de 
grootste internationale donor in TB-bestrijding voor de 
betrokkenheid van de particuliere sector bij TB-bestrijding? 
• Ontvangen gevangenissen met ongeveer 10 miljoen 
gedetineerden, waaronder tuberculose een belangrijke 
oorzaak is van morbiditeit en mortaliteit, adequate 
financiering voor TB-bestrijding? 
Het inleidende hoofdstuk presenteert het onderzoeksprobleem en de 
onderzoeksvragen en beschrijft daarbij TB als een wereldwijd 
probleem voor de volksgezondheid. Verder wordt aandacht besteed 
aan wereldwijde en landelijke pogingen om TB te beheersen, TB-
bestrijdingskwesties in de publieke en private gezondheidssectoren, 
en “Publiek-Private Mix” (PPM) als strategie voor TB-bestrijding. 
 
Hoofdstuk 2. Introductie 
Dit hoofdstuk biedt een uitgebreid overzicht van TB-epidemiologie, 
multiresistente TB en andere co-morbiditeiten van TB, met name 
HIV/TB. Het hoofdstuk bespreekt ook de sociale determinanten van 
TB. De verschillende manieren van diagnose, behandeling en 
preventie van tuberculose worden besproken. Voorts wordt 
ingegaan op de lopende wereldwijde pogingen tot TB-bestrijding en 
worden de problemen besproken rond de suboptimale inzet van de 
private gezondheidssector bij TB-bestrijding. De ontwikkeling van 
Public-Private Mix (PPM)-benaderingen bij TB en de uitdagingen 
waarvoor deze staan worden in detail besproken. De situatie met 




betrekking tot TB-bestrijding in India, dat de hoogste TB-ziektelast 
heeft en wordt beheerd door een gezondheidszorgsysteem met een 
sterke aanwezigheid van de particuliere gezondheidssector, wordt in 
detail besproken. De lange geschiedenis van het Indiase TB-
programma en de betrokkenheid van de particuliere sector en de 
ontwikkeling van innovatieve PPM-modellen daarbij, wordt 
gepresenteerd als een case studie. 
 
Hoofdstuk 3. Verbetering van tuberculosebestrijding door 
publiek-private samenwerking in India: literatuuronderzoek 
(artikel gepubliceerd in British Medical Journal).  
Dit hoofdstuk gaat in op de kenmerken van publiek-private 
mixprojecten in India en hun effect op de melding van gevallen en 
de behandelresultaten voor tuberculose. De studie analyseerde 
gegevens van 14 projecten en vond dat PPM-activiteiten 
geassocieerd waren met een verhoogde melding van gevallen, met 
instandhouding van acceptabele behandelresultaten. De studie 
benadrukt dat de samenwerking tussen publieke en private 
zorgverleners aanzienlijke mogelijkheden biedt om de 
tuberculosebestrijding in India te verbeteren. 
 
Hoofdstuk 4. Geïntensiveerde opschaling van publiek-private 
mix: een systeembenadering van tuberculosezorg en -controle in 
India (artikel gepubliceerd in International Journal of Tuberculosis 
and Lung Disease).  




Dit hoofdstuk beschrijft de processen en resultaten van de 
systeembenadering van de geïntensiveerde opschaling van PPM 
geïmplementeerd door het Nationale 
Tuberculosebestrijdingsprogramma(NTP) van India, dat 50 miljoen 
inwoners in 14 grote steden omvat. Intensievere PPM resulteerde in 
een toename van 12% in de melding van nieuwe uitstrijk-positieve 
gevallen van pulmonaire TB. Het behandelingssucces voor alle 
sectoren samen lag boven het streefcijfer van 85%. De studie 
concludeerde dat de systeembenadering van de geïntensiveerde 
PPM-opschaling productief was, maar er zijn nog veel uitdagingen 
en belemmeringen voor opschaling van PPM in India. 
 
Hoofdstuk 5: De rol van professionele instanties in TB-
bestrijding: een onverteld verhaal van de Indian Medical 
Association bij de bestrijding van tuberculose. 
 
De studie verschaft een overzicht van de geschiedenis van de 
benadering van Indian Medical Association (IMA) van het herziene 
nationale TB-controleprogramma (RNTCP) van India, en de rol van 
IMA in de PPM bij de bestrijding van TB in India. De studie 
analyseert ook de belemmeringen in de inspanningen van de IMA in 
de PPM. Aan de orde komen de terughoudendheid en gebrek aan 
ervaring aan zowel publieke als private zijde, de methoden en 
middelen waarmee barrières zijn aangepakt door IMA, de mate van 
succes en de resterende uitdagingen. 





Hoofdstuk 6. Financiering door het Global Fund van publiek-
private mixbenaderingen voor levering van tuberculosezorg 
(artikel gepubliceerd in Tropical Medicine and International 
Health). 
 
Dit hoofdstuk geeft een overzicht van de omvang en reikwijdte van 
PPM-interventies in TB-bestrijdingsprogramma's die worden 
ondersteund door het Global Fund. Uit de studie bleek dat 58 van de 
93 landen en transnationale partnerschappen die door het Global 
Fund werden ondersteund in 2008 PPM-activiteiten hadden. In 
Zuid-Azië was de commerciële private sector meer betrokken, 
terwijl in Oost-Europa en Centraal-Azië de activiteiten zich richtten 
op gezondheidszorg in gevangenissen. In China, India, Nigeria en 
de Filippijnen droeg PPM bij aan het opsporen van meer dan 25% 
gevallen van TB, terwijl de behandelingssuccessen hoog bleven. De 
studie concludeerde dat PPM, ondanks het bewijs van 
kosteneffectiviteit, slechts een bescheiden onderdeel vormt van de 
totale TB-controleactiviteiten. Het opschalen van PPM in 
verschillende landen kan bijdragen aan de uitbreiding van de 
toegang tot TB-zorg, het verhogen van de detectie van gevallen, het 
verbeteren van de behandelresultaten en het behalen van de 
wereldwijde TB-bestrijdingsdoelstellingen. Deze studie werpt meer 
licht op de situatie van TB-bestrijding in gevangenissen. Uit de 
studie bleek dat hoewel het aandeel van het TB-budget voor PPM in 
Oost-Europa en Centraal-Azië en Latijns-Amerika en het Caribisch 




gebied lager is dan in andere regio's, beide regio's veel subsidies 
hadden voor samenwerking met de gezondheidsdiensten in 
gevangenissen, die niet altijd gerapporteerd worden als PPM. In de 
conclusie wordt het belang benadrukt van een diepere analyse van 
PPM-componenten van Global Fund-voorstellen en van de 
prestaties van gesubsidieerde initiatieven. 
 
Hoofdstuk 7. Financiering door het Global Fund van 
tuberculosebehandeling in gevangenissen (artikel gepubliceerd in 
Journal of Infectious Diseases). 
 
Dit hoofdstuk geeft een overzicht van de gegevensbank van het 
Global Fund-fonds om TB- en HIV/ TB-subsidies en -activiteiten te 
identificeren. Het gaat hierbij om subsidies en activiteiten om de 
tuberculosebehandeling en ondersteunende activiteiten in 
penitentiaire instellingen te monitoren. Het onderzoek bracht de 
verspreiding en trends in kaart van het aantal landen met 
tuberculosebestrijding in gevangenissen per jaar, geografische regio, 
tuberculose of multiresistente tuberculose ziektelast, en de 
bevolkingsdichtheid van de gevangenissen. De studie wees uit dat 
drieënvijftig van de 105 landen die door het Global Fund 
ondersteund werden diensten leverden in gevangenissen. Bijna 64% 
van deze subsidies werd uitgevoerd door regeringen, de rest door 
het maatschappelijk middenveld en andere partners. Bij 36 van de 
73 verstrekte beurzen ging het om diagnose en behandeling. In 27% 
van de gevallen werd voorzien in screening en monitoring van 




tuberculose voor gevangenen. Het bereik van de gevolgde diensten 
was beperkt qua reikwijdte en schaal, 69% bood slechts 1 soort 
dienst aan, en minder dan een vijfde bood 2 soorten diensten aan. 
 
Hoofdstuk 8. Discussie 
 
Dit hoofdstuk verschaft een samenvatting van de analyse van de 
manier en de verschillende condities van betrokkenheid van de 
private gezondheidssector in het licht van de doelstellingen van de 
End TB Strategie van de Wereldgezondheidsorganisatie (WHO). 
Het hoofdstuk bespreekt ook de kansen van PPM, de noodzaak van 
PPM, ruimte voor innovaties en aanpassingen in PPM, 
kosteneffectiviteit van PPM, de uitdagingen waarmee PPM te 
maken heeft, lessen die zijn getrokken uit India en andere landen, en 
ten slotte de gevolgen van de End TB Strategie om de TB mijlpalen 
en doelen te halen. Meerdere uitdagingen en de complexe situaties 
maken het voor TB-programmamanagers moeilijk om systematische 
PPM-activiteiten te organiseren. Om het ideaal van een TB-vrije 
wereld te bereiken zijn de interventies uit de WHO plannen en 
strategieën niet onderhandelbaar. Bij deze interventies gaat het om: 
optimaal gebruik van huidige en nieuwe instrumenten, evenals de 
introductie van een nieuw vaccin, nieuwe geneesmiddelen voor de 
behandeling van TB-ziekte en latente TB-infecties, een point of 
care-test voor het diagnosticeren van tuberculose en het nastreven 
van universele ziektekostenverzekering en sociale bescherming. 
Bovendien moeten nieuwere strategieën en innovatieve 




benaderingen die succesvol zijn gebleken in PPM-interventies in 
India en elders worden gerepliceerd en uitgebreid in relevante 
omgevingen en landen. Nationale TB preventie-porgramma’s 
dienen proactief de particuliere sector te betrekken bij het maken 
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AYUSH Ayurveda, Yoga, Unani, Siddha, Homeopathy, 
Naturopathy 
BCG  Bacille Calmette-Guerin 
CBNAAT Cartridge-based Nucleic Acid Amplification Test 
CGHS  Central Government Health Scheme  
CHC   Community Health Centre  
CTD  Central TB Division  
DOT   Directly Observed Treatment  
DOTS  Directly Observed Treatment, Short-course  
DRC  Democratic Republic of Congo 
EECA   Eastern Europe and Central Asia  
EFR   Enhanced Financial Reporting System  
ESI   Employees State Insurance 
HIV  Human Immunodeficiency Virus  
IMA  Indian Medical Association  
IMPACT  Indian Medical Professional Associations’ Coalition 
against TB 
ISTC  International Standards for TB Care  
LAC   Latin America and the Caribbean 
LTBI  Latent TB Infection  
MDG  Millennium Development Goals  
MDR-TB Multidrug-resistant Tb  
MoH  Ministry of Health  




NCD  Non-Communicable Disease  
NGO  Non-Governmental Organization  
NSP   new smear-positive 
NTP  National TB control Programme  
OAEs   Own-Account-Enterprises  
PHC  Primary Health Centers 
PMDT  Programmatic Management of Drug-resistant TB  
PPIA  Public-Private Interface Agency  
PPM   Public-Private Mix 
PTB  Pulmonary TB  
RNTCP Revised National Tuberculosis Control programme  
SC   Sub Centre  
SDG  Sustainable Development Goal  
STCI  Standards for TB Care in India 
TB   Tuberculosis  
TOG  Technical and Operational Guidelines  
UHC  Universal Health Care  
UNOPS  United Nations Office for Project Services  
US$  United States Dollars  
WCA  West and Central Africa 
WHO  World Health organization  









                   
A private practitioner of Unani (Perso-Arabic traditional medicine as 
practiced in Mughal India and in Muslim culture in South Asia and modern day 
Central Asia) in Jaipur city of Rajasthan, India who became a treatment supervisor 
for patients in his neighborhood. While he practised Unani in his clinic, he referred 
presumptive TB patients to the health care facilities that provided services under 
the Revised National TB programme of India. He was trained by the Revised 
National TB Control Programme of India in identifying and referring presumptive 
TB patients, supervising drug consumption by TB patients until their last dose and 
ensuring their follow up test done in time until their treatment outcome is reported.   
 
But I have promises to keep,  
And miles to go before I sleep,  
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